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ABSTRACT 
 
 
 Melanoma is the most dangerous form of skin cancer and accounts for the 
majority of skin cancer death. Although considerable advances have been made in 
melanoma treatment in recent years, there are many problems associated with current 
therapies. Drug resistance to targeted therapies is almost inevitable after short term 
treatment. Immunotherapies generally have low response rate and the effects vary among 
patients. Therefore, the need to develop new and more effective treatment for melanoma 
is high.  
 
 The work presented here focuses on discovery of novel anticancer agents for 
melanoma by targeting two important cancer targets: tubulin and survivin. Microtubules 
play important role in mitosis and cell division. Cancer cells divide more rapidly than 
normal cells, and thus are more sensitive to tubulin targeting agents which disrupt 
mitosis. Targeting tubulin for anticancer treatment has been very successful. Chapter 3 
describes our discovery process of a series of novel tubulin polymerization inhibitors. 
Our lab previously reported a set of 2-aryl-4-benzoyl-imidazoles (ABI) derivatives with 
potent anti-proliferative activity against melanoma cells and xenografts. A new series of 
4-aryl-2-benzoyl-imidazoles were designed and synthesized after further optimization of 
the ABI series. The new scaffold reversed the position of the aryl group and benzoyl 
group on the imidazole ring of ABI structure and thus was named RABI. Those newly 
synthesized compounds were tested against eight different cancer cells, including 
multidrug-resistant cancer cell lines. The in vitro results showed that several compounds 
in this series had excellent anti-proliferative activities. The best compound displayed IC50 
value in single-digit nano-molar against several tumor cell lines. In addition, RABI 
compounds showed advantages in overcoming multiple drug resistance, compared with 
existing tubulin targeting agents, paclitaxel, colchicine, and vinblastine. Mechanism of 
action for the RABI compounds was investigated using cell cycle analysis, tubulin 
polymerization assay, competitive mass spectrometry binding assay, and molecular 
docking studies. These studies suggested that RABI compounds exerted their anticancer 
effects by inhibiting tubulin polymerization at the colchicine binding site. The RABI 
compounds represent promising cancer drug candidates for further development. 
 
 Another attractive target for anticancer treatment is survivin. The differential 
expression of survivin between normal differentiated cells and tumor cells and the 
essential role of survivin in tumor make it an ideal target for cancer. Although survivin is 
an attractive cancer drug target, the pool of existing survivin inhibitors is quite limited. 
Thus, it is highly significant to develop new survivin inhibitors. Our attempts to search 
for new survivin inhibitors were initiated by the identification of UC-112 which turned 
out to be a potent and selective survivin inhibitor. UC-112 was discovered through virtual 
screening from a library of compounds. It showed good potency both in vitro and in vivo. 
Structural modifications of the UC-112 oxyquinoline template generated a number of 
UC-112 analogs. The new analogs were tested on a panel of cancer cell lines. The results 
suggested that the new derivatives had strong anticancer activity. Several compounds 
showed IC50 value in the nano-molar range. The structure-activity relationships were also 
 v 
elucidated through the structural modifications. Our best compounds along with UC-112 
were submitted for NCI-60 cancer cell line screening. The results from the screening 
indicated the best compound in this series improved potency in terms of GI50. The most 
potent compound also showed good drug-like properties. Mechanism of action for the 
UC-112 analogs was investigated using Western blot and drug affinity responsive target 
stability (DARTS) assay. This set of compounds selectively inhibited the expression of 
survivin over other IAP proteins and also protected survivin from digestion by pronase in 
the DARTS assay. The most potent compound from the in vitro assay effectively 
suppressed tumor growth in melanoma xenograft. This novel scaffold represents a new 
structure template for survivin inhibitors and can be further developed as potential 
anticancer agents. 
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CHAPTER 1.    INTRODUCTION 
 
 
Facts about Melanoma 
 
Melanoma causes the greatest morbidity and mortality of all skin cancers [1]. The 
blueprint of melanoma statistics, risk factors and major biology mutations is summarized 
here. 
 
 
Statistics for Melanoma 
 
According to the up-to-date data from National Cancer Institute, melanoma is one 
of the top 10 most common cancers in the United States with steadily increasing rate over 
the past decade. It is estimated that there will be 73, 870 new cases and 9,940 new death 
of melanoma in 2015. About 4% patients develop distal metastasis in the whole 
melanoma population and poor prognosis is associated with the disease at this stage. The 
five-year survival rate for metastasis melanoma is only 16.6%, which indicates the 
aggressiveness of disease and the missing of effective therapeutics.  
 
 
Melanoma Causes and Risk Factors 
 
Men with fair complexion and red hair is more likely to develop melanoma with 
the growing of age, compared with other group of people [2]. Although 40% of 
melanoma is considered to be a benign disease, ultraviolet radiation (UVR) remains the 
leading cause of melanoma. People with heritable factors including the history of 
sunburn, excessive exposure to UVR, and close relative history of melanoma, multiple 
benign and unusual moles are at higher risk for the development of melanoma [3].  
 
Melanoma origins from the malignant transformation of melanocytes, which can 
be found between the epidermis and dermis layer of skin. When the melanocyte begins to 
grow out of control due to factors like DNA-damage caused by UVR and hereditary gene 
mutation, it enters to early stage of melanoma (radial growth phase) [3]. Melanoma at this 
stage hasn’t yet contacted with the blood vessel buried deeper and is not able to spread to 
distal tissues. Comparing with other skin cancers like basal cell carcinoma and squamous 
cell carcinoma, melanoma has characteristic asymmetry, border irregularity, color 
variation and large diameter look. When the melanoma cells begin to grow towards 
vertical direction into papillary dermis, they reach invasive stage of melanoma and 
further spread to both surrounding and distal tissues (especially lung) through blood or 
lymph circulation [4].  
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Major Genetic Recurrent Driver Mutations of Melanoma 
 
Melanoma can be categorized by the histological and anatomic sites of origin into 
different subtypes like nodular melanoma, uveal melanoma and superficial spreading 
melanoma. But with the in-depth understanding of the molecular and genetic aspects of 
melanoma during the recent decades, researchers find that several “driver” mutations are 
closely associated with the disease progression, prognosis and tumorigenesis [1, 5-7]. 
Melanoma arises when mutations of these cancer driver genes accumulate and alter the 
melanocyte cell proliferation, programmed death and differentiation. Target therapies for 
melanoma have been studied based on these findings in gene mutation status. The 
landscape of melanoma genomic alteration subtypes are summarized here and respective 
insights of therapeutic choices are discussed later in brief as well. 
 
 
BRAF mutation 
 
BRAF gene codes a serine/threonine kinase, BRAF, which is a part of RAS-RAF-
MEK-ERK signaling pathway [7-10]. More than 30 mutations of the BRAF gene have 
been found in most types of cancers with wide variation of abundance. Around 60% of 
malignant melanoma patients bear BRAF V600E mutation, which alters the sequence at 
the hydrophobic activation loop of BRAF and changes the sensitivity of protein to 
proteasome inhibitors. The wild-type BRAF protein works as homodimer, while the 
mutant (e.g. V600E, V600K) protein can be activated as monomer [11]. Mutant BRAF 
protein usually is hyper-activated and thus leads to the over-stimulation of downstream 
MEK kinase and progressive disease status.  
 
 
RAS mutation 
 
About 10~20% of melanoma carry RAS mutations and they are considered as the 
marker for the derivation of malignant melanoma. Among three pro-oncogene of human 
RAS (HRAS, KRAS, NRAS), NRAS has the most common mutations in melanoma. RAS 
protein is membrane-bound small GTPase [10, 12-14]. Its active form translocates RAF 
protein from cytoplasm to plasma membrane and phosphorylates it in response to the 
extracellular growth factors [5]. RAS protein is among the first onco-proteins studied in 
human, which plays roles like a “switch” of events determining cell growth, 
differentiation and survival. Downstream effectors that bind to RAS and trigger signaling 
cascade include Aiolos transcription factor, RAF proteins, phosphatidylinositol 3-kinase 
(PI3K), Ral guanine nucleotide dissociation stimulator, PLCε and PKCζ [13].  
 
 
KIT mutation 
 
Although small portion of melanomas have KIT mutations compared with BRAF 
or RAS mutations, melanomas arising from mucosal and genital regions commonly have 
amplifications or activating mutations of KIT, which encode c-KIT (also known as 
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CD117), a type III transmembrane receptor tyrosine kinase (RTK) for binding of stem 
cell factor (SCF) [7, 11, 15]. Upon stimulation, c-KIT will be dimerized, auto-
phosphorylated, and activate several signaling pathways. Interestingly, the response of c-
KIT to RTK inhibitor imatinib is dependent on the mutation status of KIT gene. It is 
reported that melanoma patients harboring K642E mutation as well as a 7-codon 
duplication of exon 11 in KIT achieved durable benefits of imatinib treatment, while 
patients with mutations on exon 17 did not [15]. 
 
 
Current Therapies for Melanoma 
 
 There are mainly five types of therapies to treat melanoma currently, including 
surgery, chemotherapy, immunotherapy, targeted therapy, and radiation therapy. In this 
section, these therapies and the drugs used are reviewed. 
 
 
Surgery 
 
 Surgery remains the main treatment option for most melanomas. It usually can 
cure early stage melanomas and thus is the best choice for patients with early stage 
melanomas. After a diagnosis of melanoma is made, the tumor site will be cut out along 
with a small amount of normal non-cancerous skin, which is referred as margin [16]. The 
surgical margins will vary depending on the tumor thickness and also sometimes the 
location of the tumor. Sometimes, the lymph nodes close to the primary melanoma will 
also be removed to prevent spreading. Surgery is unlikely to cure metastatic melanoma. 
Yet surgery is sometimes performed in patients with advanced melanomas either to 
control the cancer or to help improve quality of life. 
 
 
Chemotherapy 
 
 Dacarbazine is the primary chemotherapeutical agent used to treat advanced 
melanoma. Dacarbazine was approved by Food and Drug Administration (FDA) in 1975 
and has been used for the treatment of metastatic melanoma for several decades. This 
agent works by alkylation of DNA via the super active methyl radical formed after 
activation in vivo. The overall response rate of dacarbazine has fallen over the years [17-
18]. But it remains the mainstay of many chemotherapy regimens. Since 
chemotherapeutical drugs generally work by attacking fast-dividing cells, those normal 
cells that are also dividing fast in our body, such as those in bone marrow, the lining of 
the mouth and intestine, and the hair follicles, will also be affected, causing many side 
effects. With the advent of new immunotherapies and targeted drugs which target cancer 
cells more selectively and have less adverse effects, chemotherapeutical drugs are used 
less often now. 
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Immunotherapy 
 
 Melanoma has long been considered as a promising target for immunotherapy. 
Currently there are several types of immunotherapies used to treat melanoma patients, 
which are discussed in the following part. 
 
 
 Immune checkpoint inhibitors 
 
 The most successful immunotherapy up to date has been immune checkpoint 
inhibition. Checkpoints are essentially molecules on immune cells to control immune 
response. An important purpose for their existence is to protect normal cells from being 
attacked. Melanoma and other cancers can escape from immunological attack in many 
ways involving the checkpoints [3]. Restoring immune response to melanoma by 
inhibiting checkpoints proves a very effective way to treat melanoma. Two checkpoints, 
cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1(PD-1), that 
mediate immune tolerance, have been best studied. CTLA-4 is a molecule expressed on 
the surface of activated T cells which can obstruct T cells activation. PD-1 is expressed 
by activated T cells and B cells, while PD-1 ligand, PD-L1, is expressed by antigen-
presenting cells. The interaction between PD-1 on T cells and PD-L1 deactivates T cells. 
Many cancers including melanoma evade immune surveillance by expressing PD-L1 
themselves. 
 
 Ipilimumab, a CTLA-4 blocking monoclonal antibody, was the first drug to 
extend survival for patients with metastatic melanoma [19]. It was approved by FDA for 
the treatment of advanced melanoma in 2011. Anti-PD-1 monoclonal antibodies showed 
even better effects than ipilimumab in clinical trials [20]. Pembrolizumab, an PD-1 
blocking agent, won FDA approval in September 2014 for the treatment of patients with 
unresectable or metastatic melanoma and disease progression following ipilimumab [21]. 
Another anti-PD-1 drug, nivolumab, was approved by the FDA for the same indications 
as pembrolizumab in December 2014. 
 
 
 Cytokines 
 
 Cytokines are small proteins in the body that can boost immune system. Two 
cytokines, interleukin-2 and interferon-alfa, have been used in clinical for the treatment 
of melanoma. Interleukin-2 was a type I cytokine which activates cytotoxic T cells. It was 
approved by the FDA in 1998 for patients with advanced melanoma and represents the 
first FDA-approved immunotherapy drug. Interleukin-2 has many side effects including 
severe tiredness, drowsiness, and low blood cell counts, which limit their use [22]. 
Despite of this, it can produce long-term remissions in some patients [23]. Interferon-alfa 
has been used both as a single agent after surgery or in combination with other drugs for 
advanced melanoma treatment [24-25]. The use of interferon-alfa can prevent remaining 
cancer cells after surgery from growing and spreading. For both interleukin-2 and 
interferon-alpha to be effective, high doses must be used. But many patients cannot 
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tolerate the severe adverse effects associated with high doses. Therefore, they are used 
less as of now. 
 
 
 Bacille calmette-guerin vaccine 
 
 Cancer vaccines are another type of immunotherapy used in clinical. They are 
designed to induce immune responses against tumor-specific or tumor-associated 
antigens, which will encourage the immune system to attack cancer cells containing these 
antigens. Bacille Calmette-Guerin vaccine is a germ related to the one that causes 
tuberculosis. It boosts the entire immune system similarly as cytokines. This vaccine is 
not specific for melanoma cells. It is sometimes used to treat melanomas by directly 
injecting the vaccine into the tumors [26]. 
 
 
Targeted Therapy 
 
 Targeted therapy of melanoma began with the identification of mutations in 
BRAF, a serine/threonine protein kinase, by Davies et al in 2002 [9]. It is reported that 
more than 50% melanomas have position 600 mutations in BRAF, with V600E mutation 
being the majority (80%) and the next being V600K mutation [10, 27]. Drugs that target 
BRAF mutations have been very successful in recent years with three targeted drugs 
including vemurafenib, dabrafenib, and trametinib, approved by the FDA. The three 
drugs are discussed in more details in the following part. 
 
 
 BRAF inhibitors 
 
 BRAF plays an important role in the RAS-RAF-MEK-ERK signaling pathway, 
and regulates many critical cellular functions, such as cell division, proliferation, and 
apoptosis resistance [28]. Various mutations of BRAF have been identified in melanoma. 
Vemurafenib works by preferentially inhibiting the active form of BRAF [29] and is the 
first targeted drug to show substantial efficacy against melanoma [30]. In the phase III 
clinical trial, vemurafenib induced significant tumor shrinkage in the majority of patients 
with melanomas bearing BRAFV600E mutations and showed advantages over dacarbazine 
treatment group [8]. This drug was approved by the FDA in 2011 for use in patients with 
advanced or unresectable melanomas. Dabrafenib, another selective BRAF inhibitor, is 
the first identified drug that can efficiently treat melanoma with brain metastases [31]. It 
provided similar clinical benefits as vemurafenib [32]. It was approved by the FDA as a 
single agent for the treatment of advanced melanoma with BRAFV600E mutations in 2013.  
 
 
 MEK inhibitors 
 
 MEK is another member of the MAPK signaling pathway and is in the 
downstream of RAF. Thus drugs that block MEK protein are also useful in treating 
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melanomas with BRAF mutations. MEK inhibitors such as trametinib and selumetinib, 
showed good responses in clinical trials with melanoma patients [33-34]. Trametinib was 
approved by the FDA in 2013 as a monotherapy agent for the treatment of metastatic 
melanoma with BRAF mutations. It is the first orally available, allosteric MEK inhibitor. 
Many studies have been done to study the combinatory effects of using MEK inhibitors 
together with other anticancer agents, especially BRAF inhibitors. In one recent clinic 
trial, co-administration of dabrafenib with trametinib demonstrated improved clinical 
benefits with fewer toxicities compared with single agent treatment [14]. 
 
 
Radiation Therapy 
 
 Radiation therapy uses high-energy rays to kill tumor cells. It is not often used in 
the original melanoma that started on the skin. Radiation therapy is sometimes used after 
surgery to the region where lymph nodes have been removed in order to prevent cancer 
from recurring. It is often used to relieve symptoms caused by the spread of the 
melanoma. Some possible side effects include hair loss, fatigue, nausea and weight loss. 
The side effects can become worse when radiation is given with chemotherapy. 
 
 
Problems with Current Therapies 
 
 Recent years have witnessed several revolutionary therapeutical advances that 
have significantly improved the outcomes of melanoma patients. The success lies in 
immunotherapy and targeted therapy of melanoma with six new anti-melanoma drugs 
being approved by the FDA in the recent five years. These advances mark the era of 
immunotherapy and targeted therapy. The new drugs bring considerable clinical benefits 
to patients with advanced melanomas. However, there are many limitations with these 
therapies. Problems with current therapies for melanoma are summarized in this section. 
 
 
Resistance to Targeted Therapy 
 
 The efficacy of BRAF inhibitors like vemurafenib or dabrafenib is restricted to 
melanomas harboring BRAF mutations. Even in BRAF-mutant patients, drug resistance 
and disease progression occurred in most cases within 6 months during the treatment [8]. 
The melanomas that are resistant to BRAF inhibitors often confer resistance to MEK 
inhibitors such as trametinib or selumetinib as well [12]. It is therefore not surprising that 
trametinib monotherapy shows minimal clinical activity to patients with acquired 
resistance to BRAF inhibitors [35]. 
 
 Mechanisms of resistance to BRAF inhibition include innate resistance and 
acquired resistance. Innate resistance generally comes from BRAF wild type melanomas. 
Pretreatment factors including BCL2A1 expression, PTEN loss, and CCND1 activation 
can cause innate resistance [36]. For acquired resistance, various mechanisms have been 
identified, which can be divided into two categories (Figure 1-1): BRAFV600E-bypass,   
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Figure 1-1. The mechanisms of acquired resistance to BRAF inhibition 
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mechanisms and MAPK-bypass mechanisms [37-40]. In the first category, MAPK 
signaling is reactivated. Such mechanisms include MEK1 mutations, COT upregulation 
and NRAS mutations. MEK1 mutations increase the catalytic activity of MEK and lead 
to BRAF-independent ERK phosphorylation [41]. COT, is a MEK kinase encoded by 
gene MAP3K8. The upregulation of COT activates MEK signaling without RAF protein 
[42]. Although NRAS is in the upstream of BARF, hyperactive or mutant NRAS can 
restore MAPK signaling through paradoxical activation of CRAF [43]. Many MAPK 
pathway-independent mechanisms work by activating the PI3K-AKT signaling pathway. 
This pathway can be activated by the overexpression of receptor tyrosine kinases such as 
insulin-like growth factor 1 receptor and platelet-derived growth factor receptor beta [44]. 
 
 
Limitations of Immunotherapy 
 
 Although recently approved immunotherapy drugs improve overall survival rate 
of patients with metastatic melanomas, their clinical benefits are accompanied by several 
limitations. First, the portion of patients who respond to current immunotherapies is still 
low. For example, the response rate for ipilimumab is only around 15%, and long-term 
durability of response occurs in an even smaller set of patients [45]. Another concern 
with immunotherapies is their side effects. Because these immunotherapies sometimes 
allow the immune system to attack normal cells in the body, serious side effects can 
occur to some patients. It was reported that ipilimumab caused hypophysitis in around 
17% of the patients treated with this drug [46-47]. 
 
 
Tubulin and Survivin as Cancer Drug Targets 
 
 Tubulin and survivin share several common features. First, both of them are 
crucial in the process of cell mitosis and division. During mitosis, proper functioning of 
microtubule dynamics is required for the correct movements of the duplicated 
chromosomes and their segregation into two daughter cells [3]. Survivin participates in a 
multi-protein complex called the chromosomal passenger complex which is essential for 
accurate sister chromatid segregation and cytokinesis in mitosis [48]. Secondly, both of 
them are important for the formation and maintenance of tumor cells. Microtubules, as 
key components of cytoskeleton, are critical for the development and maintenance of 
tumor cell shape. Survivin is a nodal protein involved in many signaling mechanisms 
controlling tumor maintenance [49]. Third, blocking tubulin and survivin can both lead to 
cell apoptosis. Inhibition of microtubule dynamics causes cell cycle arrest and eventually 
results in cell death by apoptosis. One major function of survivin is inhibition of 
apoptosis. Blocking of survivin causes induction of apoptosis. These common features 
make tubulin and survivin important cancer drug targets, which are also the focuses of 
my research projects in this dissertation. Besides these common features in the two 
targets, survivin and tubulin are also correlated in many ways [49]. Survivin has been 
reported to directly modulate microtubule dynamics by binding to polymerized 
microtubules [50]. Survivin has also been shown to promote drug resistance to 
microtubule targeting agents [51]. Details about tubulin and tubulin targeting agents will 
 9 
be presented in Chapter 2. Survivin and its inhibitors will also be discussed in details in 
Chapter 4.  
 
 
Concluding Remarks 
 
 Melanoma is an extremely complex disease with many gene mutations and 
signaling pathways involved. The huge complexity of this disease may account for its 
poor prognosis and survival rate at metastatic stage. Although tremendous research work 
has been done to find better treatments for melanoma, especially metastatic melanoma, 
for the past several decades, major successes are elusive until recently. Notable 
therapeutic advances in immunotherapy and targeted therapy of melanoma have been 
made in recent five years, which significantly improve the outcomes of patients with 
advanced melanoma. Despite of these advances, it should be recognized that the majority 
of patients with advanced melanoma still die of this disease. Besides, there are many 
limitations with the new therapies, such as drug resistance to targeted therapies and low 
response rate to immunotherapies. Therefore, the need to find new treatments for 
melanoma is still high. To fulfill this need, we have done a lot of work to develop novel, 
potent anticancer agents for melanoma treatment. I will describe these efforts in the next 
several chapters. 
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CHAPTER 2.    OVERVIEW OF TUBULIN AND TUBULIN POLYMERIZATION 
INHIBITORS 
 
 
Introduction 
 
 Microtubule is critical in the process of mitosis, making it an important 
therapeutic target for anticancer drugs. Many successful microtubule-targeted agents have 
been discovered and used in clinical for decades, such as paclitaxel and vinca alkaloids. 
However, there are certain problems with existing tubulin targeting agents which limit 
their usages. Considerable research efforts are underway to develop novel microtubule-
targeted agents with high potency and selectivity and less toxicity. 
 
 In this chapter, we first describe the structure and functions of microtubule and 
different binding sites of tubulin. Then we review current tubulin polymerization 
inhibitors and problems with these agents. Several novel colchicine domain binding 
agents previously developed in our group are also discussed. 
 
 
Structure and Functions of Microtubule 
 
 Microtubules are long, filamentous, tube-shaped protein polymers which are 
composed of heterodimers of α-tubulin and β-tubulin (Figure 2-1). The heterodimers first 
assemble to form a microtubule nucleus. Then more dimers are added head to tail at both 
ends to form a cylinder structure with 13 protofilaments [52]. Each microtubule has two 
ends, one end is designated as (+) end with β-tubulin exposed to the solvents, the other 
end is designated as (-) end with α-tubulin exposed to the solvents. Both α-tubulin and β-
tubulin can bind to a molecule of guanosine triphosphate (GTP) [53]. GTP-tubulins form 
a short region at both ends of microtubule called GTPcap, which prevents microtubule 
from disassembly. Tubulin dimer adds to the end of microtubule only at GTP-bound 
state. The hydrolysis of tubulin-bound GTP to guanosine diphosphate (GDP) will 
destabilize microtubule, leading to depolymerization. The switch from growing or paused 
state to shortening state is called ‘catastrophe’; the switch of opposite direction is called 
“rescue”.  
 
 Microtubule is a key component of cytoskeleton and is involved in many cellular 
processes. It is critical in cell shape maintenance, intracellular transportation, and cell 
division and mitosis. The functional diversity of microtubule is accomplished in several 
ways: through the binding of various regulatory proteins to soluble tubulin and to the 
microtubule surfaces and ends; by expression of different tubulin isotypes; and through 
several post-translational modifications of tubulin [52]. The biological functions of 
microtubules are largely determined by their polymerization dynamics [54]. Microtubules 
have two types of non-equilibrium dynamics. One type of dynamic behavior is called 
‘dynamic instability’, which is a process in which microtubule ends switch between 
growth and shortening phases. The two ends of a microtubule are not the same in terms 
of instability. The plus end grows and shortens more rapidly than the minus end. The   
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Figure 2-1. Structure of microtubule 
Reprinted with permission from Macmillan Publishers Ltd. Jordan, M. A.; Wilson, L. 
Microtubules as a target for anticancer drugs. Nat Rev Cancer, 2004, 4(4), 253-265. 
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second dynamic behavior is called ‘treadmilling’. It is essentially net growth at one end 
of microtubule balanced by the shortening at the opposite end. It involves the intrinsic 
flow of tubulin subunits from one end to the opposite one. This behavior is very common 
both in cells and in vitro and is very important in mitosis [55]. 
 
 
Binding Sites of Tubulin Targeting Agents 
 
 Tubulin targeting agents are classified into two main groups: microtubule 
stabilizing agents and microtubule destabilizing agents, based on their effects on 
microtubule polymer mass at high concentrations [56]. Microtubule stabilizing agents 
inhibit tubulin depolymerization at high concentrations and include several compounds 
such as the taxanes, paclitaxel, docetaxel and cabazitaxel, the epothilones, ixabepilone, 
patupilone and sagopilone, cyclostreptin, dictyostatin, eleutherobins, discodermolide, 
sarcodictyins, rhazinilam, laulimalide, and peloruside A. Microtubule destabilizing agents 
inhibit tubulin polymerization when present at high concentrations and this type of agents 
include the vinca alkaloids, vinblastine, vincristine, and vindesine, the dolastatins, 
eribulin, maytansinoids, and spongistatin, cryptophycins, halichondrins, estramustine, 
colchicine and its analogues, podophyllotoxin, combretastatins, 2-methoxyestradiol, 
phenylahistins, steganacins and curacins. These tubulin targeting agents are known to 
interact with at least four binding sites: the vinca binding domain, the taxol binding 
domain, the colchicine binding domain, and the laulimalide binding domain. The four 
binding sites as shown in Figure 2-2 are discussed in details in the following subsections. 
 
 
Vinca Binding Domain 
 
 The vinca alkaloids, identified more than 50 years ago [57] were originally 
isolated from periwinkle plant Catharanthus rosea and are the oldest family of tubulin 
targeting agents. The cancer chemotherapeutical potential of vinca alkaloids was 
discovered by research groups at both Eli Lilly Research Laboratories and at the 
University of Western Ontario in the 1950s [52]. The vinca alkaloids were used widely 
for the single-agent treatment for childhood and adult hematological malignancies. They 
were very successful in the treatment of childhood leukemia and were regarded as the 
“wonder drugs”. The vinca alkaloids bind to a distinct region called the vinca-binding 
domain located at the β-subunit of tubulin dimers. They generally bind at the ends of 
tubulin but do not copolymerize into microtubules. Vinblastine was found to introduce a 
wedge at the interface of two α, β-tubulin heterodimers and such interference prevents 
tubulin assembly [58]. 
 
 
Taxol Binding Domain 
 
 Paclitaxel, a complex molecule that was isolated from the bark of the yew tree in 
1967 by Monroe Wall and Mansukh Wani [59]. The development of paclitaxel was slow 
until Peter Schiff and Susan Horwitz made the surprising discovery that paclitaxel   
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Figure 2-2. Binding sites of tubulin targeting agents 
Reprinted with permission from Springer. Lu, Y.; Chen, J.; Xiao, M.; Li, W.; Miller, D. 
D. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm 
Res, 2012, 29(11), 2943-2971. 
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stimulated tubulin polymerization which is totally different from vinca alkaloids that 
inhibit tubulin polymerization [60]. In 1995, paclitaxel was approved for its clinical use 
for the treatment of cancer. A lot of semisynthetic analogues have been made since then. 
Successful examples include docetaxel and cabazitaxel. Paclitaxel and its analogues are 
among the most important additions to the chemotherapeutic arsenal. The binding site of 
paclitaxel is located at the inner surface of the β-subunit [61]. It is presumed that 
paclitaxel exerts its effects of stabilizing the microtubule and increasing tubulin 
polymerization by inducing a conformational change in tubulin [62]. Such 
conformational change increases the affinity of one tubulin molecule for its neighboring 
tubulin molecules.  
 
 
Colchicine Binding Domain 
 
 Colchicine was extracted from the poisonous meadow saffron Colchicum 
autumnale L and is a tubulin destabilizing agents. Colchicine binds to soluble tubulin and 
forms a tubulin–colchicine complex [63-64], which can be incorporated into 
microtubules. It has been shown that binding of colchicine to a site located on β-tubulin 
causes a steric clash between colchicine and α-tubulin, which prevents curved tubulin 
from adopting a straight conformation. This is the possible mechanism of colchicine’s 
activity in inhibiting tubulin assembly. Colchicine has been clinically used to treat gout 
for many years, but neither colchicine nor other colchicine site binding agents have been 
approved for the treatment of cancer until now. Research efforts are now ongoing to 
develop agents targeting colchicine binding site for cancer treatment.  
 
 
Laulimalide Binding Domain 
 
 Laulimalide is a structurally novel cancer therapeutic lead isolated from Pacific 
marine sponges [65]. It stabilizes microtubule and enhances tubulin assembly in a similar 
mode of action as taxol. It was reported that laulimalide was unable to inhibit the binding 
of radiolabeled paclitaxel to tubulin polymer [66], which means it binds to a novel 
binding site distinct from that of paclitaxel. Laulimalide would be the first example of a 
ligand for this site.  
 
 
Existing Tubulin Polymerization Inhibitors 
 
 Existing tubulin polymerization inhibitors are consisted of two groups of agents: 
vinca domain-binding agents and colchicine domain-binding agents. Among vinca 
domain-binding agents, there are several drugs that have been approved for cancer 
treatment, including vinblastine, vincristine, vinorelbine, vinflunine and vindesine [56]. 
However, none colchicine binding site inhibitor (CBSI) has been approved by FDA for 
clinical use in the treatment of cancer. Therefore, there is strong need to develop novel 
anticancer drugs targeting colchicine binding site, which is also the focus of our research. 
In the following part, representative reported CBSIs will be reviewed.  
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CBSIs in Clinical Trials 
 
 In this section, we discuss several CBSIs in clinical trials (Figure 2-3).  
 
 
 Combretastatin A-4  
 
 Combretastatin A-4 (CA-4) was extracted from the bark of the South African 
willow Combretum caffrum and is a potent tubulin and cell growth inhibitor [67]. 
Although CA-4 exhibits potent anti-proliferative activity, its poor aqueous solubility 
impinged its clinical development. Combretastatin A-4 phosphate (CA-4P), which is the 
phosphate form and a prodrug of CA-4, was developed to resolve the solubility issue. 
CA-4P is dephosphorylated to its active metabolite CA-4 in vivo. There are several phase 
II clinical trials going on for the use of CA-4P in the treatment of anaplastic thyroid 
cancer, non-small cell lung cancer, and relapsed ovarian cancer [68]. 
 
 
 2-Methoxyestradiol 
 
 2-Methoxyestradiol (2-ME) is an endogenous estrogen metabolite, formed by 
hepatic cytochrome P450 2-hydroxylation of β-estradiol and 2-O-methylation via 
catechol O-methyltransferase. 2-ME showed potent inhibition of angiogenesis and tumor 
growth [69]. Many studies have been done to elucidate the mechanism for the cytotoxic 
effects of 2-ME [70-71]. Competitive binding studies with [3H] colchicine suggested that 
2-ME inhibited tubulin polymerization by interacting with the colchicine binding site on 
tubulin [72-73]. Because of the potent antiangiogenic activity and tubulin polymerization 
inhibition of 2-ME, several clinical trials for using 2-ME in the treatment of prostate 
cancer, breast cancer and multiple myeloma have been performed [74-76]. Some of the 
adverse effects of 2-ME include fatigue, nausea, diarrhea, neuropathy, edema, and 
dyspnea in these clinical studies. 
 
 
 ABT-751 
 
 ABT-751, also known as E7010, was first reported by Yoshino, et al in 1992 [77]. 
It is a novel sulfonamide antimitotic agent which was shown to inhibit microtubule 
assembly by binding to the colchicine site on tubulin [78]. Such inhibition leads to cell 
cycle arrest at the G2/M phase, resulting in cellular apoptosis. ABT-751 was shown to be 
active against several cancer cell lines that were resistant to vincristine, doxorubicin and 
cisplatin because it is not a substrate for the multiple drug resistance transporter. It also 
displayed good in vivo activity against various human tumor xenografts. Several clinical 
trials for using ABT-751 as a single agent treatment or in combination with other agents 
have been completed [79-81]. Some dose-limiting toxicities of ABT-751 found in the 
clinical trials include abdominal pain, constipation, and fatigue. 
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Figure 2-3. Chemical structures of representative CBSIs in clinical trials 
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 CI-980  
 
 CI-980 is a novel synthetic antimicrotubule agent belonging to the class of 1, 2-
dihydropyrido [3, 4-b] pyrazines. CI-980 bears a chiral center and is the S-isomer form. 
The R-isomer NSC 613863 also showed inhibitory effects of tubulin polymerization and 
tumor cell growth, but the S-isomer CI-980 was more potent [82]. Treatment of cancer 
cells with CI-980 caused arrest in the M-phase of the cell cycle, leading to cell death 
subsequently. This agent has a wide spectrum of antitumor activity, including leukemia, 
melanoma, sarcoma, mammary adenocarcinoma, and colon adenocarcinomas. It has 
entered phase II clinical trial. Neurotoxicity is one major adverse effect of this agent. It 
can cause a significant but reversible decline in recent memory functioning [83]. So the 
cognitive function of patients taking this agent should be closely monitored. 
 
 
 Indibulin  
 
 Indibulin, N-(pyridin-4-yl)-[1-(4-chlorbenzyl)-indol-3-yl]-glyoxyl-amide, was 
identified through a cell-based screening to discover cytotoxic compounds [62]. It is a 
potent microtubule destabilizing agent and blocks cell cycle at G2/M phase specifically. 
This compound exhibited potent anti-proliferative activity against a series of human 
cancer cell lines including SKOV3 ovarian cancer, U87 glioblastoma, and ASPC-1 
pancreatic cancer cells. Animal experiment showed that treatment of rats bearing Yoshida 
AH13 sarcomas with indibulin induced complete tumor regression without systemic 
toxicity observed. Indibulin did not have the neurotoxicity which is associated with 
tubulin targeting agents like paclitaxel or vincristine. It has been found to be able to 
discriminate between mature neuronal tubulin and immature neuronal or nonneuronal 
tubulin [84]. This agent is currently in phase II clinical trials.  
 
 
Reported CBSIs in Preclinical Studies 
 
 With the rapid development of colchicine binding site inhibitors, many structures 
that showed excellent potency and drug-like properties for their preclinical applications 
have been reported. In this section, we will summarize several classes of CBSIs reported 
in preclinical studies. Representative structures for each class are shown in Figure 2-4. 
 
 
 Combretastatin A-4 analogs 
 
 Although CA-4 showed potent anti-proliferative activities, two major problems 
impinged the clinical development of this drug. The first problem of CA-4 is its poor 
aqueous solubility. The other one is due to the cis-olefinic bridge which represents a 
weak point for metabolic stability. The cis-olefinic conformation can easily isomerize to 
the trans- olefinic conformation, which is an inactive form of CA-4. Many CA-4 analogs 
have been developed to overcome the above two problems. Replacement of the olefinic 
bridge with a sulfonate linker generates compound 1. It is a potent inhibitor of tubulin  
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Figure 2-4. Chemical structures of reported CBSIs in preclinical studies 
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polymerization and tumor cell growth. This compound was also active against P-
glycoprotein (Pgp) overexpressing cancer cell lines. A number of CA-4 analogs that uses 
a heterocyclic ring as the linker have also been prepared to restrict the cis-conformation. 
Imidazole (2), 1, 3-oxazole (3), oxazolone (4), triazole (5) and 2-aminothiazole (6) 
linkers have been tried to improve drug-like properties [85]. Compound 2 is the first CA-
4 analog that shows potent oral antitumor activity in vivo. Compounds 6 exhibited anti-
proliferative activity at picomolar concentrations against several tested cancer cell lines 
[86]. Among the linkers, certain five-membered ring systems seem to be the best option 
for modification. 
 
 
 Chalcones 
 
 Chalcone compounds are characterized by bearing an aromatic ketone and an 
enone as the central core. They can be found in many natural products and exhibit various 
biological activities including anti-cancer, anti-inflammatory, and anti-fungi [87-89]. A 
number of studies have shown chalcone compounds are potent microtubule destabilizing 
agents that bind to the colchicine binding site, which is possible mechanism for their 
anticancer activities [90-91]. The biological activities of chalcones are largely attributed 
to α, β-unsaturated ketone moiety, thus modifications on chalcone scaffold mainly focus 
on the two terminal aromatic rings in the screening of active chalcones. MDL-27048 (7) 
and JAI-51 (8) are two examples. MDL-27048 is a potent reversible microtubule 
inhibitor that interacts with the colchicine binding site [92-93]. JAI-51 acted as a 
microtubule destabilizing agent and an inhibitor of the Pgp and exhibited strong potency 
in glioblastoma models [94]. 
 
 
 Sulfonamides  
 
 Sulfonamide drugs have been used in clinical for many years because of their 
various biological activities such as antibacterial, antidiabetic, and antiviral activities. 
Many novel sulfonamides analogs have been reported to show strong antitumor activity 
in recent years. ELR510444 (9) is a novel microtubule disrupting agent that directly 
interacts with the colchicine binding site on tubulin [95]. It potently inhibited cell 
proliferation with an IC50 value of 30.9 nM in MDA-MB-231 cells and disrupted 
endothelial cell shape at a low concentration of 30 nM. In vivo study demonstrated that 
ELR510444 provided significant antitumor efficacy with minimal side effects at daily 
dose of 6 mg / kg. One good thing about ELR510444 is that it does not serve as a 
substrate of the Pgp transporter and thus can possibly circumvent clinically relevant drug 
resistance. 
 
 
 Indole-based compounds 
 
 Many clinically used drugs contain an indole ring in their structures. The indole 
ring is also a structural component of a number of antimitotic agents. A series of tubulin 
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polymerization inhibitors that bear indole moiety have been reported. Arythioindole 
analogs containing 3-(3, 4, 5-trimethoxyphenyl) thio moiety were potent tubulin 
polymerization inhibitors [96-97]. Compound 10 was one of the most potent one among 
reported arythioindole derivatives. It inhibited the growth of MCF-7 cells at IC50 of 13 
nM. Compounds 11 and 12 which replaced the sulfur linker of compound 10 with 
methylene linker and ketone linker were also reported as potent tubulin assembly 
inhibitors. In terms of growth inhibitory effect of MCF-7 cells, sulfur linker was slightly 
better or equivalent than ketone linker, while methylene linker was significantly less 
effective. 
 
2-Aroylindoles is another indole-containing scaffold reported as tubulin assembly 
inhibitors. D-64131 (13) was discovered as a potent antitumor agent from a series of 
synthetic 2-aroylindole derivatives [98]. It displayed high cytotoxicity in HeLa/KB 
cervical, SKOV3 ovarian, and U373 astrocytoma carcinoma cell lines. It acts by 
interfering with the mitotic spindle and destabilizing microtubules, leading to the arrest in 
G2/M phase of the cell cycle. It also showed excellent oral antitumor activity in MEXF 
989 model. BPR0L075 (14) is another potent tubulin polymerization inhibitor belonging 
to this scaffold [99]. It exhibited strong cytotoxic activity in a panel of cancer cell lines, 
including several KB-derived multidrug resistant cell lines, with IC50 values in single-
digit nano-molar ranges. BPR0L075 also displayed potent activity against the growth of 
xenograft tumors including gastric carcinoma MKN-45 and human cervical carcinoma 
KB. 
 
 
Problems with Existing Tubulin Targeting Agents  
 
 Two major problems associated with existing tubulin targeting agents are 
development of drug resistance and the significant toxicity. In the following part, 
mechanisms of drug resistance and toxicities of these agents are discussed.  
 
 
Drug Resistance to Tubulin Targeting Agents 
 
 It is crucial to understand the mechanisms of resistance to microtubule-targeted 
agents in order to develop novel compounds that can overcome multidrug resistance. 
Two known mechanisms for these agents are presented in the following subsections. 
 
 
 ATP binding cassette proteins and drug efflux 
 
 The main resistance mechanism of inherent or developed resistance to 
microtubule-targeted agents is a family of membrane-associated transporters called ATP 
binding cassette (ABC) transporters [56]. These membrane efflux pumps are 
overexpressed in many cancer cell lines. Pgp, which is encoded by the human multidrug 
resistance protein 1(MDR1) gene, was the first one identified in the ABC transporter 
class [100]. The Pgp pump works by actively effluxing antimitotic agents out of cell, 
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thereby decreasing intracellular drug concentrations and leading to cross resistance to 
these drugs. Considerable efforts are ongoing to develop novel tubulin targeting agents 
that are not substrates of these pumps [101-102]. 
 
 
 Alterations in microtubules 
 
 Another mechanism of resistance comes from alterations of the target, the tubulin-
microtubule complex. Modifications of microtubules can affect the binding of 
microtubule-targeted agents to the target. Microtubules are consisted of at least 13 
isotypes of α-tubulin and β-tubulin. The overexpression of class III β-tubulin is an 
indicator of resistance to microtubule-targeted agents such as taxanes [56]. 
 
 
Toxicity of Tubulin Targeting Agents 
 
 Besides drug resistance, the other major problem of tubulin targeting agents is 
their toxicity. Neurological toxicity is the chief issue associated with many tubulin 
targeting agents [103]. The mechanism why these agents are preferentially toxic to 
nervous system is not clearly understood yet. However, two possible reasons can partially 
explain it. First, tubulin is relatively abundant in neurons. Secondly, it is important to 
keep an intact, functional microtubule cytoskeleton for adequate nerve conduction [56]. 
Myeloid toxicity is another frequently observed adverse effect with microtubule-binding 
agents [104]. The possible mutagenic properties of microtubule-binding agents and the 
increase in the risk of secondary tumors by these agents is also a concern. It has been 
described that chromosomal instability and an aneuploid-prone phenotype were 
correlated with response to taxanes [105-106]. 
 
 
Novel Colchicine Binding Site Inhibitors 
 
 Up to now, no antitubulin drug targeting colchicine binding site has entered the 
market. Many research efforts are underway to search novel anticancer agents that 
interact with colchicine binding site. Our group is one of them. We have discovered 
several new scaffolds of tubulin polymerization inhibitors as shown in Figure 2-5. A 
series of 4-substituted methoxy benzoylaryl-thiazoles (SMART) were first discovered 
based on lead compounds 2-arylthiazolidine-4-carboxylic acid amides [107].In order to 
improve the aqueous solubility of SMART compounds, 2-aryl-4-benzoyl imidazoles 
(ABI) and phenyl-aminothiazole (PAT) series were made [108-109]. The ABI scaffold 
replaced the thiazole ring in SMART structure with imidazole ring, which is more 
hydrophilic and has improved aqueous solubility. The PAT template inserted an amino 
linkage between the A ring and B ring of SMART structure. Further optimization of these 
templates is ongoing is our group. 
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Figure 2-5. Novel colchicine binding site inhibitors 
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Summary 
 
 Microtubules are among the most successful anticancer drug targets. A number of 
drugs that target microtubule dynamics have been approved by FDA for cancer treatment, 
including the taxanes, paclitaxel, docetaxel and cabazitaxel, and vinca alkaloids such as 
vinblastine, vincristine and vinorelbine. However, there are several limitations with these 
drugs. First, they generally have poor aqueous solubility. Secondly, they suffer from 
different mechanisms of resistance. The structural complexities of taxanes and vinca 
alkaloids make them difficult to be modified. Colchicine binding site agents have simpler 
structures and are more feasible for modification. Furthermore, several preclinical studies 
suggested that colchicine binding site inhibitors have less susceptibility to ABC 
transporter mediated drug resistance [110-111]. Many anticancer agents that interact with 
the colchicine binding domain have been developed, yet none of them have been 
approved for clinical use. The need to develop more effective, less toxic colchicine 
binding site inhibitors is strong. In Chapter 3, our recent efforts in developing novel 
potent anticancer agents that interact with colchicine binding site will be described. 
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CHAPTER 3.    DISCOVERY OF 4-ARYL-2-BENZOYL-IMIDAZOLES AS 
TUBULIN POLYMERIZATION INHIBITORS WITH POTENT 
ANTIPROLIFERATIVE PROPERTIES* 
 
 
Introduction 
 
 We previously reported the discovery of ABI analogs targeting the colchicine 
binding site in tubulin as potent anti-proliferative agents. [108, 112-116] Compared with 
existing tubulin-targeting agents such as paclitaxel, colchicine, or vinblastine, ABI 
compounds have comparable in vitro and in vivo potency but can effectively circumvent 
several clinically relevant multidrug resistant mechanisms, including drug resistance 
mediated by Pgp, multidrug resistance-associated proteins (MRPs), and breast cancer 
resistant proteins (BCRP). [113-114] ABI compounds have also shown excellent oral 
bioavailability [113], a potential advantage over existing tubulin inhibitors which can 
only be administrated by intravenous injection. To further optimize the potency of ABI 
analogues and to gain further insight in their structure-activity relationships (SAR), we 
designed and synthesized several new series of ABI analogs (summarized in Figure 3-1) 
by introducing three major changes to the parental ABI scaffold as described below.  
 
 First, we varied the substitutions at the para-position on the A-ring of ABI 
analogs. This was accomplished by using previously established synthetic strategies. 
[108, 112, 115] Second, we reversed the two major substitutions on the B-ring to produce 
the 4-aryl-2-benzoyl-imidazoles (reverse ABI, or RABI) compounds. We developed a 
one-pot synthetic strategy to synthesize RABI analogs in good yields based on the 
literature for synthesizing similar scaffold. [117] Finally, we systematically incorporated 
additional substitutions in the B-ring of the RABI analogs to determine molecular 
shape/conformational requirements for their anticancer potency. Biological testing of 
those RABI compounds revealed their excellent anti-proliferative activity against several 
cancer cell lines including multidrug-resistant cancer cell lines. Mechanism of action of 
RABIs was investigated using cell cycle analysis, tubulin polymerization assay, 
competitive mass spectrometry binding assay and molecular modeling. These studies 
showed that their antitumor activity was achieved through the antimitotic effect by the 
inhibition of tubulin polymerization, similar to their parental ABI analogs.  
 
 
Chemistry 
 
 The general synthesis of the A ring modified analogs (5a-c) of ABI compounds is 
outlined in Figure 3-2 using the same protocol as the method reported previously. [108, 
112, 115] The general synthesis of the substituted imidazoles (8a-e) is shown in Figure 
 
-------------------- 
*Modified with permission. Xiao, M.; Ahn, S.; Wang, J.; Chen, J.; Miller, D. D.; Dalton, 
J. T.; Li, W. Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization 
inhibitor with potent anti-proliferative properties. J Med Chem, 2013, 56(8), 3318-3329.  
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Figure 3-1. Design protocol for synthesis of RABI analogs 
 
 
 
 
 
 
Figure 3-2. Synthesis of compounds 5a-5c 
Reagents and conditions: (a) oxalaldehyde, NH4OH, EtOH, 0 
oC-rt; (b) NaH, PhSO2Cl, 
THF, 0 oC-rt; (c) t-BuLi, substituted benzoyl chloride, THF, -78 oC; (d) Bu4NF, THF, rt. 
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3-3. A series of diketones (7a-e) [118] in ethanol reacted with 3, 4, 5-trimethoxy 
benzeneacetaldehyde 6 and ammonium hydroxide to generate a series of substituted 
imidazoles. [119] RABI compounds (11-14) were synthesized utilizing a one-pot, one-
step reaction, which is outlined in Figure 3-4. [117] The arylglyoxal [120] reacts with 3, 
4, 5-trimethoxyphenyl glyoxal in the presence of ammonium acetate in ethanol to give 
four products with similar yields around 20% in one pot. The ratio of compounds 12a-i to 
13a-i is approximately 1:1. Two dimensional 1H-13C heteronuclear multiple bond 
correction spectroscopy (HMBC) NMR experiments were used to distinguish the 
structures between 12a-i and 13a-i. Strategies to incorporate additional substitutions on 
the B-ring of the RABI compounds are shown in Figure 3-5. In Figure 3-5, there are 
three conditions to introduce substitution to the N1-position. In condition a, compound 
12a react with methyl iodide, ethyl bromide, and benzyl bromide in the presence of 
sodium hydride in anhydrous THF to generate compounds 15a-c. [115] In condition b, 
compound 12a reacts with n-propyl iodide, i-propyl iodide and cyclopentyl bromide in 
the presence of potassium carbonate in acetonitrile to generate compounds 15d-f. [121-
122] In condition c, copper iodide, cesium carbonate and a ligand are used to introduce a 
pyridine ring or a thiophene ring to N1-position of compound 12a to make compounds 
15g-h. [123] A similar method to that in Figure 3-4 was employed to synthesize a series 
of 5-substituted RABI compounds (17a-c) as shown in Figure 3-6. 
 
 
Biological Results and Discussion 
 
 All the compounds were evaluated for their cytotoxicity in human melanoma cell 
lines and prostate cancer cell lines. Colchicine, vinblastine and docetaxel, the well-known 
antimitotic agents were included in the assays, serving as positive controls and as basis 
for comparison. 
 
 
Effect of Substitutions on the A Ring of ABI Analogs 
 
 As shown in Table 3-1, compound 5a (average IC50 = 18 nM) maintained potent 
activity in most cancer cells compared with compound 5da [108, 114](average IC50 = 10 
nM) which has a methyl substitution on A ring para position. Introducing a larger 
isopropyl group (5b, average IC50 = 254 nM) into this position on the A ring caused a 20-
fold decrease of potency compared with compound 5da. Further increasing the size of 
this substitution using a tert butyl group to this position resulted in a 100-fold loss of 
activity compared with 5da. The activity trend in terms of para substitution in this A ring 
is Me > Et > H > i-Pr > t-Bu, clearly suggesting a relatively small binding pocket to the 
receptor around the A-ring, with a methyl group being the optimal size. Since A ring 
modification did not generate a more potent compound than 5da, we decided to design 
and synthesize analogs by modifying the B ring. 
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Figure 3-3. Synthesis of compounds 8a-8e 
 
 
 
 
 
 
Figure 3-4. Synthesis of compounds 11-14 
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Figure 3-5. Synthesis of compounds 15a-15h 
Reagents and conditions: (a) NaH, CH3I for 15a, CH3CH2Br for15b and BnBr for 15c; 
(b) K2CO3, ACN, CH3CH2CH2I for 15d, (CH3)2CHI for 15e and cyclopentyl bromide for 
15f; (c) CuI, Cs2CO3, DMF, Ligand, 2-bromo-pyridine for 15g, 2-bromothiophene for 
15h. 
 
 
 
 
 
Figure 3-6. Synthesis of compounds 17a-17c 
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Table 3-1. In vitro growth inhibitory effects of ABI compounds with A ring substitutions 
 
Structure ID R1 
IC50 ± SEM(nM) 
Average 
IC50 
LNCaP PC3 PPC1 DU145 A375 
MDA-MB 
-435 
MDA-MB 
-435/LCC-
6MDR1 
 
5aa H 152 ± 35 288 ± 30 133 ± 6 196 ± 29 160 ± 20 ND ND 186 
5da Me 12 ± 1 9 ± 0.4 15 ± 1 11 ± 0.1 9 ± 2 5 ± 1 11 ± 2 10 
5a Et 9 ± 1 13 ± 1 15 ± 1 25 ± 2 14 ± 5 25 ± 4 27 ± 3 18 
5b i-Pr 171 ± 34 136 ± 20 173 ± 0.3 482 ± 40 ND 312 ± 4 250 ± 4 254 
5c t-Bu 423 ± 71 436 ± 115 294 ± 2 1698 ± 400 ND 3691 ± 60 3074 ± 50 1603 
 
Note: ND: Not Determined. Dr. Sunjoo Ahn and Dr. Jin Wang performed the biological testing in this table.  
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The Ketone Linker Remains Critical for RABI Analogs 
 
 We previously reported that a ketone linker is essential for the activity of the 
parental ABI and its related analogs [107]. To test whether this is still a critical 
requirement, we synthesized five RABI analogs containing a methylene linker instead of 
a carbonyl linker (Figure 3-3). The biological activity of these five compounds was 
shown in Table 3-2. All of them were basically inactive, consistent with results reported 
previously which indicated the essential role of the carbonyl linker.  
 
 
Effect of Substitutions on the A Ring of RABIs 
 
 After confirming the essential role of the carbonyl linker in the RABI analogs, we 
converted the methylene linker to carbonyl linker using a slightly modified approach as 
shown in Figure 3-4 and produced RABI analogs 11-13. All RABI compounds were 
evaluated for their anti-proliferative activity and the results were shown in Table 3-3. 
Compound 12a was most potent with IC50 values ranging from 6 to 24 nM. Introducing 
an electron withdrawing group with increasing sizes to the para position on the A ring (4-
fluro, 4-chloro, 4-bromo and 4-trifluromethyl) generally decreased activity (compare 
12b-e with 12a). Among the three halogen substituted RABI compounds, the trend of 
activity was F< Cl< Br. Introduction of an electron donating group such as methyl to the 
compound maintained the activity (12f, IC50: 10-27 nM), while the introduction of 
methoxy and dimethylamino group caused loss of activity to some extent (12g, IC50: 30-
210 nM; 12h, IC50: 96-263 nM). Compound 12i with phenol group as A ring was the 
least potent one among compounds 12a-12i. These results are consistent with the SAR 
identified in the parental ABI analogs (Table 3-1 and earlier studies [108, 115]). 
 
 
Effect of Substitutions on the C Ring of RABIs  
 
 Several RABI compounds (11a-11i) which did not have the 3, 4, 5-trimethoxy 
moiety on C ring showed poor activity as shown in Table 3-3. The RABI compounds 
with unsubstituted phenyl ring as A ring and C ring caused complete loss of activity (11a, 
IC50> 50 μM). Compounds with a single halogen substituent in the para position of A and 
C rings lost activity completely (IC50> 5 μM for 11b-d). When methyl, methoxy, 
trifluoromethyl, dimethylamino, or hydroxyl was introduced to the para position of the A 
and C rings, the activity was also lost. All these results suggested the essential role of 3, 
4, 5-trimethoxy substituents on the C ring. Interestingly, when 3,4,5-trimethoxy group 
was put on the A ring, the activity of two compounds 13a and 13d returned to some 
extent (13a, IC50: 195-5770 nM; 13d, IC50: 131-429 nM) even though there is no 3,4,5-
trimethoxy substituents on C ring, perhaps suggesting that the orientation of the 
compound changed when binding to tubulin. One results worth noting is that when 3, 4, 
5-trimethoxy group was introduced to both A ring and C ring, the activity was lost 
completely. This is consistent with results in previous sections that a bulky A-ring 
containing a 3, 4, 5-trimethoxy moiety cannot be tolerated at the receptor.  
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Table 3-2. In vitro growth inhibitory effects of RABI compounds with methylene 
linker 
 
Structure ID R1 
IC50 ± SEM (μM) 
A375 
MDA-MB-
435 
MDA-MB-
435/LCC-
6MDR1 
 
8a H 10.2 ± 0.4 ND ND 
8b Me > 50 ND ND 
8c Et ND > 50 > 50 
8d n-Pr ND 10.9 ± 0.1 15.9 ± 0.2 
8e Ph ND > 50 > 50 
 
Note: ND: Not Determined. Dr. Jin Wang performed the biological testing in this table. 
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Table 3-3. In vitro growth inhibitory effects of RABI compounds without B ring substitution 
 
Structure ID R1 R2 
IC50 ± SEM(nM) 
LNCaP PC3 PPC1 DU145 A375 WM164 
MDA-MB-
435 
MDA-MB-
435/LCC 
-6MDR1 
 
11a H H > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 
11b F F > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 
11c Cl Cl > 50000 > 50000 > 50000 > 50000 
35674 ± 
665 
> 50000 > 50000 > 50000 
11d Br Br 
16930 ± 
6183 
18940 ± 
1068 
13210 ± 
706 
25490 ± 
5144 
24960 ± 35 
26320 ± 
211 
14355 ± 
178 
17814 ± 
155 
11e CF3 CF3 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 
26460 ± 
533 
11f Me Me 
3762 ± 
1720 
5159 ± 386 2405 ± 308 6541 ± 460 2535 ± 30 3693 ± 18 3020 ± 23 3271 ± 33 
11g OMe OMe 
6419 ± 
4365 
23370 ± 
1471 
38150 ± 
2325 
9839 ± 503 > 50000 > 50000 > 50000 > 50000 
11h N(CH3)2 N(CH3)2 ND ND ND ND > 50000 > 50000 > 50000 > 50000 
11i OH OH ND ND ND ND 38769 ± 97 
48218 ± 
113 
47986 ± 
104 
21421 ± 93 
12a H 3,4,5-(OMe)3 6 ± 1 14 ± 1 13 ± 0.3 22 ± 2 9 ± 6 14 ± 3 24 ± 3 11 ± 2 
12b F 3,4,5-(OMe)3 114 ± 7 196 ± 6 134 ± 0.1 353 ± 10 197 ± 15 298 ± 13 320 ± 14 263 ± 10 
12c Cl 3,4,5-(OMe)3 22 ± 6 64 ± 7 51 ± 1 125 ± 12 51 ± 13 63 ± 11 106 ± 15 75 ± 11 
12d Br 3,4,5-(OMe)3 15 ± 5 33 ± 2 30 ± 1 66 ± 2 29 ± 7 31 ± 4 58 ± 14 43 ± 11 
12e CF3 3,4,5-(OMe)3 47 ± 35 93 ± 3 74 ± 2 210 ± 18 123 ± 18 143 ± 8 120 ± 15 175 ± 9 
12f CH3 3,4,5-(OMe)3 13 ± 1 19 ± 1 18 ± 0.3 30 ± 4 13 ± 2 14 ± 3 27 ± 11 21 ± 5 
12g OMe 3,4,5-(OMe)3 30 ± 14 61 ± 4 54 ± 1 210 ± 147 33 ± 8 41 ± 12 55 ± 9 59 ± 18 
12h N(CH3)2 3,4,5-(OMe)3 96 ± 6 118 ± 17 120 ± 12 263 ± 16 141 ± 23 129 ± 19 200 ± 20 162 ± 12 
12i OH 3,4,5-(OMe)3 219 ± 101 155 ± 23 122 ± 6 518 ± 10 487 ± 35 549 ± 24 669 ± 31 455 ± 29 
13a 3,4,5-(OMe)3 H 195 ± 91 632 ± 42 408 ± 11 1301 ± 264 1023 ± 23 1273 ± 30 4606 ± 78 5770 ± 63 
13d 3,4,5-(OMe)3 Br 131 ± 175 371 ± 247 106 ± 3 429 ± 0.2 136 ± 12 177 ± 16 186 ± 11 161 ± 11 
13g 3,4,5-(OMe)3 OMe 708 ± 334 
10390 ± 
6646 
5685 ± 325 > 50000 
35414 ± 
106 
36007 ± 98 10956 ± 96 11428 ± 87 
13h 3,4,5-(OMe)3 N(CH3)2 ND ND ND ND 
47878 ± 
563 
46131 ± 98 29175 ± 88 
40618 ± 
112 
13i 3,4,5-(OMe)3 OH ND ND ND ND > 50000 > 50000 > 50000 > 50000 
14 3,4,5-(OMe)3 3,4,5-(OMe)3 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 > 50000 
 
Note: ND: Not Determined. Dr. Sunjoo Ahn and Dr. Jin Wang performed the biological testing in this table. 
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Effect of Substitutions on the B Ring of RABIs  
 
 Modifications on the B ring in two different sites were investigated: the N1- and 
5-position of the imidazole ring. Introducing methyl, ethyl, or propyl at the 5-position of 
the imidazole ring resulted in inactive compounds (17a-c) as shown in Table 3-4. A trend 
in activity for the substituted alkyl groups: Me> Et> Pr, was also observed, which 
suggests big bulky groups at this position are detrimental to activity. In contrast, when 
different substitution groups were introduced to the N1-position of the imidazole ring, the 
activity was maintained with only minimal loss compared with the parent compound, 
12a. First some alkyl groups were tried on the N1-position including methyl, ethyl, n-
propyl, i-propyl and cyclopentyl groups. Introduction of methyl did not affect the activity 
compared with 12a (15a, IC50: 9-26 nM), while the activity began to lose as the size of 
the alkyl groups increased, suggesting that a bulky alkyl group at this position was 
unfavorable. Benzyl group, which was also a relatively big group at the N1-position of 
the imidazole ring, decreased the activity (15c, IC50: 34-160 nM). Surprisingly, when the 
substituents were changed from alkyl groups to heterocyclic rings, the ‘effect of big size’ 
disappeared. The introduction of a pyridine ring to the N1-position generated a very 
potent compound with IC50 ranging from 6 to 37 nM. The introduction of a thiophene 
ring also produced a potent compound with IC50 ranging from 8 to 20 nM. The excellent 
activity of 15g and 15h promises the future optimization at this position using other ring 
systems. 
 
 
Effect of RABI Compounds against Multidrug-Resistant Melanoma Cells 
 
 Pgp-mediated drug efflux represents a major mechanism for cancer cells to 
prevent the buildup of effective intracellular drug concentrations. We have previously 
shown that the parent ABI analogs can effectively overcome a variety of clinically 
relevant multidrug resistant mechanisms including Pgp-mediated drug resistance. [113-
114] To determine whether the new RABI analogs maintain this ability, we compared the 
activity of the RABI compounds against multidrug-resistant melanoma cells (MDA-MB-
435/LCCMDR1) and their parental nonresistant cancer cells (MDA-MB-435). This pair 
of cell lines have been well validated and widely used to assess abilities of drugs 
overcoming Pgp-mediated multidrug resistance. [124-127] Compound 12a, 12d and 12e 
together with colchicine, vinblastine and paclitaxel were tested on both the multidrug 
resistant melanoma cells and their parental melanoma cell lines (Table 3-5). Compound 
12a, 12d and 12e showed much better resistance index (0.5 for 12a, 0.7 for 12d, 0.8 for 
12e) than colchicine (58.5), vinblastine (27.5) and paclitaxel (69.3). Although colchicine, 
vinblastine, and paclitaxel showed excellent activity in nonresistant melanoma cell lines, 
they were much less potent in resistant melanoma cell lines. In contrast, compounds 12a, 
12d and 12e showed comparable or even better activity against Pgp-overexpressed 
melanoma cells than their parental, nonresistant melanoma cells. 
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Table 3-4. In vitro growth inhibitory effects of RABI compounds with B ring substitution 
 
Structure ID R1 R2 
IC50 ± SEM(nM) 
LNCaP PC3 PPC1 DU145 A375 WM164 
MDA-
MB-435 
MDA-
MB-
435/LCC
-6MDR1 
 
15a Me H 10 ± 1 16 ± 1 13 ± 0.2 26 ± 3 9 ± 2 33 ± 5 16 ± 2 18 ± 2 
15b Et H 29 ± 20 25 ± 4 30 ± 8 66 ± 2 28 ± 3 16 ± 3 26 ± 3 33 ± 4 
15c Bn H 66 ± 6 72 ± 5 77 ± 2 160 ± 41 104 ± 17 34 ± 7 94 ± 18 156 ± 18 
15d n-Pr H 49 ± 10 26 ± 6 10 ± 4 72 ± 13 42 ± 3 14 ± 3 37 ± 2 44 ± 4 
15e i-Pr H 62 ± 8 53 ± 9 15 ± 3 114 ± 20 38 ± 4 23 ± 5 18 ± 3 44 ± 4 
15f  H 51 ± 6 56 ± 1 63 ± 4 167 ± 16 135 ± 13 56 ± 13 134 ± 15 161 ± 19 
15g  H 20 ± 5 11 ± 3 8 ± 2 37 ± 6 14 ± 3 6 ± 1 11 ± 3 15 ± 5 
15h  H ND ND ND ND 20 ± 2 8 ± 2 25 ± 3 27 ± 3 
17a H Me 938 ± 65 
1617 ± 
144 
860 ± 5 
2001 ± 
163 
1302 ± 
106 
1897 ± 
116 
1634 ± 
102 
1586 ± 
104 
17b H Et 
2029 ± 
880 
3654 ± 
192 
2078 ± 
90 
5079 ± 
635 
2151 ± 
48 
5514 ± 
35 
8795 ± 
23 
5114 ± 
27 
17c H n-Pr 
3094 ± 
330 
12360 ± 
7566 
11410 ± 
5918 
16350 ± 
6724 
36977 ± 
73 
19595 ± 
91 
30540 ± 
103 
14270 ± 
362 
 
Note: ND: Not Determined. Dr. Sunjoo Ahn and Dr. Jin Wang performed the biological testing in this table. 
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Table 3-5. In vitro growth inhibitory effects of RABI compounds comparison to 
other anticancer drugs on multidrug-resistant melanoma cell and parent cell line 
 
ID 
IC50 ± SEM (nM) 
MDA-MB-435 
MDA-MB-
435/LCC-
6MDR1 
Resistance 
Index 
12a 24 ± 3 11 ± 2 0.5 
12d 58 ± 14 43 ± 11 0.7 
12e 27 ± 11 21 ± 5 0.8 
colchicine 11 ± 2 643 ± 9 58.5 
vinblastine 0.4 ± 0.1 11 ± 1 27.5 
paclitaxel 4 ± 1 277 ± 41 69.3 
 
Note: Dr. Jin Wang performed the biological testing in this table. 
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Mechanism of Action Studies on RABIs 
 
 Since the parental ABI analogs kill cancer cells by inhibiting mitotic process, we 
hypothesized that RABIs maintain their mechanism of action. To test this hypothesis, we 
first performed the cell cycle analysis after the treatment of RABIs on PC3 cells. Cell 
cycle distribution was determined by propidium iodide (PI) staining. Treated cells were 
fixed with 70% ice-cold ethanol and the fixed cells were stained with PI in the presence 
of RNase A. Cell cycle distribution was analyzed by fluorescence-activated cell sorting 
(FACS) analysis. Compounds 5a, 12a, 12d, 12f, 15a, and 15b were treated on PC3 cells 
for 24 h. Four different concentrations 1, 10, 50, and 100 nM of each compound were 
chosen to examine the dose effect. Results indicated that RABIs arrest cells in the G2/M 
phase (Figure 3-7A). In the vehicle treated group, about 18% of PC3 cells were 
distributed in the G2/M phase. RABIs increased the proportion of cells in G2/M phase up 
to 70% approximately in a concentration-dependent manner (Figure 3-7B). The potency 
of the different concentrations in arresting cells in the G2/M phase positively correlated 
with in vitro cell growth inhibitory activity. 
 
 Based on their effect on cell cycle distribution, we next investigated the effect on 
tubulin polymerization of RABI analogs. To determine the effect of drug on tubulin 
polymerization, a fluorescence-enhanced tubulin polymerization assay kit was used. The 
control drug, vinblastine inhibited tubulin polymerization and destabilized microtubule, 
while paclitaxel promoted microtubule stability (Figure 3-8). RABI compounds, 12a and 
15a inhibited tubulin polymerization as the tubulin destabilizer, vinblastine in a 
concentration-dependent manner (Figure 3-8) and 15a showed more potent inhibitory 
effect than 12a. In the competitive mass spectrometry binding assay, the amount of 
unbound colchicine in the presence or absence of any competitor would explain whether 
there is the competition of compounds and colchicine to bind in tubulin. 12a and 15g 
competed effectively with colchicine for tubulin binding (Figure 3-9) with potency 
similar to podophyllotoxin. Vinblastine, the negative control, did not inhibit colchicine 
binding to tubulin. Collectively, these data confirmed that new RABI analogs maintain 
their anti-mitotic mechanisms of action, most likely binding to the colchicine binding site 
in tubulin, as is the case for the parental ABI analogs. [114-115]  
 
 
Molecular Modeling Studies 
 
 One surprising results from the analysis of the SAR for the RABI analogs is that 
incorporating a 5- or 6-membered heterocyclic ring substitution at the N1-position in the 
B-ring produced highly active compounds, while both similar-sized alkyl substitutions or 
a larger benzyl substitution resulted in significantly reduced activity (Table 3-4). To 
better understand how the N1-substituted RABI analogues interact with tubulin, the 
potential binding modes for two of the most potent compounds, 12a and 15g, were 
investigated at colchicine binding site in tubulin dimer using Schrodinger 2011 molecular 
modeling suite (Schrodinger, Inc., New York, NY). Both compounds were docked into 
two different tubulin crystal structure (PDB ID code: 1SA0 or 3HKD), representing two 
potential binding geometries for colchicine site ligands. Interestingly, non-substituted   
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Figure 3-7. Effect of compounds 5a, 12a, 12d, 12e, 15a and 15b on cell cycle 
Note: Dr. Sunjoo Ahn performed the experiments for this figure. 
 
 
  
 38 
 
 
Figure 3-8. Effect of RABI compounds on tubulin polymerization in vitro 
Note: Dr. Sunjoo Ahn performed the experiments for this figure. 
 
 
 
 
 
 
Figure 3-9. Competitive mass spectrometry binding assay 
RABI compounds competitively bound to the colchicine-binding site on tubulin. 
Podophyllotoxin is a known ligand binding to the colchicine site in tubulin and serves as 
a positive control. Vinblastine binds to a different site in tubulin and serves as a negative 
control. 
Note: Dr. Sunjoo Ahn performed the experiments for this figure. 
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RABI analog 12a demonstrated best glide docking score of -9.2 in 3HKD compared with 
a score of -6.4 in 1SA0, while substituted RABI analog 15g showed best glide score of -
9.0 in 1SA0 and could not fit into the binding pocket of 3HKD. 
 
 The overview of the binding site of 12a and TN-16 (native ligand of 3HKD) is 
shown in Figure 3-10A. This binding pocket is located on the interface between the α- 
and β-subunits of the tubulin dimer and extended slightly out of the β-subunit.[128-129] 
Figure 3-10B illustrated the close view of the potential binding pose. Generally, 12a 
(green stick) overlapped well with TN-16 (blue stick). The A ring of 12a went deep into 
the pocket and overlapped very well with the first phenyl ring of TN-16. There are very 
little space between the A-ring and its surrounding amino acids in the β-subunit (Figure 
3-10B), and this explains why little tolerance is allowed for larger substitution in the A-
ring for both ABI and RABI compounds. The imidazole ring overlapped well with the 
pyrrolidinedione ring of TN-16. A potential hydrogen bond is formed between the 
imidazole NH of 12a and VAL238 in β-H7 (Figure 3-10B), similar to the one formed 
between the native ligand TN-16 and VAL238 in β-H7. This hydrogen bond stabilized 
the interaction of 12a with the binding pocket. The 3, 4, 5-trimethoxybenzoyl group (C 
ring) of 12a extends toward the α/β-tubulin interface, similar to the mode of the active 
parental ABI analogs.[112, 115]  
 
 Unlike 12a which does not possess a large N1-substitution, the much “fatter” 
RABI 15g cannot fit into the cylinder shaped binding pocket in 3HKD, but dock 
reasonably well into the shallower pocket in 1SA0. The potential binding mode of 15g 
was shown in Figure 3-10C and Figure 3-10D. Figure 3-10C showed the general view 
of the binding site of 15g and the native ligand colchicine in 1SA0. Figure 3-10D 
illustrated the closed view of the potential binding pose. Interestingly, in this binding 
mode, part of 15g (green stick) overlapped well with the native ligand colchicine (blue 
stick), while the original A ring of 15g extended out of the colchicine binding pocket into 
the α/β-tubulin interface. The pyridine ring substitute on the N1- position occupied the 
site where the 7-membered ring in colchicine binds, while the 3,4,5-trimethoxybenzoyl 
group (C ring) of 15g overlapped very well with the 3,4,5-trimethoxyphenyl ring in 
colchicine. A hydrogen bond between the oxygen of 4-OMe in 15g and SH group of β-
CYS241 stabilized the interaction. A similar hydrogen bond was also observed between 
the oxygen of one methoxy group in colchicine and SH of β-CYS241. This binding mode 
is well consistent with the SAR observed for substituted RABI compounds: a smaller, 
alkyl substitution could not fill this region of the binding pocket and lacks the planar 
geometry required for binding, while too large benzyl substitution could not fit into the 
pocket and also lacks the needed geometry. A 5- or 6-membered heterocyclic ring has the 
desirable shape and size to fit into the pocket well. These data also suggest that while the 
original “A ring” may not be critical for binding when a suitable N1-substitution is 
present, an optimized substitution replacing this original A ring moiety may take 
advantage of the added interactions between the ligand and receptor and provide even 
better ligand than 15g. 
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Figure 3-10. Binding modes of compounds 12a and 15g 
(A) The overview of the binding modes of 12a and the native ligand TN-16 in tubulin 
crystal structure 3HKD. (B) The close view of the potential binding pose of 12a and TN-
16 in 3HKD. (C) The overview of the binding modes of 15g and the native ligand 
colchicine in tubulin crystal structure 1SA0.(D) The close view of the potential binding 
pose of 15g and colchicine in 1SA0. 
Note: Dr. Jin Wang performed the studies for this figure. 
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Experimental Section 
 
 
General 
 
 All reagents were purchased from Sigma-Aldrich Chemical Co., Fisher Scientific 
(Pittsburgh, PA), Alfa Aesar (Ward Hill, MA), and AK Scientific (Mountain View, CA) 
and were used without further purification. Routine thin layer chromatography (TLC) 
was performed on aluminum-backed Uniplates (Analtech, Newark, DE). NMR spectra 
were obtained on a Varian Inova-500 spectrometer (Agilent Technologies, Santa Clara, 
CA) or a Bruker Ascend 400 (Billerica, MA) spectrometer. Chemical shifts are reported 
as parts per million (ppm) relative to TMS in CDCl3. High Resolution Mass spectra were 
collected on a Waters Xevo G2-S Tof instrument. The purity of the final compounds was 
tested via Agilent series HPLC system (Agilent 1100 Series, Agilent 1100 Chemstation, 
Agilent Technology Co, Ltd.) installed with a photodiode array detector. Four RP-HPLC 
methods were conducted using a Phenomenex 5 μm C-18 column (250 mm × 4.6 mm) at 
ambient temperature and a flow rate of 1.0 mL/min. HPLC1: solvent A (water) and 
solvent B (methanol), 0-30 min 90% B. HPLC2: solvent A (water) and solvent B 
(methanol), 0-30 min 85% HPLC3: solvent A (water) and solvent B (methanol), 0-30 min 
80% B. HPLC4: solvent A (water) and solvent B (methanol), 0-15 min 50-100% B 
(linear gradient), 15-25 min 100% B, 25-28 min 100-50% B, 28-33 min 50% B. UV 
detection at 254 nm. Purities of the compounds were established by careful integration of 
areas for all peaks detected and are reported for each compound in the following section.  
 
 
General Procedure for the Preparation of 2a-c 
 
 To a solution of appropriate benzaldehyde 1 (100 mmol) in ethanol (350 mL) at 0 
oC was added a solution of 40% oxalaldehyde in water (12.8 mL,110 mmol) and a 
solution of 29% ammonium hydroxide in water (1000 mmol, 140 mL). After stirring for 
2-3 days at room temperature, the reaction mixture was concentrated and the residue was 
subjected to flash column chromatography with dichloromethane as eluent to yield the 
titled compound as a yellow powder. Yield: 20-40%. 
 
 
General Procedure for the Preparation of 3a-c 
 
 To a solution of 2-aryl-1H-imidazole 2 (20 mmol) in anhydrous THF (200 mL) at 
0°C was added sodium hydride (60% dispersion in mineral oil, 1.2 g, 30 mmol) and 
stirred for 30 min. Benzenesulfonyl chloride (2.82 mL, 22 mmol) was added, and the 
reaction mixture was stirred overnight. After dilution by 100 mL of saturated NaHCO3 
solution (aqueous), the reaction mixture was extracted by ethyl acetate (500 mL). The 
organic layer was dried over magnesium sulfate and concentrated. The residue was 
purified by flash column chromatography (hexane: ethyl acetate 2:1) to give a pale solid. 
Yield: 40-50%. 
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General Procedure for the Preparation of 4a-c 
 
 To a solution of 2-aryl-1-(phenylsulfonyl)-1H-imidazole (6.0 mmol) 3 in 
anhydrous THF (30 mL) at -78 oC was added 1.7 M tert-butyl lithium in pentane (5.3 mL, 
9.0 mmol) and stirred for 10 min. Appropriate substituted benzoyl chloride (7.2 mmol) 
was added at -78 oC and stirred for overnight. The reaction mixture was diluted with100 
mL of saturated NaHCO3 solution (aqueous) and extracted by ethyl acetate (200 mL). 
The organic layer was dried over magnesium sulfate and concentrated. The residue was 
purified by flash column chromatography (hexane: ethyl acetate 4:1) to give a white 
solid. (Note. Due to the limited amount of starting material or the difficulty of separation, 
the following products formed in this step were used without further purification as a 
mixture for the next step. Yield: 15%-40%. 
 
 
General Procedure for the Preparation of 5a-c 
 
 To a solution of aryl (2-aryl-1-(phenylsulfonyl)-1H-imidazol-4-yl) methanone 
(2.0 mmol) 4 in THF (20.0 mL) was added 1.0 M tetrabutyl ammoniumfluoride (4.0 
mmol) and stirred overnight. The reaction mixture was diluted by 50 mL of saturated 
NaHCO3 solution (aqueous) and extracted by ethyl acetate (100 mL). The organic layer 
was dried over magnesium sulfate and concentrated. The residue was purified by flash 
column chromatography (hexane: ethyl acetate 3:1) or recrystallized from water and 
methanol to give a white solid. Yield: 80-95%. 
 
(2-(4-Ethylphenyl)-1H-imidazol-4-yl)(3, 4, 5-trimethoxyphenyl) methanone 
(5a). 1H NMR (500 MHz, CDCl3) δ 10.40 (br, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.85 (s, 1H), 
7.36 (d, J = 8.0 Hz, 2H), 7.27 (s, 2H), 3.99 (s, 3H), 3.97 (s, 6H), 2.75 (q, d = 7.5 Hz, 2H), 
1.313(t, d=7.5Hz,3H); Exact Mass for C21H22N2O4: 366.158; HRMS: [M+H]
+: 367.1764; 
HPLC1: tR 4.97 min, purity 97.8%. 
 
(2-(4-Isopropylphenyl)-1H-imidazol-4-yl)(3, 4, 5-trimethoxyphenyl) 
methanone (5b). 1H NMR (500 MHz, CDCl3) δ 10.38 (br, 1H), 7.82 (d, J = 8.0 Hz, 2H), 
7.75 (s, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.15 (s, 2 H), 3.88 (s, 3H), 3.86 (s, 6H), 2.90 (m, 
1H), 1.331(d, d = 6.5Hz, 6H); Exact Mass for C22H24N2O4: 380.1700; HRMS: [M+H]
+: 
381.1818; HPLC1: tR 5.26 min, purity 97.5%. 
 
(2-(4-Tertbutylphenyl)-1H-imidazol-4-yl)(3, 4, 5-trimethoxyphenyl) 
methanone (5c). 1H NMR (500 MHz, CDCl3) δ 10.42 (br, 1 H), 7.94 (d, J = 8.0 Hz, 2H), 
7.84 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.25 (s, 2H), 3.98 (s, 3H), 3.96 (s, 6H), 1.385(s, 
9H); Exact Mass for C23H26N2O4: 394.1900; HRMS: [M+H]
+: 395.2054; HPLC2: tR 7.75 
min, purity >99%. 
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General Procedure for the Preparation of 8a-e 
 
 To a solution of the aldehyde 6 (5 mmol) in ethanol (20 mL) at 0°C was added the 
phenyl alkyl dione 7 (5.5 mmol) and a solution of 29% ammonium hydroxide in water 
(50 mmol, 7 mL). After stirring for 2-3 days at room temperature, the reaction mixture 
was concentrated and the residue was subjected to flash column chromatography with 
dichloromethane as eluent to yield the titled compound as a yellow powder. Yield: 20-
30%. 
 
5-Phenyl-2-(3, 4, 5-trimethoxybenzyl)-1H-imidazole and 4-phenyl-2-(3, 4, 5-
trimethoxybenzyl)-1H-imidazole (8a). 1H NMR (500 MHz, Chloroform-d) δ 7.91 – 
7.62 (m, 2H), 7.43 – 7.34 (m, 2H), 7.27 – 7.21 (m, 2H), 6.51 (s, 2H), 4.12 (s, 2H), 3.86 
(s, 3H), 3.84 (s, 6H); Exact Mass for C19H20N2O3: 324.1500; HRMS: [M+H]
+: 325.1684. 
 
5-Methyl-4-phenyl-2-(3, 4, 5-trimethoxybenzyl)-1H-imidazole and 4-methyl-
5-phenyl-2-(3, 4, 5-trimethoxybenzyl)-1H-imidazole (8b). 1H NMR (500 MHz, 
Chloroform-d) δ 7.55 (d, J = 7.6 Hz, 2H), 7.43 – 7.37 (m, 2H), 7.25 (d, J = 6.7 Hz, 1H), 
6.49 (s, 2H), 4.03 (s, 2H), 3.84 (d, J = 1.3 Hz, 3H), 3.81 (d, J = 1.2 Hz, 6H), 2.42 (s, 3H); 
Exact Mass for C20H22N2O3: 338.1600; HRMS: [M+H]
+: 339.1799. 
 
5-Ethyl-4-phenyl-2-(3,4,5-trimethoxybenzyl)-1H-imidazole and 4-ethyl-5-
phenyl-2-(3,4,5-trimethoxybenzyl)-1H-imidazole (8c). 1H NMR (500 MHz, 
Chloroform-d) δ 8.47 (s, 0.42H), 8.39 (s, 0.58H), 7.86 – 7.62 (m, 2H), 7.41 (m, 2H), 7.35 
– 7.31 (m, 1H), 6.54 (m, 2H), 4.10 (m, 2H), 3.90 – 3.83 (m, 9H), 2.79 (m, 2H), 1.38 – 
1.17 (m, 3H); Exact Mass for C21H24N2O3: 352.1800; HRMS: [M+H]
+: 353.1912. 
 
4-Phenyl-5-propyl-2-(3,4,5-trimethoxybenzyl)-1H-imidazole and 5-phenyl-4-
propyl-2-(3,4,5-trimethoxybenzyl)-1H-imidazole (8d). 1H NMR (400 MHz, 
Chloroform-d) δ 8.63 (s, 0.48H), 8.50 (s, 0.52H), 7.70 – 7.64 (m, 1H), 7.41 (m, 3H), 7.37 
– 7.32 (m, 1H), 6.52 (d, J = 1.3 Hz, 2H), 4.08 (d, J = 5.1 Hz, 2H), 3.87 (m, 3H), 3.86 – 
3.84 (m, 6H), 2.73 (m, 2H), 1.88 – 1.75 (m, 1H), 1.64 (m, 1H), 0.98 (m, 3H); Exact Mass 
for C22H26N2O3: 366.1900; HRMS: [M+H]
+: 367.2011. 
 
4, 5-Diphenyl-2-(3,4,5-trimethoxybenzyl)-1H-imidazole (8e). 1H NMR (400 
MHz, Chloroform-d) δ 7.44 – 7.36 (m, 4H), 7.28 – 7.20 (m, 6H), 6.50 (s, 2H), 4.08 (s, 
2H), 3.78 (m, 9H); Exact Mass for C25H24N2O3: 400.1800; HRMS: [M+H]
+: 401.1977. 
 
 
General Procedure for the Preparation of 11-14 
 
 To ammonium acetate (10 mmol) in ethanol (5 ml) and water (0.3 ml) was added 
arylglyoxal hydrate 9 (1 mmol) in ethanol (5 ml) and 3, 4, 5-trimethoxyphenyl glyoxal 
hydrate 10 (1 mmol) in ethanol (10 ml). The mixture was stirred at room temperature for 
30-45 min. The reaction was stopped after the consumption of the starting material 
monitored by TLC. The mixture was then extracted with ethyl acetate. The organic layer 
was washed with brine, dried over anhydrous sodium sulfate and concentrated to get the 
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crude product. The crude was purified by flash chromatography (dichloromethane: 
methanol 50:1). 
 
Phenyl-(4-phenyl-1H-imidazol-2-yl) methanone and phenyl-(5-phenyl-1H-
imidazol-2-yl) methanone (11a). 1H NMR (500 MHz, DMSO-d6): d 13.80 (s, 0.25H), 
13.63 (s, 1H), 8.60 (d, J = 7.76 Hz, 2H), 8.47 (d, J = 7.7 Hz, 0.5H,),8.08 (s, 1H,), 7.97 (d, 
J = 7.95 Hz, 0.5H), 7.94 (d, J = 7.64 Hz, 2H), 7.79(s, 0.25H), 7.69 (t, J = 7.1 Hz, 1H), 
7.66 (t, J = 7.6 Hz, 0.25H), 7.60 (t, J = 7.6 Hz, 2H), 7.57 (t, J = 8.1 Hz, 0.5H), 7.47 (t, J = 
7.55 Hz, 0.5H), 7.42 (t, J = 7.7 Hz, 2H), 7.37 (t, J = 7.1 Hz, 0.25H), 7.28 (t, J = 7.3 Hz, 
1H); Exact Mass for C16H12N2O: 248.095; HRMS: [M+H]
+: 249.1058; HPLC4: tR 10.83 
min, purity 97.6%. 
 
(4-Fluorophenyl)(4-(4-fluorophenyl)-1H-imidazol-2-yl)methanone and (4-
fluorophenyl)(5-(4-fluorophenyl)-1H-imidazol-2-yl)methanone (11b). 1H NMR (400 
MHz, Chloroform-d) δ 10.68 (s, 1H), 10.52 (s, 1H), 8.93 – 8.82 (dd, J = 5.89, 8.64 Hz, 
2H), 8.72 (dd, J = 5.60, 8.70 Hz, 0.39H), 7.89 (dd, J = 5.39, 8.72 Hz, 2H), 7.63 (dd, J = 
5.05, 8.25 Hz, 0.46H), 7.59 (d, J = 2.2 Hz, 0.29 H), 7.55 ( d, J = 2.8 Hz, 1H) 7.25-7.20 
(m, 2H), 7.20 – 7.13 (m, 2H); Exact Mass for C16H10F2N2O: 284.0761; HRMS: [M+H]+: 
285.0830; HPLC4: tR 13.97 min, purity 98.0%. 
 
(4-Chlorophenyl)(4-(4-chlorophenyl)-1H-imidazol-2-yl)methanone and (4-
chlorophenyl)(5-(4-chlorophenyl)-1H-imidazol-2-yl)methanone(11c). 1H NMR (400 
MHz, Chloroform-d) δ 10.70 (s, 0.65 H), 10.55 (s, 1H), 8.78 (d, J = 8.65 Hz, 2H), 8.63 
(s, 1H), 7.87 (s, 2H), 7.66 – 7.52 (m, 5H), 7.50 – 7.39 (m, 2H); Exact Mass for 
C16H10Cl2N2O: 316.017; HRMS: [M+H]+: 317.0292; HPLC4: tR 16.30 min, purity 
98.8%. 
 
4-Bromophenyl-(4-(4-bromophenyl)-1H-imidazol-2-yl)ketone and 4-
bromophenyl-(5-(4-bromophenyl)-1H-imidazol-2-yl)methanoe(11d). 1H NMR (500 
MHz, DMSO-d6) δ 13.91(s, 0.16H),13.73 (s, 1H), 8.51 ( d, J = 8.4 Hz, 2H), 8.42 (d, J = 
8.3 Hz, 0.32H), 8.16 (s, 1H), 7.93 (d, J = 8.15 Hz, 0.32H), 7.89 (d, J = 8.35 Hz, 2H),7.83 
(d, J = 8.45 Hz,2H), 7.80 (d, J = 8.4 Hz, 0.32H), 7.79 (s,0.16H), 7.67(d, J = 8.05 Hz, 
0.32H), 7.62 (d, J = 8.35 Hz, 2H); Exact Mass for C16H10Br2N2O: 403.916; HRMS: 
[M+H]+: 404.9241; HPLC4: tR 16.53 min, purity 95.5%. 
 
(4-(Trifluoromethyl) phenyl)(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-
yl)methanone and (4-(trifluoromethyl)phenyl)(5-(4-(trifluoromethyl)phenyl)-1H-
imidazol-2-yl)methanone (11e). 1H NMR (400 MHz, Chloroform-d) δ 10.83 (s, 0.38H), 
10.60 (s, 1H), 8.78 (d, J = 8.19 Hz, 2H), 8.64 (d, J = 8.13 Hz, 0.48H), 7.93 (d, J = 8.34 
Hz, 2H), 7.76 (d, J = 8.56 Hz, 2H), 7.66 – 7.59 (m, 3H); Exact Mass for C18H10F6N2O: 
384.0697; HRMS: [M+H]+: 385.0790; HPLC1: tR 7.76 min, purity 98.3%. 
 
p-Tolyl(4-p-tolyl-1H-imidazol-2-yl)methanone and p-tolyl(5-p-tolyl-1H-
imidazol-2-yl)methanone(11f). 1H NMR (400 MHz, Chloroform-d) δ 10.96 (s, 1H), 
10.73 (s, 1H), 8.71 (d, J = 8.26 Hz, 2H), 8.54 (d, J = 8.23 Hz, 2H), 7.82 (d, J = 8.11 Hz, 
2H), 7.67 – 7.49 (m, 4H), 7.37 (t, J = 7.62, 7.62 Hz, 4H), 7.30 (s, 1H), 7.28 (s, 2H), 7.26 
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(s, 1H), 2.49 (d, J = 4.52 Hz, 6H), 2.42 (d, J = 4.95 Hz, 6H); Exact Mass for C18H16N2O: 
276.1263; HRMS: [M+H]+: 277.1385; HPLC3: tR 10.27 min, purity 98.7%. 
 
(4-Methoxyphenyl)(4-(4-methoxyphenyl)-1H-imidazol-2-yl)methanone and 
(4-methoxyphenyl)(5-(4-methoxyphenyl)-1H-imidazol-2-yl)methanone (11g). 1H 
NMR (400 MHz, Chloroform-d) δ 10.50 (s, 1H), 10.38 (s, 1H), 8.77 (d, J = 8.90 Hz, 2H), 
8.60 (d, J = 8.89 Hz, 2H), 7.77 (s, 1H), 7.75 (s, 1H), 7.48 (d, J = 8.75 Hz, 1H), 7.45 – 
7.36 (m, 2H), 7.03 – 6.87 (m, 5H), 3.86 (s, 2H), 3.85 (s, 2H), 3.84 (s, 2H), 3.80 (s, 2H), 
3.79 (s, 2H); Exact Mass for C18H10F6N2O: 384.0697; HRMS: [M+H]
+: 385.0790; 
HPLC2: tR 6.05 min, purity 97.2%. 
 
(4-(Dimethylamino)phenyl)(4-(4-(dimethylamino)phenyl)-1H-imidazol-2-
yl)methanone and (4-(dimethylamino)phenyl)(5-(4-(dimethylamino)phenyl)-1H-
imidazol-2-yl)methanone(11h). 1H NMR (500 MHz, DMSO-d6) δ 13.17 (s, 0.35H), 
13.12 (s, 1H), , 8.64 (d, J = 8.95 Hz, 2H), 8.50 (d, J = 8.95 Hz, 1H), 7.80 – 7.69 (m, 4H), 
7.50 (s, 1H), 6.82 (d, J = 8.99 Hz, 2H), 6.76 (t, J = 7.70, 7.70 Hz, 5H), 3.07 (s, 6H), 3.05 
(s, 4H), 2.95 (s, 4H), 2.93 (s, 6H) ); Exact Mass for C18H10F6N2O: 384.0697; HRMS: 
[M+H]+: 385.0790; HPLC1: tR 5.43 min, purity 95.3%. 
 
(4-Hydroxyphenyl)(4-(4-hydroxyphenyl)-1H-imidazol-2-yl)methanone and 
(4-hydroxyphenyl)(5-(4-hydroxyphenyl)-1H-imidazol-2-yl)methanone(11i). 1H NMR 
(500 MHz, DMSO-d6) δ 13.37 (s, 0.37H), 13.29 (s, 1H), 10.39 (s, 1H), 9.46 (s, 1H), 8.60 
(d, J = 7.88 Hz, 3H), 8.47 (s, 1H), 7.79 (s, 2H), 7.73 (d, J = 7.48 Hz, 4H), 7.55 (s, 1H), 
6.92 (d, J = 8.02 Hz, 4H), 6.81 (d, J = 8.03 Hz, 4H); Exact Mass for C16H12N2O3: 
280.0800; HRMS: [M+H]+: 281.0967; HPLC2: tR 3.54 min, purity 99.8%. 
 
(4-Phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone and (5-
phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (12a). 1H NMR (400 
MHz, Chloroform-d) δ 10.63 (s, 0.48H), 10.47 (s, 1H), 8.19 (s, 2H), 7.98 (s, 1H), 7.82 (t, 
J = 1.67, 1.67 Hz, 1H), 7.81 (t, J = 1.11, 1.11 Hz, 1H), 7.60 – 7.53 (m, 1H), 7.51 (d, J = 
1.97 Hz, 1H), 7.46 – 7.30 (m, 3H), 7.29 – 7.22 (m, 1H), 3.95 (s, 5H), 3.91 (s, 3H), 3.91 
(s, 3H), 3.89 (s, 1H); Exact Mass for C19H18N2O4: 338.1267; HRMS: [M+H]
+: 339.1423; 
HPLC2: tR 6.40 min, purity 95.0%. 
 
(4-(4-Fluorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (5-(4-fluorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (12b). 
1H NMR (400 MHz, Chloroform-d) δ 10.60 (s, 0.30H), 10.46 (s, 1H), 8.15 (s, 2H), 7.97 
(s, 1H), 7.77 (dd, J = 5.35, 8.90 Hz, 2H), 7.58 – 7.50 (dd, J = 5.10, 8.20 Hz, 0.47 H), 7.48 
(s, 0.46 H), 7.46 (s, 1H), 7.45 (s, 1H), 7.10 – 7.02 (m, 2H), 3.94 (s, 6H), 3.92 (s, 3H), 
3.91 (s, 2H), 3.89 (s, 1H); Exact Mass for C19H17FN2O4: 356.1172; HRMS: [M+H]
+: 
357.1245; HPLC2: tR 6.90 min, purity 99.3%. 
 
(4-(4-Chlorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (5-(4-chlorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (12c). 
1H NMR (400 MHz, Chloroform-d) δ 10.57 (s, 0.33H), 10.45 (s, 1H), 8.15 (s, 2H), 7.97 
(s, 0.49H), 7.81 – 7.68 (m, 2H), 7.51 – 7.47 (m, 1H), 7.36 – 7.30 (m, 2H), 3.94 (s, 6H), 
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3.91 (s, 3H), 3.89 (s, 0.75H); Exact Mass for C19H17ClN2O4: 372.0877; HRMS: [M+H]
+: 
373.0992; HPLC4: tR 15.76 min, purity 95.6%. 
 
(4-(4-Bromophenyl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanoneand (5-(4-bromophenyl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(12d). 1H NMR (400 MHz, Chloroform-d) δ 10.77 (s, 
0.36H), 10.59 (s, 1H), 8.24 (s, 2H), 8.06 (s, 1H), 7.78 (d, J = 1.86 Hz, 1H), 7.76 (d, J = 
1.98 Hz, 1H), 7.69 – 7.47 (m, 4H), 4.03 (s, 6H), 4.01 (s, 3H), 4.00 (s, 2H), 3.99 (s, 1H); 
Exact Mass for C19H17BrN2O4: 416.0372; HRMS: [M+H]
+: 417.0496; HPLC1: tR 6.37 
min, purity 96.7%. 
 
(4-(4-(Trifluoromethyl)phenyl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone and (5-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-
yl)(3,4,5trimethoxyphenyl)methanone (12e). 1H NMR (400 MHz, Chloroform-d) δ 
10.90 (s, 0.16H), 10.67 (s, 1H), 8.26 (s, 2H), 8.08 (s, 0.36H), 8.01 (d, J = 7.30 Hz, 2H), 
7.80-7.88 (m, 0.79H), 7.76 – 7.62 (m, 3H), 4.08 – 3.95 (m, 11H); Exact Mass for 
C20H17F3N2O4: 406.114; HRMS: [M+H]
+: 407.1319; HPLC2: tR 9.60 min, purity 95.1%. 
 
(4-p-Tolyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone and (5-p-
tolyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (12f). 1H NMR (400 
MHz, Chloroform-d) δ 10.57 (s, 0.77H), 10.44 (s, 1H), 8.18 (s, 2H), 7.96 (s, 1H), 7.71 (d, 
J = 1.87 Hz, 1H), 7.69 (d, J = 1.88 Hz, 1H), 7.47 (d, J = 2.44 Hz, 2H), 7.22 (s, 1H), 7.16 
(s, 1H), 3.94 (s, 6H), 3.92 (s, 3H), 3.90 (s, 3H), 3.89 (s, 2H); Exact Mass for C20H20N2O4: 
352.1423; HRMS: [M+H]+: 353.1527; HPLC1: tR 5.63 min, purity 95.9%. 
 
(4-(4-Methoxyphenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (5-(4-methoxyphenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(12g). 1H NMR (400 MHz, Chloroform-d) δ 10.60 (s, 1H), 10.50 (s, 1H), 8.27 (s, 2H), 
8.05 (s, 1H), 7.84 (s, 1H), 7.82 (s, 1H), 7.59 (d, J = 8.87 Hz, 1H), 7.54 (d, J = 1.90 Hz, 
1H), 7.51 (d, J = 2.31 Hz, 1H), 7.05 – 6.97 (m, 4H), 4.04 (s, 5H), 4.01 (s, 3H), 4.00 (s, 
3H), 3.98 (s, 2H), 3.89 (s, 2H), 3.88 (s, 3H); Exact Mass for C20H20N2O5: 368.1372; 
HRMS: [M+H]+: 369.1572; HPLC4: tR 13.78 min, purity 96.5%. 
 
(4-(4-(Dimethylamino)phenyl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone and (5-(4-(dimethylamino)phenyl)-1H-imidazol-2-
yl)(3,4,5-trimethoxyphenyl)methanone (12h). 1H NMR (500 MHz, Chloroform-d) δ 
10.67 (s, 1H), 10.54 (s, 0.49H), 8.28 (s, 1H), 8.03 (s, 2H), 7.78 (s, 1H), 7.76 (s, 1H), 7.53 
(d, J = 8.79 Hz, 2H), 7.50 (d, J = 1.56 Hz, 1H), 6.78 (m, 4H), 4.03 (s, 4H), 3.99 (s, 8H), 
3.97 (s, 3H), 3.04 (s, 6H), 3.02 (s, 4H); Exact Mass for C21H23N3O4: 381.1689; HRMS: 
[M+H]+: 382.1842; HPLC1: tR 5.53 min, purity 96.0%. 
 
(4-(4-Hydroxyphenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (5-(4-hydroxyphenyl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone)(12i). 1H NMR (500 MHz, Chloroform-d) δ 11.19 (s, 
1H), 10.75 (s, 1H), 8.23 (s, 2H), 7.98 (s, 2H), 7.77 (s, 1H), 7.75 (s, 1H), 7.54 (d, J = 5.13 
Hz, 3H), 7.49 (s, 1H), 6.90 (t, J = 9.24, 9.24 Hz, 4H), 4.01 (s, 6H), 3.99 (s, 3H), 3.97 (s, 
 47 
5H), 3.96 (s, 3H); Exact Mass for C19H18N2O5: 354.1216; HRMS: [M+H]
+: 355.1378; 
HPLC2: tR 4.46 min, purity 98.1%. 
 
Phenyl(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone and 
phenyl(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone(13a). 1H NMR (400 
MHz, Chloroform-d) δ 10.67 (s, 1H), 10.51 (s, 1H), 8.68 – 8.63 (m, 2H), 8.53 – 8.49 (m, 
1H), 7.62 – 7.53 (m, 2H), 7.53 – 7.44 (m, 5H), 7.04 (s, 2H), 6.75 (s, 1H), 3.89 (s, 6H), 
3.89 (s, 3H), 3.83 (s, 2H), 3.82 (s, 3H);Exact Mass for C19H18N2O4: 338.1267; HRMS: 
[M+H]+: 339.1348; HPLC2: tR 5.23 min, purity 97.4%. 
 
(4-Bromophenyl)(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone 
and (4-bromophenyl)(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone(13d). 
1H NMR (400 MHz, Chloroform-d) δ 10.66 (s, 1H), 10.57 (s, 1H), 8.72 – 8.62 (m, 2H), 
8.56 – 8.50 (m, 1H), 7.80 – 7.75 (m, 1H), 7.75 – 7.67 (m, 4H), 7.57 (q, J = 2.04 Hz, 2H), 
7.12 (s, 2H), 6.82 (s, 1H), 3.99 (s, 6H), 3.98 (s, 4H), 3.93 (s, 2H), 3.92 (s, 3H); Exact 
Mass for C19H17BrN2O4: 416.0372; HRMS: [M+H]
+: 417.0454; HPLC2: tR 7.28 min, 
purity 97.9%.  
 
(4-Methoxyphenyl)(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone 
and (4-methoxyphenyl)(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-
yl)methanone(13g). 1H NMR (400 MHz, Chloroform-d) δ 10.80 (s, 1H), 10.66 (s, 1H), 
8.87 – 8.79 (m, 2H), 8.73 – 8.67 (m, 1H), 7.56 (d, J = 1.83 Hz, 1H), 7.53 (d, J = 2.32 Hz, 
1H), 7.14 (s, 2H), 7.05 (dd, J = 3.59, 8.90 Hz, 3H), 6.83 (s, 1H), 3.99 (s, 6H), 3.96 (s, 
3H), 3.95 (s, 3H), 3.94 (s, 2H), 3.92 (s, 2H), 3.91 (s, 3H); Exact Mass for C20H20N2O5: 
368.1372; HRMS: [M+H]+: 369.1494; HPLC2: tR 5.94 min, purity 97.4%. 
 
(4-(Dimethylamino) phenyl)(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-
yl)methanone and (4-(dimethylamino)phenyl)(5-(3,4,5-trimethoxyphenyl)-1H-
imidazol-2-yl)methanone(13h). 1H NMR (400 MHz, Chloroform-d) δ 11.20 (s, 1H), 
10.94 (s, 1H), 8.94 – 8.75 (m, 2H), 8.74 – 8.61 (m, 1H), 7.54 (s, 1H), 7.50 (s, 1H), 7.15 
(d, J = 2.41 Hz, 2H), 6.86 (s, 1H), 6.76 (dd, J = 5.30, 9.05 Hz, 3H), 3.99 (s, 7H), 3.93 (s, 
4H), 3.91 (s, 6H), 3.14 (s, 6H), 3.13 (s, 4H); Exact Mass for C21H23N3O4: 381.1689; 
HRMS: [M+H]+: 382.1842; HPLC1: tR 4.82 min, purity 97.8%. 
 
(4-Hydroxyphenyl)(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-yl)methanone 
and (4-hydroxyphenyl)(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-
yl)methanone(13i). 1H NMR (500 MHz, Chloroform-d) δ 11.81 (s, 1H), 11.45 (s, 1H), 
8.62 – 8.44 (m, 2H), 8.39 – 8.19 (m, 2H), 7.53 (d, J = 31.95 Hz, 2H), 7.07 (s, 2H), 6.82 
(dd, J = 12.16, 30.47 Hz, 6H), 3.90 (s, 5H), 3.88 (s, 8H), 3.84 (s, 6H); Exact Mass for 
C19H18N2O5: 354.1216; HRMS: [M+H]
+: 355.1339; HPLC1: tR 4.00 min, purity 97.4%. 
 
3,4,5-Trimethoxyphenyl-(4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-
yl)methanone and 3,4,5-trimethoxyphenyl-(5-(3,4,5-trimethoxyphenyl)-1H-imidazol-
2-yl)methanone(14). 1H NMR (400 MHz, Chloroform-d) δ 10.76 (s, 0.40H), 10.61 (s, 
1H), 8.20 (s, 2H), 7.95 (s, 1H), 7.48 (d, J = 1.90 Hz, 0.40H), 7.47 (d, J = 2.34 Hz, 1H), 
7.06 (s, 2H), 6.75 (s, 1H), 3.93 (s, 5H), 3.91 (d, J = 0.84 Hz, 4H), 3.89 (s, 1H), 3.87 (s, 
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2H), 3.86 ( s, 5H) 3.83 (s, 1H), 3.82 (s, 2H); Exact Mass for C22H24N2O7: 428.1584; 
HRMS: [M+H]+: 429.1677; HPLC3: tR 9.60min, purity 96.4%. 
 
 
General Procedure for the Preparation of 15a-c 
 
 To a solution of 12a (135 mg, 0.4 mmol) in THF (10 mL) in ice-bath was added 
sodium hydride (60% dispersion in mineral oil, 28 mg, 0.60 mmol) followed by adding 
methyl iodide (85 mg, 0.60 mmol) (for 15a) or ethyl iodide (93 mg, 0.60 mmol) (for 
15b)or benzyl bromide(102 mg, 0.60 mmol) (for 15c). The resulting reaction mixture was 
stirred overnight under reflux condition. After dilution by 50 ml of saturated NaHCO3 
solution (aqueous), the reaction mixture was extracted by ethyl acetate (100 ml). The 
organic layer was dried over magnesium sulfate and concentrated. The residue was 
purified by flash column chromatography.  
 
(1-Methyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
(15a). 1H NMR (500 MHz, Chloroform-d) δ 7.97 (d, J = 2.38 Hz, 2H), 7.85 (d, J = 6.01 
Hz, 2H), 7.46 – 7.39 (m, 3H), 7.28 (d, J = 2.39 Hz, 1H), 4.16 – 4.10 (m, 3H), 3.99 (d, J = 
2.82 Hz, 9H) ; Exact Mass for C20H20N2O4: 352.1423; HRMS: [M+H]
+: 353.1527; 
HPLC1: tR 6.03 min, purity 96.4%. 
 
(1-Ethyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(15b). 1H NMR (400 MHz, Chloroform-d) δ 7.95 (s, 2H), 
7.89 – 7.83 (m, 2H), 7.51 (s, 1H), 7.43 (t, J = 7.61, 7.61 Hz, 2H), 7.36 – 7.31 (m, 1H), 
4.56 (q, J = 7.19, 7.19, 7.19 Hz, 2H), 3.99 (s, 6H), 3.98 (s, 3H), 1.30 (t, J = 7.19, 7,19 Hz, 
3H); Exact Mass for C21H22N2O4: 366.158; HRMS: [M+H]
+: 367.1725; HPLC1: tR 6.47 
min, purity 97.1%. 
 
(1-Benzyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(15c). 1H NMR (500 MHz, Chloroform-d) δ 7.94 (d, J = 
1.70 Hz, 2H), 7.84 (d, J = 7.73 Hz, 2H), 7.47 – 7.28 (m, 9H), 5.74 (s, 2H), 3.98 (s, 9H); 
Exact Mass for C26H24N2O4: 428.1736; HRMS: [M+H]
+: 429.1931; HPLC1: tR 6.70 min, 
purity 95.4%. 
 
 
General Procedure for the Preparation of 15d-f 
 
 To a solution of 12a (135 mg, 0.4 mmol) in ACN (10 mL) was added potassium 
carbonate (82 mg, 0.60 mmol) followed by n-propyl iodide (82 mg, 0.48 mmol) (for 15d) 
or i-propyl iodide (82 mg, 0.48 mmol) (for 15e) or cyclopentyl bromide (72 mg, 0.48 
mmol) (for 15f). The resulting reaction mixture was stirred overnight under reflux 
condition. After dilution by 50 ml of saturated NaHCO3 solution (aqueous), the reaction 
mixture was extracted by ethyl acetate (100 ml). The organic layer was dried over 
magnesium sulfate and concentrated. The residue was purified by flash column 
chromatography. 
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(4-Phenyl-1-propyl-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(15d). 1H NMR (500 MHz, Chloroform-d) δ 7.94 (s, 2H), 
7.90 – 7.82 (m, 2H), 7.47 (s, 1H), 7.42 (t, J = 7.67 Hz, 2H), 7.34 – 7.28 (m, 1H), 4.51 – 
4.40 (m, 2H), 3.98 (d, J = 1.49 Hz, 9H), 1.96 (h, J = 7.40 Hz, 2H), 1.03 (t, J = 7.42 Hz, 
3H); Exact Mass for C22H24N2O4: 380.1700; HRMS: [M+H]
+: 381.1897; HPLC1: tR 6.88 
min, purity 98.0%. 
 
(1-Isopropyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(15e). 1H NMR (400 MHz, Chloroform-d) δ 7.79 (s, 3H), 
7.78 – 7.73 (m, 1H), 7.57 (s, 1H), 7.34 (dd, J = 6.87, 8.44 Hz, 2H), 7.25 – 7.21 (m, 1H), 
5.66 – 5.21 (m, 1H), 3.89 (s, 9H), 1.52 (s, 6H); Exact Mass for C22H24N2O4: 380.1700; 
HRMS: [M+H] +: 381.1937; HPLC1: tR 6.90 min, purity 98.3%. 
 
(1-Cyclopentyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone(15f). 1H NMR (500 MHz, Chloroform-d) δ 7.90 – 7.82 
(m, 4H), 7.61 (d, J = 1.7 Hz, 1H), 7.42 (td, J = 7.7, 1.7 Hz, 2H), 7.33 – 7.28 (m, 1H), 5.88 
– 5.32 (m, 1H), 3.98 (t, J = 1.9 Hz, 9H), 2.64 – 2.20 (m, 2H), 2.00 – 1.77 (m, 6H); Exact 
Mass for C24H26N2O4: 406.1893; HRMS: [M+H]
+: 407.2103; HPLC1: tR 8.07 min, purity 
98.3%. 
 
 
General Procedure for the Preparation of 15g-h 
 
Under inert atmosphere, a Schlenk flask was charged with Cs2CO3 (260 mg, 0.8 
mmol), CuI (76 mg, 0.4 mmol), ligand (0.4 mmol), compound 12a (135 mg, 0.4 mmol), 
2-pyrimidyl bromide (124 mg, 0.8 mmol) (for 15g) or 2-bromothiophene (130 mg, 0.8 
mmol) (for 15h) and DMF (5 mL). The reaction mixture was stirred for 30 min at room 
temperature, and then heated to 110 oC for 2 days. The reaction mixture was monitored 
by TLC. After the starting material was completely consumed, the reaction was stopped 
and the mixture was cooled to room temperature. The reaction mixture was directly 
passed through a plug of silica gel. After being rinsed with ethyl acetate, the combined 
filtrate was washed with saturated brine. After the organic layer was dried by sodium 
sulfate, it was concentrated. The residue was purified by column chromatography on 
silica gel to provide the desired product. 
 
(4-Phenyl-1-(pyridin-2-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15g). 1H NMR (500 MHz, Chloroform-d) δ 8.59 (dt, J = 
1.70, 4.33 Hz, 1H), 7.91 (ddt, J = 1.67, 3.99, 7.42 Hz, 3H), 7.86 (d, J = 1.52 Hz, 2H), 
7.82 (d, J = 1.57 Hz, 1H), 7.48 – 7.40 (m, 4H), 7.34 (td, J = 1.38, 7.27 Hz, 1H), 3.98 (d, J 
= 1.62 Hz, 3H), 3.96 (d, J = 1.41 Hz, 6H). Exact Mass for C24H21N3O4: 415.1500; 
HRMS: [M+H]+: 416.1692; HPLC1: tR 4.85 min purity, 97.9%. 
 
(4-Phenyl-1-(thiophen-2-yl)-1H-imidazol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (15h). 1H NMR (500 MHz, Chloroform-d) δ 7.87 – 7.76 
(m, 4H), 7.52 (d, J = 1.84 Hz, 1H), 7.37 (td, J = 1.83, 7.63, 8.06 Hz, 2H), 7.30 – 7.23 (m, 
2H), 7.06 (dd, J = 1.95, 3.59 Hz, 1H), 6.97 (dp, J = 1.70, 5.60 Hz, 1H), 3.89 (d, J = 1.94 
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Hz, 3H), 3.88 (d, J = 1.95 Hz, 6H); Exact Mass for C23H20N2O4S: 420.1100; HRMS: 
[M+H]+: 421.1298; HPLC1: tR 6.33 min, purity 98.2%.  
 
 
General Procedure for the Preparation of 18a-c 
 
 To ammonium acetate (10 mmol) in ethanol (5 ml) and water (0.3 ml) was added 
phenyl alkyl diones 17(a-c) (1 mmol) in ethanol (5 ml) and 3, 4, 5-trimethoxyphenyl 
glyoxal hydrate 10 (1 mmol) in ethanol (10 ml). The mixture was stirred at room 
temperature for 30-45 min. The reaction was stopped after the consumption of the 
starting material monitored by TLC. The mixture was then extracted with ethyl acetate. 
The organic layer was washed with brine, dried over anhydrous sodium sulfate and 
concentrated to get the crude product. The crude was purified by flash chromatography. 
 
(5-Methyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (4-methyl-5-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (18a). 
1H NMR (400 MHz, Chloroform-d) δ 10.43 (s, 0.59H), 10.32 (s, 1H), 8.24 (s, 2H), 8.05 
(s, 1H), 7.87 – 7.71 (m, 3H), 7.62 – 7.38 (m, 6H), 4.02 (s, 5H), 4.01 (s, 3H), 3.99 (s, 2H), 
3.98 (s, 2H), 3.95 (s, 2H), 2.64 (s,3H), 2.56 (s, 1H); Exact Mass for C19H17ClN2O4: 
372.0877; HRMS: [M+H]+: 373.0992; HPLC2: tR 6.42 min, purity 95.4%. 
 
(5-Ethyl-4-phenyl-1H-imidazol-2-yl)(3, 4, 5-trimethoxyphenyl)methanone 
and (4-ethyl-5-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (18b). 
1H NMR (400 MHz, Chloroform-d) δ 10.85(s, 1H), 8.28 (s, 2H), 8.15 (s, 1H), 7.75 (m, 
1H), 7.45-7.30 (m, 5H), 4.00(m, 9H), 3.05(m, 2H), 1.40 (m, 3H); Exact Mass for 
C19H17ClN2O4: 372.0877; HRMS: [M+H]
+: 373.0992; HPLC1: tR 5.37 min, purity 
96.3%. 
 
(4-Phenyl-5-propyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone 
and (5-phenyl-4-propyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone(18c). 
1H NMR (400 MHz, Chloroform-d) δ 10.52 (s, 0.52 H), 10.47 (s, 1H), 8.24 (s, 2H), 8.14 
(s, 1H), 7.78 (d, J = 7.39 Hz, 2H), 7.60 – 7.43 (m, 5H), 7.36 (t, J = 7.40, 7.40 Hz, 1H), 
4.01 (s, 5H), 4.00 (s, 3H), 3.99 (s, 4H), 3.00 – 2.93 (t, J = 7.40, 7.40 Hz, 2H), 2.84 (t, J = 
7.50, 7.50 Hz, 1H), 1.94 – 1.87 (m, 1H), 1.87 – 1.78 (m, 2H), 1.07 (t, J = 7.33, 7.33 Hz, 
3H), 0.98 – 0.92 (t, J = 7.10, 7.10 Hz, 1H); Exact Mass for C19H17ClN2O4: 372.0877; 
HRMS: [M+H]+: 373.0992; HPLC: tR 12.46 min, purity 96.1%. 
 
 
Cell Culture and Cytotoxicity Assay 
 
 We examined the anti-proliferative activity of the RABI compounds in four 
human melanoma cell lines (A375 and WM-164, MDA-MB-435 and MDA-MB-
435/LCC6MDR1) and four human prostate cancer cell lines (LNCaP, DU 145, PC-3, and 
PPC-1). All these cell lines were purchased from ATCC (American Type Culture 
Collection, Manassas, VA). Melanoma cells were cultured in DMEM (Cellgro Mediatech 
Inc., Herndon, VA), and prostate cancer cells were cultured in RPMI 1640 (Cellgro 
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Mediatech, Inc., Herndon, VA) supplemented with 10% fetal bovine serum (Cellgro 
Mediatech). Cultures were maintained at 37oC in a humidified atmosphere containing 5% 
CO2. Then 1000-5000 cells were plated into each well of 96-well plates depending on 
growth rate and exposed to different concentrations of a test compound for 48 h (fast 
growing melanoma cells) or 96 h (slow growing prostate cancer cells) in three-five 
replicates. Cell numbers at the end of the drug treatment were measured by the 
sulforhodamine B (SRB) assay. Briefly, the cells were fixed with 10% trichloroacetic 
acid and stained with 0.4% SRB, and the absorbances at 540 nm were measured using a 
plate reader (DYNEX Technologies, Chantilly VA). Percentages of cell survival versus 
drug concentrations were plotted, and the IC50 (concentration that inhibited cell growth 
by 50% of untreated control) values were obtained by nonlinear regression analysis using 
GraphPad Prism (GraphPad Software, San Diego, CA). 
 
 
Cell Cycle Analysis 
 
 Cell cycle distribution was determined by propidium iodide (PI) staining. Treated 
cells were washed with PBS and fixed with 70% ice-cold ethanol overnight. Fixed cells 
were then stained with 20 μg/mL of PI in the presence of RNase A (300 μg/mL) at 37° C. 
for 30 min. Cell cycle distribution was analyzed by fluorescence-activated cell sorting 
(FACS) analysis core services at the University of Tennessee Health Science Center, TN. 
 
 
Tubulin Polymerization Assay 
 
 The drug effects on tubulin polymerization were determined using a fluorescence-
enhanced tubulin polymerization assay kit (Cytoskeleton, cat# BK011P). Porcine brain 
tubulin (0.56 mg, >99% pure) was mixed with test compounds and incubated in 50 μL of 
tubulin buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, 1 mM GTP, and 10 μM 
fluorescent reporter) with 10% glycerol at 37 oC. The assay was monitored every 1 min 
for 40 min by the SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT) 
at the excitation wavelength 340 to 360 nm and emission 410 to 460 in kinetic mode. 
Polymerization is measured by fluorescence enhancement. 
 
 
Competitive Mass Spectrometry Binding Assay 
 
 The binding site of 12a and 15g in tubulin protein was evaluated by the 
competitive mass spectrometry binding assay as previously described [130]. Briefly, 
colchicine (1.2 μM) was incubated with bovine brain tubulin (1.0 mg/mL) in the 
incubation buffer [80 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), 2.0 mM 
magnesium chloride (MgCl2), 0.5 mM ethylene glycol tetra acetic acid (EGTA), pH 6.9] 
at 37 °C for 1 h. Different concentrations (0.5–10 μM) of podophyllotoxin (positive 
control), 12a, 15g, and vinblastine (negative control) were used to compete with the 
binding of colchicine to tubulin. After 1 h incubation, the amount of unbound colchicine 
was obtained from the filtrate by ultrafiltration (Amicon Ultra-0.5 Centrifugal Filter Unit 
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with Ultracel-30 membrane, Millipore, Billerica, MA). The amount of unbound 
colchicine in the presence or absence of any competitor was measured. Each experiment 
was performed in triplicate. 
 
 
Molecular Modeling 
 
 All molecular modeling studies were performed with Schrodinger Molecular 
Modeling Suite 2011 (Schrodinger LLC, New York, NY) running on a Dell Linux 
workstation. We selected tubulin complex with TN16 (PDB code: 3HKD) and tubulin 
complex with colchicine (PDB code: 1SA0) as our modeling system. RABIs were built 
and prepared using the Ligprep module, and they were docked into the TN16 site and 
colchicine site by the Glide module in the Schrodinger Suite. The best docking 
complexes were subject to restricted molecular dynamics to release any strains by using 
the Macromodel module with OPLS-2005 force field. The ligand and its surrounding 
residues within 15Å were allowed to move freely while the outer atoms are frozen. 
 
 
Summary 
 
 Novel RABI analogs were designed and synthesized based on rational structural 
modification of previous ABI analogs. SAR (Figure 3-11) was investigated by 
introducing different substituents into the A, B and C rings. Several RABIs showed 
excellent anti-proliferative activity which was comparable to existing tubulin-targeting 
agents such as paclitaxel, colchicine, or vinblastine but could overcome Pgp-mediated 
multiple drug resistance effectively. Among them compound 12a was the most potent 
one with IC50 in the low nano-molar range, while compound 15g provided very 
interesting insights in future optimization of these analogs. Mechanism of action studies 
confirmed that RABI analogs maintain their ability to inhibit tubulin polymerization at 
colchicine binding site and arrest cells in G2/M phase. These results strongly suggest that 
novel RABI analogs can be further developed as a promising antitumor agent for the 
more efficacious treatment of advanced cancers. 
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Figure 3-11. SAR of RABI analogs 
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CHAPTER 4.    OVERVIEW OF SURVIVIN AND SURVIVIN INHIBITORS* 
 
 
Introduction 
 
 Survivin, an anti-apoptotic protein, was discovered by Grazia Ambrosini and 
Dario C. Altieri in 1997 [131]. Survivin is a member of the inhibitor of apoptosis proteins 
(IAP) family of which there are eight members: NAIP (NLR family, apoptosis inhibitory 
protein), c-IAP1, c-IAP2, XIAP (X-linked inhibitor of apoptosis), livin, ILP-2, Apollon, 
and survivin (Figure 4-1) [132-135]. Each member contains at least a single baculoviral 
IAP repeat (BIR) domain at the N-terminus region [132]. Survivin is encoded by 
baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), so it is also called BIRC5. 
Compared with other IAPs that contain multiple domains, survivin is structurally unique 
because it contains only one single BIR domain. It is the smallest member of the IAP 
family, has a molecule weight of 16.5 kDa, and contains 142 amino acid residues [136-
137]. Unlike other IAPs that are expressed in both cancerous and normal cells, survivin is 
expressed only in the vast majority of neoplasms but not in most normal differentiated 
tissues [49, 138-140]. Survivin also contributes to tumor formation and maintenance 
because of its functional properties [48, 141]. Therefore, targeting survivin represents a 
very attractive strategy in cancer drug discovery. However, due to the requirement of 
efficiently disrupting protein-protein interactions which typically have large interface 
areas, the development of small-molecule survivin inhibitors have been very challenging. 
Thus the number of currently available survivin inhibitors is small. In addition, most of 
these inhibitors target other biomolecules and ultimately reduce the level of survivin, 
rather than directly interact with survivin protein itself. Despite these challenges and 
limitations, developing new potent and selective small-molecule survivin inhibitors will 
be important in both basic science and translational research to develop them into 
potentially effective, broad-spectrum therapeutic agents. In this chapter, we first describe 
the functions of survivin, its role in cancer progression and potential therapy. Then we 
focus on recently developed small-molecule survivin inhibitors. Challenges for 
developing survivin inhibitors and future direction will also be covered.  
 
 
Functions of Survivin  
 
 The main established functions of survivin are the regulation of cell mitosis and 
the inhibition of apoptosis as illustrated in Figure 4-2. Survivin plays an essential role in 
cell mitosis [142], during which survivin regulates cell division through a multiprotein 
complex called chromosomal passenger complex (CPC) as shown in Figure 4-2. In this 
complex, survivin is associated with other regulators of cytokinesis including aurora 
kinase B, INCENP, and borealin [143-145]. CPC is essential for accurate 
 
 
-------------------- 
*Reprinted with permission. Xiao, M.; Li, W. Recent Advances on Small-Molecule 
Survivin Inhibitors. Curr Med Chem, 2015, 22(9), 1136-1146.  
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Figure 4-1. Schematic diagram of human IAPs 
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Figure 4-2. Functions of survivin and targets of survivin inhibitors 
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chromosome segregation and cytokinesis. Survivin and its molecular partners in the CPC 
fundamentally control genetic stability of cells [146]. Survivin has also been shown to be 
associated with regulating microtubule dynamics [147-149]. Survivin stabilizes the 
microtubules, thereby contributing to the formation of the bipolar spindle [149].  
Similar to other members in the IAP family, one main function of survivin is inhibition of 
apoptosis as shown in Figure 4-2 [150-153]. Although it has been confirmed that 
survivin inhibits apoptosis, the exact mechanism of inhibition is still under debate over 
two major theories. One theory is that survivin directly binds to caspases and 
subsequently inhibits apoptosis. The interaction between survivin and the effector 
caspases has been reported by several groups [150-151]. The second theory is that 
survivin inhibits caspase activity through indirect mechanisms to inhibit apoptosis [30, 
154-155]. One example proposes that survivin binds to XIAP to form a complex that 
inhibits the activation of caspase-9 [30, 154]. In another example, a survivin-hepatitis B 
X-interacting protein (HBXIP) complex binds to procaspase-9 to suppress apoptosis 
[155].  
 
 
Roles of Survivin in Cancer 
 
 Both the functions of promoting cell proliferation and inhibiting apoptosis 
contribute to the formation and maintenance of tumors. Because the expression level of 
survivin in normal cells and malignant cells is largely different, survivin can be used as a 
tumor biomarker [156-158]. Many studies have confirmed that survivin is overexpressed 
in a variety of cancers (e.g., lung, breast, pancreatic, and melanoma) [159-162]. Survivin 
has also been shown to be responsible for multiple types of drug resistance [163-166]. 
For example, it has been reported that taxol-treated HeLa cells show an increased level of 
survivin expression, which provides a cell survival pathway to counteract taxol-induced 
apoptosis [147]. Overexpression of survivin has also been reported in prostate cancer and 
thyroid cancer cells that are resistant to cisplatin treatment [167-168]. Because survivin is 
crucial in the process of carcinogenesis, knockout of survivin impedes the development 
of cancer. A recent study showed that loss of survivin in the prostate epithelium inhibited 
the progression of prostatic premalignant lesions to adenocarcinoma in the Pten-deletion 
mouse model [169]. The study confirms the role of survivin in cancer progression. 
 
 
Targeting Survivin for Cancer Treatment 
 
 Survivin has been proposed as an attractive target for selective cancer treatment 
because of its unique attributes [170]. The following features are some reasons that 
targeting survivin is a good strategy. First, the expression of survivin is typically very 
high in tumor cells but very low or even undetectable in normal adult tissues [49] . This 
feature is highly significant, because it provides selectivity, a major problem for current 
cancer drug development. Second, the functions of survivin contribute to the formation 
and maintenance of tumors [171], so targeting survivin will be very effective for treating 
cancer. Furthermore, survivin has been shown to be associated with resistance to multiple 
types of cancer therapies [172-174]. Targeting survivin can help overcome the multidrug 
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resistance which is the one of the major reasons many therapeutic agents fail in clinic. 
However, there are also significant challenges associated with using survivin as a drug 
target. Small-molecule survivin inhibitors have to disrupt the protein-protein interaction 
between survivin and other proteins, which could be difficult because most interfaces in 
protein-protein interactions (PPIs) are not well suitable for effective small molecule 
binding [175]. Despite the difficulties for small molecules to disrupt protein-protein 
interactions, there are some successful PPI inhibitors [176], including tirofiban (targeting 
the integrins) and maraviroc (targeting CCR5–gp120 interactions) which are already on 
the market [177-178]. Those successes are probably attributed to the fact that most PPIs 
have “hot spots” which are small parts of the interface that are essential for high-affinity 
binding [179]. Small-molecule PPI inhibitors can either interact with those hot spots or 
bind to allosteric sites to cause conformational change that will prevent protein-ligand 
binding, which will result to the desired disruption of protein-protein interactions. In the 
case of developing small-molecule survivin inhibitors, the Ala-Val-Pro-Ile (AVPI) 
peptide binding region has been proposed as a hot spot for small molecule inhibition 
[180-181]. Therefore, targeting survivin is tractable for cancer treatment in spite of the 
challenges. 
 
 Many survivin inhibitors have been reported in the literature. These survivin 
inhibitors are mainly composed of six categories: antisense oligonucleotides, dominant-
negative mutant, ribozymes, small interfering RNAs, cancer vaccine, and small-molecule 
inhibitors. Several reviews have been published covering the six categories of survivin 
inhibitors in general [136, 182-183], but no review specifically focuses on small-
molecule survivin inhibitors, which is the focus of this review. As we discussed earlier, 
most existing survivin inhibitors do not directly bind and interact with survivin protein 
itself, instead, they usually target other biomolecules and ultimately reduce survivin 
expression. Figure 4-2 shows three representative examples. The first example is YM155 
which inhibits survivin by inhibiting survivin gene promoter on the transcriptional level 
[184]. The second example is represented by cyclin-dependent kinase (CDK) inhibitors. 
For example, the CDK inhibitor flavopiridol inhibits survivin phosphorylation on Thr34 
which leads to progressive loss of survivin expression [185]. The last example shown in 
Figure 4-2 for indirect targeting survivin are Hsp90 inhibitors which disrupt the 
interaction between survivin and Hsp90, destabilize survivin protein and ultimately lead 
to survivin degradation. In the following sections, we will discuss each reported small-
molecule survivin inhibitor (arranged alphabetically) in detail (Figure 4-3).  
 
 
Existing Small-Molecule Survivin Inhibitors 
 
 
AICAR (1) 
 
 The nonpeptidic, small-molecule 5-aminoimidazole-4-carboxamide-1-b-D-
ribofuranoside (AICAR) as a structurally novel inhibitor of Hsp90 was developed 
through a combined structure- and dynamics-based computational design [186]. AICAR 
mimics the binding and functional properties of the peptidic antagonist of the survivin-  
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Figure 4-3. Chemical structures of recently developed small-molecule survivin 
inhibitors 
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Hsp90 complex, shepherdin. The AICAR/Hsp90 interaction studies revealed that AICAR 
is involved in direct contacts with Asp93 of Hsp90 through the two hydroxyl groups on 
position 3 and 5 of the ribose ring, suggesting that replacement of these residues with 
other polar groups may strengthen the interaction. This is also true for the polar 
substituents on the imidazole ring. AICAR has been shown to exhibit excellent anti-
proliferative activities in multiple cancer cell lines including DU145, JR8 and Hela cells. 
While AICAR is very potent in inhibiting the growth of tumor cells, it does not affect the 
proliferation of normal human fibroblasts. AICAR exerts its anticancer activities by 
inhibiting the chaperone function with destabilization of multiple Hsp90 client proteins, 
including survivin [186]. 
 
 
Arctigenin (2) 
 
 Arctigenin, a ligand isolated from the seeds of Arctium lappa, shows anti-
proliferative activities against a series of cancers [187-188]. A study illustrates the 
mechanism of its anticancer effect [188]. The results showed that arctigenin executed its 
antitumor effect by inhibiting STAT3 phosphorylation and survivin expression. The level 
of survivin was significantly reduced in arctigenin-treated ovarian cancer cells. 
Arctigenin has also been shown to sensitize tumor cells to cisplatin treatment by 
inhibiting survivin [187]. 
 
 
Cephalochromin (3) 
 
 Cephalochromin, a compound isolated from the fermented broth of Cosmospora 
vilior YMJ89051501 [189], is used as an antibacterial. It has been reported that 
cephalochromin can inhibit cell growth and induce apoptosis in human lung cancer cells 
with an IC50 value of 2.8 μM [189]. Cephalochromin was found to exert its antitumor 
effect by downregulating several anti-apoptotic proteins, including survivin. The 
expression level of survivin was significantly reduced in cephalochromin-treated A549 
lung cancer cells compared with untreated cells. Due to the survivin suppression effect, 
caspases-8, -9, and -3 are activated, which is responsible for the induced apoptosis. The 
anti-proliferative effect of cephalochromin reveals the therapeutical potential of this 
antibacterial agent in treating cancer. 
 
 
FL118 (4) 
 
 FL118 was first reported by Ling et al. in 2012 [190]. FL118 was identified 
through high throughput screening of compound libraries following in vitro and in vivo 
analysis. FL118 can inhibit cancer cell growth in a concentration of less than 1 nM. It has 
shown excellent antitumor activity in a series of cancer cell lines including HCT116 
colon cancer cells, A549 lung cancer cells, MCF7 breast cancer cells, and PC-3 prostate 
cancer cells. Its antitumor activity results from inhibiting survivin promoter activity and 
survivin gene expression. [190] The superior anticancer activity of FL118 largely 
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depends on its steric configuration. FL118 which has an R-configuration has much better 
activity than its analog FL113 with an S-configuration. In addition, the free hydroxyl 
group on position 20 of FL118 is essential for activity. Esterification of the hydroxyl 
group on position 20 resulted in almost complete loss of activity. The study also 
demonstrated that FL118 can inhibit expression of other cancer-associated IAPs such as 
Mcl-1, XIAP, and cIAP2, further enhancing its anticancer activity. The in vivo studies 
indicated that FL118 has excellent antitumor efficacy without significant toxicity [190]. 
The antitumor activity of FL118 highly depends on its primary structure and steric 
configuration [191]. The superior efficacy and selectivity hold significant promise for the 
further clinical development of FL188 and its core structure-derived analogs. 
 
 
Flavopiridol (5) 
 
 Flavopiridol is a broad spectrum, cyclin-dependent kinase (CDK) inhibitor. In the 
study by Nathan et al., flavopiridol caused progressive loss of survivin expression by 
inhibiting survivin phosphorylation on Thr34 when incubated with HeLa cells [185]; 
Thr34 phosphorylation of survivin is a critical requirement for survivin function [192]. 
Sequential treatment with flavopiridol and other anticancer agents enhanced anticancer 
activity both in breast carcinoma MCF-7 cells and SCID/bg mice bearing MCF-7 
xenograft tumors [185]. A recent study showed that flavopiridol inhibited human uterine 
leiomyoma growth both in vitro and in a xenograft model [193]. Flavopiridol is now in 
Phase II clinical trial [194-195]. In one phase II clinical trial of flavopiridol, the 
combination of flavopiridol and cisplatin treatment showed clinical activity in platin 
resistant and sensitive ovarian/primary peritoneal cancers [195]. 
 
 
ICG-001 (6) 
 
 ICG-001 is a small-molecule inhibitor of β-catenin/T cell factor (TCF)-mediated 
transcription [196]. It has been shown that the survivin gene is mediated by TCF/β-
catenin. The treatment of SW480 and HCT116 colon cancer cells with ICG-001clearly 
showed the inhibition of survivin gene transcription. The survivin inhibition effect was 
also observed in the SW620 xenograft tumors in the ICG-001-treated group. The 
inhibition of survivin expression results in induction of apoptosis, which causes tumor 
growth inhibition. Because survivin is up-regulated in most cancer cells but not in normal 
tissues, ICG-001 increases caspase activity in colon carcinoma cell lines (SW480 or 
HCT116) but not in normal colonic epithelial cells [196]. The specificity and strong 
potency of ICG-001 promise it to be a new anticancer therapeutic agent. 
 
 
KPT-185 (7) 
 
 KPT-185, a selective inhibitor of nuclear export, has been shown to be effective 
in several cancers including pancreatic cancer, acute myeloid leukemia, mantle cell 
lymphoma, and nonsmall cell lung cancer (NSCLC) [197-200]. KPT-185 can 
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significantly induce growth inhibition and apoptosis of tumor cells. A recent study 
showed that the survivin level is downregulated in KPT-185-treated NSCLC cell lines. 
The survivin level was also suppressed in an NSCLC H1975 xenograft model when 
treated with KPT-185 [200]. The survivin inhibition effect of KPT-185 contributes to its 
antitumor efficacy. Although KPT-185 has strong cytotoxicity, it is not suitable for in 
vivo use due to poor PK properties, while its analog KPT-330 which attaches a 2-
pyrazinyl hydrazinyl group to the carbonyl group and replace the methoxy substitution on 
the phenyl ring with a trifluoromethyl group compared with the structure of KPT-185, 
has comparable potency as KPT-185 and optimal PK properties [201]. 
 
 
Lapatinib (8) 
 
 Lapatinib, a potent small-molecule inhibitor of ErbB1 and ErbB2 tyrosine 
kinases, has been shown to markedly suppress survivin expression and subsequently 
induce apoptosis when treated in ErbB2-overexpressing breast cancer cell lines, such as 
BT 474 [202]. The inhibition of survivin by lapatinib is primarily posttranslational 
through the promoted ubiquitin-proteasome degradation of the survivin protein. The 
observation that the protein levels of His-tagged surviving, which are under the 
transcriptional control of a heterologous promoter and endogenous survivin are equally 
downregulated in response to lapatinib provides evidence for a posttranslational 
mechanism by which lapatinib regulates survivin. Lapatinib causes synergistic effects 
when used with other cytotoxic agents such as sorafenib [203]. Lapatinib is now in Phase 
3 clinical trial [204-205]. 
 
 
MK-2206 (9) 
 
 MK-2206, a novel allosteric inhibitor of Akt [206-207], has strong anticancer 
efficacy in a series of cancer cells [206-207]. It has been show that Akt phosphorylation 
is associated with the formation of survivin/XIAP complex. Deactivating Akt 
phosphorylation can lead to downregulation of survivin [208]. As an Akt inhibitor, MK-
2206 suppresses survivin. In a study, the level of survivin was reduced both in GEO 
cancer cells and GEO cell xenograft model when treated with MK-2206, which led to 
increased cancer cell death via apoptosis [209]. MK-2206 is now actively evaluated as a 
new anticancer agent and is now in Phase II clinical trial. 
 
 
NU6140 (10) 
 
 NU6140, (4-(6-cyclohexylmethoxy-9Hpurin-2-ylamino)-N, N-diethyl-benzamide) 
is a novel CDK inhibitor developed by Davies et al. in 2002 through structure-based 
design [210]. Structure-activity relationships for this compound indicate that a cyclic 
hydrophobic substituent at O6-poisiton such as cyclohexylmethyl is optimal and the 
extended groups at N2-position increased potency and selectivity. It has been shown that 
CDK1-mediated phosphorylation of survivin on Thr34 is essential for the cytoprotective 
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function of survivin [192]. As a CDK inhibitor, NU6140 induced a concentration-
dependent decrease in the level of survivin protein when treated in HeLa Cells. In 
addition, the level of the active, Thr34-phosphorylated form of survivin was reduced in a 
concentration-dependent manner after HeLa cells were treated with NU6140 [211]. 
Because the CDK inhibitor NU6140 can inhibit the expression and phosphorylation of 
survivin, a combination treatment of taxol and NU6140 in HeLa cells causes a synergistic 
effect on tumor growth inhibition. [211] 
 
 
Panepoxydone (11) 
 
 Panepoxydone, a secondary metabolite isolated from an edible mushroom, has 
long been known for its antibacterial effect. Studies have shown that panepoxydone 
interferes with NF-kB, which can lead to tumor inhibition [212-213]. Panepoxydone 
caused significant growth inhibition in MCF-7 and TNBC cell lines MDA-MB-231, 
MDA-MB-468, and MDA-MB-453 [213]. The induction of apoptosis is one main factor 
contributing to tumor cell growth inhibition. Mechanism of action studies showed that the 
survivin level in the panepoxydone-treated cells was reduced, which was responsible for 
inducing apoptosis. The strong antitumor effect of panepoxydone promises its further 
development. 
 
 
Piperine (12) 
 
 Piperine, an alkaloid from black pepper, inhibited the growth of several colon 
cancer cell lines [214]. The mechanism of action studies showed that the survivin protein 
levels in piperine-treated HT-29 colon carcinoma cell were reduced compared with 
untreated cells. The survivin inhibition effect of piperine may account for the inhibition 
of apoptosis and cell growth observed in piperine-treated cancer cells. Piperine can also 
sensitize cancer cells to other chemotherapeutical agents due to its survivin inhibition 
effect [215-216]. 
 
 
Purvalanol A (13) 
 
 Purvalanol A is p34cdc2-specific CDK inhibitor. Studies have shown that elevated 
p34cdc2 kinase activity can lead to increased survivin expression [147]. Purvalanol A as a 
p34cdc2-specific inhibitor not only inhibit Cdc2 activity, but also suppress survivin 
expression [217]. Purvalanol A can inhibit the mitotic phosphorylation of survivin on 
Thr34, which causes protein destruction of survivin and blockage of its function. The 
hyperphosphorylation of survivin on Thr34 has been found to be associated with the drug 
resistance of taxol in tumor cells [218]. Co-administration of taxol with purvalanol A 
suppressed the hyperactivity of survivin imposed by taxol, which helped overcome the 
taxol drug resistance [147]. Purvalanol A can also inhibit ABCB1 transporter and cause 
synergistic effects when used in combination with other anticancer drugs that are ABCB1 
substrates [219]. 
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Shepherdin (14) 
 
 Shepherdin, a novel antagonist of the survivin-Hsp90 complex, was discovered by 
Janet et al. in 2005 [220]. Shepherdin is actually the survivin sequence K79-L87 
(KHSSGCAFL). It was named shepherdin because it binds to the “shepherding” 
chaperone Hsp90. Binding assay results revealed that shepherdin was bound to the N 
domain of Hsp90, while no specific binding of shepherdin to the C domain of Hsp90 was 
observed. Shepherdin disrupts the interaction between survivin and Hsp90 through the 
ATP binding pocket of Hsp90. Shepherdin can also destabilize survivin and several other 
client proteins of Hsp90, such as Akt, CDK6, and telomerase, which cause cancer cell 
death via apoptotic and nonapoptotic mechanisms. Shepherdin has very good selectivity, 
because it does not affect normal cells while maintaining excellent antitumor activity 
[220]. Shepherdin can sensitize tumor cells to different cytotoxic drugs because of its 
survivin suppression effect. For example, shepherdin sensitized imatinib mesylate-
resistant chronic myelogenous leukemia cells to hydroxyurea or doxorubicin in a recent 
study [215]. Current clinical development is through the Rapid Access to Intervention 
Development (RAID) program at the National Cancer Institute. 
 
 
Terameprocol (15) 
 
 Terameprocol, meso-tetra-O-methyl nordihydroguaiaretic acid, also known as 
M4N, has been reported to inhibit HIV transactivation [221]. Terameprocol was made 
based on 3’-O-methylnordihydroguaiaretic acid, which was isolated from larrea 
tridentata. Subsequent studies showed that terameprocol as a transcription inhibitor can 
inhibit tumor growth by inhibiting expression of Cdc2 and survivin [222-223]. In the 
study of Chang et al. [223], terameprocol-treated C3 cells showed downregulation of 
Cdc2 and survivin expression. The observation that C3 cells transfected with Cdc2 and 
survivin were resistant to terameprocol-induced cell arrest or death confirmed the tumor 
growth inhibition mechanisms of terameprocol. Terameprocol significantly enhanced the 
sensitivity of nonsmall-cell lung carcinoma cells to radiation therapy in the study of Sun 
et al [224]. Now terameprocol is in Phase I clinical trial [225-226]. The clinical results 
have shown that this agent has an excellent safety profile in cervical intraepithelial 
neoplasia, making it a promising candidate for anticancer treatment [225]. 
 
 
UC-112 (16) 
 
 UC-112 was recently reported by our group as a potent and selective survivin 
inhibitor [180]. It was identified through a similarity-based virtual screening in which the 
three-dimensional shape of the AVPI peptide in the survivin-Smac crystal complex was 
used as the template for searching hit structures, followed by biological validation. UC-
112 showed broad anti-proliferative activities as indicated by NCI-60 cell line screening 
and preliminary in vivo studies in an A375 melanoma tumor model. Interestingly, 
preliminary studies showed that UC-112 selectively downregulated survivin level with 
minimal effects on other members of IAPs. [180] This compound may represent a unique 
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scaffold for the development of new selective survivin inhibitors. Further modifications 
of this compound are currently being carried out. 
 
 
YM155 (17) 
 
 YM155, 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-
dihydro-1H-naphtho[2,3-d]imidazolium bromide, a small-molecule survivin inhibitor, 
was first discovered by Astellas Pharma in 2007 [184]. It suppresses survivin gene 
promoter in PC-3 and PPC-1 human HRPC cell lines at 10 nmol/L in cell based 
proliferation assay. It also shows very good selectivity of survivin over other IAPs. In the 
study of Nakahara et al., YM155 suppressed survivin expression but had little effect on 
the expression of other IAPs even up to 100 nmol/L. YM155 induced tumor regression in 
PC-3 xenografted tumor model [184]. YM155 can help overcome drug resistance in 
tumors when used with other chemotherapeutical agents. For example, YM155 reversed 
rapamycin resistance in rapamycin-resistant renal cell carcinoma [227], and the 
combination of YM155 and cisplatin induced apoptosis and tumor regression in cisplatin-
resistant ovarian cancer cells [228]. YM155 is now in Phase II clinical trial [229-230]. 
Recent studies have shown that YM155 is a substrate of the Pgp [231], suggesting that it 
may suffer from multidrug resistance in its later clinical use. 
 
 
Challenges for Development of Survivin Inhibitors 
 
Although survivin is a very promising target for cancer treatment and many 
studies have been carried out to develop survivin inhibitors, the pool of existing survivin 
inhibitors is still relatively small. Several problems limit the development of effective 
survivin inhibitors. Unlike an enzyme or a receptor molecule located on the cell surface, 
survivin is not a traditional target. Survivin is a nodal protein involved in multiple 
processes of cancer cell proliferation, including mitosis, apoptosis and autophagy. It also 
interferes with various molecules such as Hsp90, Borealin, INCENP, aurora B kinase and 
capases. Therefore, it is a significant challenge and is very critical to unambiguously 
confirm that the drug action is resulted from survivin-specific inhibition. Because of such 
challenges, currently it is difficult to evaluate the effectiveness and target specificity of 
survivin inhibitors accurately via high throughput assays. The lack of suitable assays to 
identify survivin inhibition by high throughput screenings is one main factor to impede 
the development of potent and selective survivin inhibitors. Moreover, recent studies 
have shown that survivin exists in certain types of normal cells, mainly hematopoietic 
and immune systems [232]. Potential side effects will be a concern for those normal cells. 
Although clinical studies of survivin inhibitors to date have shown that targeting survivin 
does not cause toxic side effects, the prolonged use of survivin inhibitors should still be 
carefully studied because of the emerging role of survivin in regulating functions in 
normal cells. 
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Conclusion Remarks and Future Directions 
 
 The results from studies in the past fifteen years provide convincing evidence that 
survivin is a promising target for cancer therapy treatment. As discussed in this review, 
survivin distinguishes itself by its unique functional properties, preferentially expressed 
in most human cancer cells, and involves in a myriad of cellular functions. Survivin 
contributes to tumor formation and progression which makes survivin a promising cancer 
drug target. Although there are significant challenges in developing effective survivin 
inhibitors and the number of small-molecule survivin inhibitors is still very limited, 
several potent survivin inhibitors have entered clinical trials, including flavopiridol, 
lapatinib, terameprocol, MK-2206 and YM155. Most of them have shown positive initial 
results, suggesting it is feasible to develop small-molecule inhibitors as efficacious 
anticancer drugs. Lapatinib is the most promising one among them, which is now in 
phase 3 trials. Currently the lack of a survivin-specific assay is limiting the development 
of novel small-molecule survivin inhibitors. Developing optimized assays will greatly 
accelerate research in this field. In addition, further investigations of differential 
mechanisms regulating survivin expression and functions in tumor and normal cells will 
be critical to develop novel strategies for selective survivin inhibition by small molecules. 
Finally, it is well recognized that the efficacy of any single agent including a survivin 
inhibitor may be limited due to high heterogeneity and plasticity in tumor cells. Not 
surprisingly, the combination of survivin inhibitors and other traditional 
chemotherapeutical agents have been evaluated and shown enhanced clinical efficacy, 
indicating the inhibition of survivin can enhance the efficacy of other agents. Thus the 
next direction will be developing the best combinations of survivin inhibitors with other 
existing chemotherapeutical agents for the most efficacious strategy 
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CHAPTER 5.    DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF 
NOVEL SURVIVIN INHIBITORS* 
 
 
Introduction 
 
 Survivin is a unique member of inhibitor of apoptosis protein (IAP) family.[131] 
It is overexpressed in most human cancer cells, but is rarely expressed in adult 
differentiated tissues.[49, 140, 150, 233] This attribute distinguishes survivin from other 
IAPs which are usually expressed in both cancer and normal cells. Survivin promotes cell 
proliferation and inhibits apoptosis, [143, 148, 150-152] facilitates angiogenesis in 
tumors,[138, 234-235] and its expression has been shown to strongly correlate with 
multiple mechanisms of drug resistance.[167-168, 236] Therefore, survivin is widely 
considered to be an ideal cancer drug target. Several molecules in different categories 
including antisense oligonucleotides, dominant-negative mutants, ribozymes, small 
interfering RNAs, cancer vaccines and small molecules have been identified as survivin 
inhibitors.[136] However, due to the challenging requirement to efficiently disrupt 
protein-protein interactions, the pool of existing small molecule survivin inhibitors is 
quite small.[182] The efficacy of those survivin inhibitors is also limited.[136] For 
example, the reported clinical candidate, small molecule survivin inhibitor YM155 has 
been shown to be a substrate of Pgp drug efflux pump, which suggests that YM155 has 
limited efficacy in multiple drug resistant phenotypes.[231] Therefore, it is highly 
significant to develop new survivin inhibitors that can overcome multidrug resistance, 
which is an important goal of our research. 
 
 We recently discovered that UC-112, [5-((benzyloxy)methyl)-7-(pyrrolidin-1-
ylmethyl)quinolin-8-ol], is a potent, selective survivin inhibitor (Figure 5-1).[180] UC-
112 inhibits tumor cell growth in several cancer cell lines in vitro and suppresses 
melanoma tumor growth in vivo. [180] Mechanistic studies indicated that UC-112 
selectively inhibits survivin expression and induces strong cancer cell apoptosis. In order 
to further optimize this unique oxyquinoline scaffold and explore its SAR, we designed 
several focused sets of new UC-112 analogs (Figure 5-1). We introduced four major 
modifications to the structure of UC-112. First, we modified the C ring moiety by 
introducing substitutions to the phenyl ring or replacing it with other groups. Secondly, 
we modified the D ring moiety with other cyclic amines. We also explored different 
chain lengths between the oxygen linker and the C ring moiety. Finally, the linker 
between the B ring and the C ring was modified. By performing these targeted 
modifications, a series of novel UC-112 analogs were obtained.  
 
 
 
-------------------- 
Modified with permission. Xiao, M.; Wang, J.; Lin, Z.; Lu, Y.; Li, Z.; White, S. W.; 
Miller, D. D.; Li, W. Design, Synthesis and Structure-Activity Relationship Studies of 
Novel Survivin Inhibitors with Potent Anti-Proliferative Properties. PLoS One, 2015, 
10(6), e0129807.  
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Figure 5-1. Targeted modification to design new UC-112 analogs 
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 Biological evaluation of these new analogs revealed their excellent anti-
proliferative activity against several cancer cell lines including multidrug resistant 
phenotypes. Mechanism of action studies confirmed that these new UC-112 analogs 
maintained their mechanisms of action by selectively downregulating the level of 
survivin among other IAP family proteins. Preliminary in vivo evaluation for the most 
active compound demonstrated its efficacy against human melanoma tumor growth.  
 
 
Chemistry 
 
 The general synthesis of C ring substituted UC-112 analogs (4a-4l) is outlined in 
Figure 5-2. First 8-hydroxyquinoline reacted with formaldehyde and catalytic zinc 
chloride in concentrated hydrochloric acid to generate salt 2.[237] This step introduced a 
chloromethyl group to the 5-position of quinoline ring. Then salt 2 was allowed to react 
with different substituted benzyl alcohols to form ethers 3a-3l, by two different methods. 
Ethers 3b-3e and ethers 3h-3l were synthesized using step b in which substituted benzyl 
alcohols were allowed to react with salt 2 in the presence of sodium hydride in anhydrous 
THF. Ethers 3a, 3f and 3g were synthesized through step c and step d. In step c, 
substituted benzyl alcohols reacted directly with salt 2 with heating to form different salts 
which were converted to free base by adjusting pH with NH4OH solution in step d.[238] 
The synthesized ethers were then submitted to Mannich reaction with paraformaldehyde 
and pyrrolidine in ethanol to form the final compounds 4a to 4l.[239] Compounds 6a-6g 
with the C ring moiety in UC-112 replaced by different functional groups were prepared 
as Figure 5-3 shown. The ethers 5a-5g were first synthesized using similar approach as 
shown in Figure 5-2. Then these ethers were converted to 6a-6g via the Mannich 
reaction. The synthesis of D ring modified UC-112 analogs 8a and 8b is shown in Figure 
5-4. Salt 2 first reacted with benzyl alcohol to form intermediate 7, which was allowed to 
react with piperidine or morpholine via the Mannich reaction to form compounds 8a and 
8b. Compounds 10a and 10b which have different chain lengths between oxygen and the 
phenyl ring from parent compound UC-112 were made using the method shown in 
Figure 5-5. First salt 2 reacted with 2-phenylethanol and 3-phenyl-1-propanol 
respectively to form 9a and 9b, which then underwent the Mannich reaction with 
paraformaldehyde and pyrrolidine to form compounds 10a and 10b. Finally, compounds 
12a and 12b, which have different linkers between the B ring and C ring as compared to 
the parent compound were made (Figure 5-6). First salt 2 reacted with benzyl mercaptan 
or N-benzymethylamine to form intermediates 11a and 11b. Then 11a and 11b 
underwent the Mannich reaction to form compounds 12a and 12b.  
 
 
Biological Results and Discussion 
 
 All UC-112 analogs were evaluated for their cytotoxicity in a panel of human 
cancer cell lines including melanoma (A375, MDA-MB-435 and its multidrug resistant 
daughter line MDA-MB-435/LCC6MDR1) and prostate cancer (PC-3). UC-112 was also 
included in the assays, serving as positive control and basis for comparison. These in 
vitro biological results are summarized and discussed in detail in the following sections.  
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Figure 5-2. Synthesis of compounds 4a-4l 
Reagents and conditions: (a) conc. HCl, ZnCl2, HCHO (37% in H2O); (b) substituted 
benzyl alcohol, NaH, THF, reflux; (c) substituted benzyl alcohol, 110 oC; (d) NH4OH, 
H2O, Et2O, pH 8-10; (e) paraformaldehyde, pyrrolidine, EtOH, reflux. 
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Figure 5-3. Synthesis of compounds 6a-6g 
Reagents and conditions: (a) R2CH2OH, NaH, THF, reflux; (b) R
2CH2OH, 110 
oC; (c) 
NH4OH, H2O, Et2O, pH 8-10; (d) paraformaldehyde, pyrrolidine,EtOH, reflux. 
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Figure 5-4. Synthesis of compounds 8a-8b 
Reagents and conditions: (a) benzyl alcohol, 110 oC; (b) NH4OH, H2O, Et2O, pH 8-10; 
(c) paraformaldehyde, piperidine for 8a, morpholine for 8b,EtOH, reflux. 
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Figure 5-5. Synthesis of compounds 10a-10b 
Reagents and conditions: (a) 2-phenylethanol for 9a, 3-phenyl-1-propanol for 9b, 110 oC; 
(b) NH4OH, H2O, Et2O, pH 8-10; (c) paraformaldehyde, pyrrolidine, EtOH, reflux. 
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Figure 5-6. Synthesis of compounds 12a-12b 
Reagents and conditions: (a) benzyl mercaptan for 11a, N-Benzylmethylamine for 11b, 
NaH, THF, reflux; (b) paraformaldehyde, pyrrolidine,EtOH, reflux. 
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Effect of Substitutions on the C Ring of UC-112 
 
 The in vitro activity for compounds 4a-4l which have substitutions on the C ring 
of UC-112 is shown in Table 5-1. Most compounds in this table are more active than the 
parent compound UC-112, suggesting that introduction of substitutions to the C ring 
moiety in UC-112 is favorable. Introducing a fluoro group (4a) to the phenyl ring caused 
the increase of activity in three of the four cancer cell lines tested(1.5 µM vs 1.9 µM in 
A375, 1.8 µM vs 2.1 µM in MDA-MB-435 and 0.7 µM vs 1.6 µM in PC-3). Introducing 
a chloro substitution (4b) resulted in even better activity in all four cell lines tested. A 
bromo substitution (4c) further increased activity. Introduction of an electron 
withdrawing group, trifluoromethyl (4d), also resulted in an increase in activity against 
all the cell lines. As the size of substitution increases from fluoro to bromo substitutions, 
a general trend of increased activity was observed (i.e. IC50 in MDA-MB-435 cell line. 
4a: 1.8 µM; 4b: 1.1 µM; 4c: 1.0 µM). This trend is also true for electron donating group 
substituted analogs 4e-4g (i.e. IC50 in MDA-MB-435/LCC6MDR1 cell line. 4e: 4.1 µM; 
4f: 2.7 µM; 4g: 1.8 µM). But the tert-butyl group substituted compound 4h does not 
further increase activity compared to iso-propyl group substituted compound 4g, 
indicating there is probably a size limit for effective binding to survivin. In addition, 
several polar groups which are hydrogen bond acceptors were also tested. However, as 
Table 5-1 shows, compounds 4i-4l do not increase activity significantly compared to 
parent compound UC-112. Compounds 4j and 4k even had decreased activity compared 
to UC-112 (i.e. IC50 in MDA-MB-435/LCC6MDR1 cell line. 4j: 12.1 µM; 4k: 5.5 µM; 
UC-112: 3.2 µM), suggesting that a bulky substitution is unfavorable. Among all the 
compounds in this table, compounds 4c, 4d and 4g are the most potent ones, indicating 
that the introduction of a hydrophobic group to the para-position of C ring is favorable 
for increased activity.  
 
 
Effect of Replacing the Phenyl Ring of UC-112 with Other Groups 
 
 After we tried different substitutions on the phenyl ring of UC-112, we replaced 
the phenyl ring with other groups to further optimize UC-112. Here, we tried seven 
different groups which included furan ring, thiophene ring, pyridine ring, cyclohexyl 
ring, methyl group, ethyl group, and n-propyl group. The in vitro activity for the seven C 
ring modified UC-112 analogs is shown in Table 5-2. In this table, compounds 6a, 6b 
and 6c were less active than UC-112 (i.e. IC50 in A375 cell line. 6a: 2.7 µM; 6b: 2.5 µM; 
6c: 8.4 µM; UC-112: 1.9 µM), indicating that replacing the phenyl ring with other 
heterocyclic rings decreases activity. Replacing the phenyl ring with a cyclohexyl ring 
resulted in an increase in activity in A375 and MDA-MB-435 cell lines. In order to see 
whether a ring is required at the C ring position of UC-112 for activity, compounds 6e, 6f 
and 6g with only aliphatic chains were synthesized. All these compounds decreased 
activity compared to parent compound UC-112 (i.e. IC50 in A375 cell line. 6e: 6.1 µM; 
6f: 5.0 µM; 6g: 3.0 µM; UC-112: 1.9 µM), suggesting a ring system is required at the C 
ring position of UC-112. For compounds 6e, 6f and 6g, there is a general trend for 
activity. As the length of the aliphatic chain increases, the activity increases as well. This 
trend is probably due to the existence of a hydrophobic pocket in the binding site, which   
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Table 5-1 In vitro growth inhibitory effects of UC-112 analogs with C ring 
substitutions 
 
ID 
IC50 ± SEM (μM)  
A375 
MDA-
MB-435 
MDA-MB-
435/LCC6MD
R1 
PC-3 
Resistance 
Index 
4a 1.5 ± 0.2 1.8 ± 0.3 4.4 ± 0.7 0.7 ± 0.2 2.4 
4b 1.5 ± 0.3 1.1 ± 0.1 2.4 ± 0.5 0.9 ± 0.1 2.2 
4c 0.9 ± 0.2 1.0 ± 0.2 1.8 ± 0.6 0.7 ± 0.3 1.8 
4d 0.9 ± 0.3 1.0 ± 0.4 1.9 ± 0.5 1.0 ± 0.1 1.9 
4e 1.7 ± 0.3 2.3 ± 0.5 4.1 ± 2.0 1.1 ± 0.2 1.8 
4f 0.9 ± 0.1 0.9 ± 0.1 2.7 ± 1.0 0.9 ± 0.1 3.0 
4g 0.9 ± 0.1 0.8 ± 0.2 1.8 ± 0.4 0.7 ± 0.1 2.3 
4h 1.1 ± 0.4 ND 1.5 ± 0.7 1.5 ± 0.3 ND 
4i 1.8 ± 0.2 1.5 ± 0.4 3.8 ± 0.6 1.0 ± 0.4 2.5 
4j 2.8 ± 0.1 ND 12.1 ± 0.5 ND ND 
4k 4.7 ± 0.8 ND 5.5 ± 1.3 ND ND 
4l 2.8 ± 0.4 3.6 ± 1.0 > 30 1.6 ± 0.3 > 8.3 
UC-112 1.9 ± 0.6 2.1 ± 0.3 3.2 ± 0.5 1.6 ± 1.0 1.5 
YM-155 ND 0.003 > 10 ND > 2941 
 
Notes: ND: Not Determined. Resistance index is calculated by dividing IC50 values on 
multidrug-resistant cell line MDA-MB-435/LCC6MDR1 by IC50 values on the matching 
sensitive parental cell line MDA-MB-435. Dr. Jin Wang performed the biological testing 
in this table. 
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Table 5-2. In vitro growth inhibitory effects of C ring modified UC-112 analogs 
 
ID 
IC50 ± SEM (μM)  
A375 
MDA-
MB-435 
MDA-MB-
435/LCC6
MDR1 
PC-3 
Resistance 
Index 
6a 2.7 ± 0.3 3.1 ± 0.3 15.3 ± 3.1 27.5 ± 2.0 4.9 
6b 2.5 ± 0.5 1.9 ± 0.9 4.2 ± 0.2 3.4 ± 0.7 2.2 
6c 8.4 ± 1.5 8.0 ± 2.2 > 30 > 30 > 3.8 
6d 1.0 ± 0.1 1.3 ± 0.6 ND ND ND 
6e 6.1 ± 0.7 5.1 ± 2.1 ND ND ND 
6f 5.0 ± 0.3 5.9 ± 1.2 ND ND ND 
6g 3.0 ± 0.5 4.9 ± 1.3 ND ND ND 
UC-112 1.9 ± 0.6 2.1 ± 0.3 3.2 ± 0.5 1.6 ± 1.0 1.5 
 
Note: ND: Not Determined. Dr. Jin Wang performed the biological testing in this table. 
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is consistent with previous observation that introduction of a hydrophobic substitution 
with bigger space occupation on the phenyl ring is favorable for activity. 
 
 
Effect of D Ring Modification on UC-112  
 
 Following C ring modification in the above, we went on with D ring modification 
of UC-112. We tried to replace the pyrrolidine ring with two different cyclic amines: 
piperidine and morpholine at current stage. The in vitro activity for the two D ring 
modified compounds 8a and 8b is show in Table 5-3.Compound 8a showed slightly 
better activity than the parent compound, while compound 8b was less active than UC-
112 (i.e. IC50 in A375 cell line. 8a: 1.1 µM; 8b: 5.0 µM; UC-112: 1.9 µM). This 
observation means the replacement of pyrrolidine ring in UC-112 with a piperidine ring 
maintains activity, while replacing pyrrolidine ring with morpholine ring decreases 
activity. Both compounds 8a and 8b can effectively inhibit the growth of resistant cell 
line MDA-MB-435/LCC6MDR1, suggesting that they can overcome the Pgp-mediated 
multiple drug resistance. The difference in activity between 8a and 8b indicates that the 
D ring position of UC-112 is an important site that further optimization can be carried 
out. 
 
 
Effect of Chain Length between Oxygen and C Ring of UC-112 Analogs 
 
 The chain length between oxygen linker and C ring in the parent compound UC-
112 is one carbon. We tried to test the importance of chain length by increasing the 
carbon numbers. Two compounds 10a and 10b were prepared and their in vitro activity is 
shown in Table 5-4. Both compounds 10a and 10b were less active than the parental 
compound, especially the activity against resistant cell line MDA-MB-435/LCC6MDR1 
reduced from 3.2 to 15~20 µM, suggesting that increasing the chain length was not a 
favorable modification for increasing activity. 
 
 
Effect of Linkers between C Ring and D Ring of UC-112 Analogs 
 
 After the D ring modification, we went on to optimize the linker. We made two 
compounds 12a and 12b with two different linkers from the parent compound. The in 
vitro activity of those tow compounds is shown in Table 5-5. Compound 12a which 
bears a sulfur linker shows increased activity compared with UC-112 (i.e. 1.4 µM vs 1.9 
µM in A375 cell line), meaning sulfur linker here is favorable. Compound 12b which 
contains a methylamine linker was less active (i.e. 7.1 µM vs 1.9 µM in A375 cell line), 
indicating that a methylamine linker is unfavorable. Both compounds 12a and 12b have 
small resistance indexes. Their activity in the resistant cell line MDA-MB-
435/LCC6MDR1 is comparable with that in the parental cell line MDA-MB-435. While 
two compounds can’t determine the optimized linker, at least they give us some 
information about the activity requirement of the linker which is very useful for further 
optimization.  
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Table 5-3. In vitro growth inhibitory effects of D ring modified UC-112 analogs 
 
ID 
IC50 ± SEM (μM)  
A375 
MDA-
MB-435 
MDA-MB-
435/LCC6
MDR1 
PC-3 
Resistance 
Index  
8a 1.1 ± 0.1 1.3 ± 0.2 2.1 ± 0.6 1.3 ± 0.3 1.6 
8b 5.0 ± 1.6 4.8 ± 0.5 3.5 ± 1.0 ND 0.7 
UC-112 1.9 ± 0.6 2.1 ± 0.3 3.2 ± 0.5 1.6 ± 1.0 1.5 
 
Note: ND: Not Determined. Dr. Jin Wang performed the biological testing in this table. 
 
 
 
 
Table 5-4.. In vitro growth inhibitory effects of UC-112 analogs with different 
chain lengths 
 
ID 
IC50 ± SEM (μM)  
A375 
MDA-MB-
435 
MDA-MB-
435/LCC-
6MDR1 
Resistance 
Index 
10a 2.8 ± 0.9 2.9 ± 0.2 15.0 ± 2.5 5.2 
10b 2.4 ± 0.7 2.3 ± 0.8 20.0 ± 1.6 8.7 
UC-112 1.9 ± 0.6 2.1 ± 0.3 3.2 ± 0.5 1.5 
 
Notes: ND: Not Determined. Dr. Jin Wang performed the biological testing in this table. 
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Table 5-5. In vitro growth inhibitory effects of UC-112 analogs with different 
linkers 
 
ID 
IC50 ± SEM (μM)  
A375 
MDA-
MB-435 
MDA-MB-
435/LCC6M
DR1 
PC-3 
Resistance 
Index 
12a 1.4 ± 0.3 1.4 ± 0.2 2.9 ± 0.6 1.1 ± 0.1 2.1 
12b 7.1 ± 0.7 6.2 ± 1.4 8.0 ± 1.0 2.5 ± 0.6 1.3 
UC-112 1.9 ± 0.6 2.1 ± 0.3 3.2 ± 0.5 1.6 ± 1.0 1.5 
 
Notes: ND: Not Determined. Dr. Jin Wang performed the biological testing in this table. 
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UC-112 Analogs Can Overcome Multidrug Resistance 
 
 In order to determine whether the new analogs we made can overcome multidrug 
resistance, we compared the activity of those analogs against multidrug resistant 
melanoma cells (MDA-MB-435/LCCMDR1) and their parental sensitive cancer cells 
(MDA-MB-435). This pair of cell lines have been well validated and widely used to 
assess abilities of drugs overcoming Pgp-mediated multidrug resistance.[124, 126-127] 
Our three best compounds 4c, 4d and 4g together with the most successful small 
molecule survivin inhibitor YM155 were tested on both the multidrug resistant melanoma 
cells and their parental cells (Table 5-1). The resistance index is calculated by dividing 
the IC50 value of the resistant cell line by IC50 value of the sensitive parental cell line. So 
the smaller this value, the better resistance overcoming effect obtained. As this table 
shows, compounds 4c, 4d and 4g all have very small resistance indexes (1.8, 1.9 and 2.3 
respectively). Their activity in the resistant cell line is comparable with that in the 
parental cell line. For existing survivin inhibitor, YM155, although it is very potent in 
parental cell line (IC50 at 3 nM), its activity in resistant cell line is considerably lower 
(IC50 is higher than 10 μΜ, resistance index is higher than 2941). This data indicates that 
the new UC-112 analogs can circumvent Pgp-mediated multidrug resistance and are 
distinct from that of YM-155. 
 
 
UC-112 Analogs Show Good Antiproliferative Effects with Selectivity in NCI-60 
Cell Line Screening 
 
 UC-112 and three potent analogs 4c, 4g and 12a were submitted to NCI for its 
one-concentration (10 µM) screening against the NCI-60 cell lines. All four compounds 
showed good activity and were selected for the subsequent five doses testing to determine 
their growth inhibition potency (GI50) in the NCI-60 cell lines. As shown in Figure 5-7, 
structure modification from UC-112 to our best compound 4g has improved the average 
GI50 by nearly four times (2.2 µM for UC-112 vs. 0.5 µM for 4g).  
 
 The heat map in Figure 5-8 summarizes the compound growth inhibition pattern 
which is characterized by the GI50 mean values from NCI-60 screening. UC-112 and its 
new analogs showed interesting selective growth inhibition behavior within the NCI 60 
cell lines. The GI50 value of compound 4g in renal cancer cell line UO-31 was as low as 
52.5 nM. Interestingly, two other cell lines, HCT-15 (colon cancer) and NCI/ADR-RES 
(ovarian cancer), were also particularly sensitive to the treatment of UC-112 and its 
analogs, with lowest GI50 value (highest activity) for compound 4g at 46.8 nM and 50.1 
nM, respectively. Since colorectal adenocarcinoma HCT-15 cells intrinsically expresses 
moderate levels of Pgp, multidrug resistance associated protein (MRP) and lung 
resistance associated protein (LRP) [240], and ovarian cancer NCI/ADR-RES cells are 
naturally over-expressing MDR1 and resistant to various chemotherapies including 
doxorubicin [241], these data have supported our findings that UC-112 and its analogs 
could effectively overcome the multidrug resistance in vitro. 
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Figure 5-7 Average GI50 data for UC-112, compound 12c, 4c and 4g tested in 
NCI-60 anti-proliferative screening 
Data is shown with mean ± SD as bar graph. 
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Figure 5-8. Heat map showing the GI50 values (nM) for UC-112 and three analogs 
in the NCI-60 screening 
High intensity (blue) cells indicate high activity and low intensity (red) cells indicate low 
activity. Average GI50 values were calculated for each compound, separately. 
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Compound 4g Possesses Good Drug-Like Properties 
 
 Adsorption, distribution, metabolism and elimination (ADME) properties are key 
elements in small molecule drug development. Poor ADME property is one of the major 
contributors of failure in advancing new compounds towards drug approval. To 
preliminarily evaluate the overall drug-like properties for the UC-112 scaffold, we sent 
our best compound 4g to an external contract research company (Eurofins Panlabs Inc., 
Redmond, WA) to determine its aqueous solubility and in vitro ADME properties. The 
aqueous solubility for compound 4g was tested in PBS solution at pH 7.4 (Table 5-6) and 
the result showed that compound 4g had very good aqueous solubility of 148.7 µM. The 
in vitro microsomal stability for compound 4g was determined in human liver 
microsomes. The result showed that it had a reasonable half life time at 51 minutes with a 
medium clearance rate at 136.6 μL/min/mg. Drug metabolism studies using cytochrome 
P450 inhibition by compound 4g (Table 5-7) showed weak inhibition for most 
cytochrome P450 enzymes (less than 30%) except CYP2D6. This study suggests that the 
UC-112 scaffold demonstrated by compound 4g has good drug-like properties, which 
clearly warrants its further development. 
 
 
Mechanism of Action Studies 
 
 In our recently report, [180] UC-112 induces apoptosis by selectively inhibiting 
the expression of survivin in cancer cells. In order to determine whether the new UC-112 
analogs maintained the same mechanism of action, we performed the caspases activation 
and Western blotting assay for two potent new analogs 4f and 4g in two cancer cell lines 
(Figure 5-9). Both compounds 4f and 4g dose-dependently suppressed survivin level in 
these two cancer cell lines, while the levels of other IAPs were minimally affected. The 
presence of compound 4g at 300 nM reduced survivin levels over 50% in both A375 and 
PC-3 cells as shown in the lane density data quantified by ImageJ software. The IC50 
values for survivin inhibition were estimated to be in the low nano-molar range. 
Furthermore, incubation of compound 12a, 4c or 4g at concentration of 1 µM for 24 h 
significantly activated the executioner caspases 3/7 up to 4 folds higher than the DMSO 
control group (Figure 5-10). This is consistent with the expected enhanced apoptosis 
induction capability due to survivin inhibition. 
 
 
Molecular Modeling Study 
 
 To understand the observed improvement in potency of compound 4g over its 
parental compound UC-112, we developed a molecular model and performed the 
molecular docking study using the complex of human survivin-SMAC AVPI (PDB entry: 
3UIH). As shown in Figure 5-11, UC-112 displayed several interesting interactions with 
the survivin protein BIR domain: (1) two hydrogen bonding interactions between the 
A/B-ring of UC-112 and residue Asp71; (2) one hydrogen bonding interaction between 
the D-ring nitrogen and residue Glu68; and (3) an π- π stacking interaction between the 
A/B-ring of UC-112 and residue Typ67 (Figure 5-11A). Examination of this proposed   
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Table 5-6 Aqueous solubility and in vitro metabolism properties of compound 4g 
 
ID 
Solubility a 
(μM) 
Half-Life b (min) 
Clint 
(μL/min/mg) 
4g 148.7 51.0 136.6 
 
Note: a: test concentration is 200 μM; b: test concentration is 100 nM. Eurofins Panlabs 
Inc. performed the experiments in this table. 
 
 
 
 
Table 5-7. Cytochrome P450 inhibition effects of compound 4g 
 
CYP enzyme Substrate 
% Inhibition of 
Control Values 
CYP1A phenacetin 18 
CYP2B6 bupropion 21 
CYP2C8 paclitaxel 21 
CYP2C9 diclofenac 17 
CYP2C19 omeprazole 45 
CYP2D6 dextromethorphan 87 
CYP3A midazolam 3 
CYP3A testosterone 29 
 
Note: Eurofins Panlabs Inc. performed the experiments in this table. 
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Figure 5-9 Western blotting assay of A375 and PC-3 cells treated with gradient 
increasing dose of 4f or 4g for 24 h 
Left panel is in A375 cancer cell line. Right panel is in PC-3 cancer cell line. 
Note: Dr. Jin Wang performed the experiments for this figure. 
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Figure 5-10. Relative in vitro caspases 3/7 activity of human melanoma A375 or 
human prostate cancer PC-3 cells were evaluated after treatment of UC-112 analogs 
( 1 µM) for 24 h (N = 3) 
The luminescence unit data was adjusted according to the cell viability results read from 
the same well in 96-well plate. ***P < 0.001, **P < 0.01 compared with corresponded 
results from control group. 
Note: Dr. Jin Wang performed the experiments for this figure. 
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Figure 5-11. Potential binding pose of UC-112 and compound 4g in the SMAC N-
terminus tetra-peptide AVPI binding site of survivin crystal structure (PDB entry: 
3UIH) 
The surface of AVPI binding site in survivin was colored according to residue charge 
(blue for positive while red for negative). (a) UC-112 (green tube) formed hydrogen 
bonds with residue Asp71 and Glu68 on the survivin protein BIR domain. (b) Compound 
4g (orange tube) displayed similar binding pose with UC-112 but had better occupied the 
grove toward the N-terminus of survivin protein. And this pose was overlapping well 
with the binding mode of native ligand, SMAC AVPI (green stick).  
Note: Dr. Jin Wang performed the experiments for this figure. 
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binding pose clearly suggests that the un-substituted phenyl ring of UC-112 failed to 
occupy a hydrophobic groove (cycled with green dash line in Figure 5-11A), and a 
properly sized, non-polar para-substitution (e.g., an isopropyl moiety as in compound 4g) 
to this ring would fill this groove and also provide excellent overlap with the bioactive 
AVPI peptide (Figure 5-11B). This is consistent with our experimental observations. 
Further refinement to this model, and ultimately an X-ray crystal structure will greatly 
facilitate the future optimization of this scaffold. 
 
 
Drug Affinity Responsive Target Stability (DARTS) Assay 
 
 To investigate that whether the survivin down-regulation effect is caused by direct 
interaction between survivin protein and UC-112 analogs, we performed DARTS assay 
which is a well-established target identification method [242-245]. DARTS assay relies 
on the increasing of proteolysis resistance of the target protein generated by the 
interaction with small molecular ligand. We utilized immunoblotting to detect the 
abundances of several proteins including survivin in MDA-MB-435 or A375 cell lysates 
either undigested or digested by different concentrations of pronase. Representative data 
shown in Figure 5-12 clearly indicated that the protease susceptibility of survivin is 
significantly reduced in cell lysates pre-treated with 20 µM 4g, comparing with the 
GAPDH control group. Consistent with its selective survivin inhibition, 4g has negligible 
effects to protease susceptibility for other IAPs such as XIAP, cIAP1 or cIAP2. This 
observation suggested a possible direct interaction between 4g and survivin protein in cell 
lysates that will be confirmed by X-ray crystallography in the future.  
 
 
In Vivo Anti-Tumor Efficacy Assessment 
 
 Since our in vitro study showed that compound 4g has the highest anti-
proliferative potency in this series of UC-112 analogs, we selected 4g to test its in vivo 
efficacy against tumor growth in a human melanoma A375 xenograft model through i.p 
injection. As shown in Figure 5-13A, compound 4g inhibited the growth of A375 
xenograft tumor in a dose-dependent manner during the three weeks of continuous 
treatment. The tumor growth in compound 4g 20 mg/kg and 40 mg/kg treatment group is 
53% and 79% slower than the vehicle control group, respectively. Furthermore, Western 
blotting analysis revealed that the expression levels of survivin and XIAP protein 
decreased in tumor tissues which were freshly collected from compound 4g treated 
groups (Figure 5-13B). Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay, which measured the nuclear DNA fragmentation, showed that a high 
dose (40 mg/kg) of compound 4g treatment caused the widely-spread cell apoptosis 
inside the tumor tissues (Figure 5-13C). 
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Figure 5-12. Representative drug affinity responsive target stability (DARTS) 
results for pronase-digested A375 or M14 cell lysates 
Immunoblotting showed protection of the target protein, survivin, by incubation with 
compound 4g at the concentration of 20 µM, whereas digestion of the non-target proteins 
like GAPDH was unchanged. 
Note: Dr. Jin Wang performed the experiments for this figure. 
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Figure 5-13.. In vivo anti-tumor efficacy of compound 4g (N = 6) 
(a) 4g effectively inhibited the growth of A375 xenograft tumor after three weeks 
continuous treatment (i.p. injection) in a dose-dependent manner (left panel) without 
causing obvious decrease of mice body weight (right panel). (b) Western blotting results 
on the A375 xenograft tumor tissues (each lane represents one single mice). (c) 
Representative images of TUNEL assay using the formalin-fixed tumor sections.  
Note: Dr. Jin Wang performed the experiments for this figure. 
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Experimental Section 
 
 
General 
 
 All animal studies described in this manuscript have been approved by the 
IACUC at the University of Tennessee Health Science Center. All reagents were 
purchased from Sigma-Aldrich Chemical Co., Alfa Aesar (Ward Hill, MA), and AK 
Scientific (Mountain View, CA) and were used without further purification. Routine thin 
layer chromatography (TLC) was performed on aluminum-backed Uniplates (Analtech, 
Newark, DE). NMR spectra were obtained on a Varian Inova-500 spectrometer (Agilent 
Technologies, Santa Clara, CA) or a Bruker Ascend 400 (Billerica, MA) spectrometer. 
Chemical shifts are reported as parts per million (ppm) relative to TMS in CDCl3. High 
Resolution Mass spectra were collected in positive detection mode on a Waters Xevo G2-
S Tof instrument equipped with an electron-spray ionization (ESI) source (Milford, MA). 
 
 
Preparation of 5-Chloromethyl-8-Quinolinol Hydrochloride (2) 
 
 A mixture of 5.84 g (40.0 mmol) of 8-quinolinol, 50 ml of concentrated 
hydrochloric acid, and 6.4 ml of 37% formaldehyde was treated with 0.6 g of zinc 
chloride and stirred for 12 h. The mixture was filtered, washed with copious acetone and 
dried to give compound 2 as a yellow solid (7.2g, 78%). 1H NMR (400 MHz, Deuterium 
Oxide) δ 9.12 (dd, J = 8.7, 1.4 Hz, 1H), 8.88 (dd, J = 5.5, 1.4 Hz, 1H), 7.97 (dd, J = 8.7, 
5.4 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.24 (d, J = 7.9 Hz, 1H), 4.93 (s, 2H).  
 
 
General Procedure for the Preparation of Compounds (3a-3l) 
 
 Method A (only for 3a,3f and 3g): 5-chloromethyl-8-quinolinol hydrochloride 2 
(1.15 g, 5 mmol) was suspended in substituted benzyl alcohol 3 (25 mmol) and the 
mixture was heated at 90 °C for 2 h, during which time the solution became completely 
homogeneous. The solution was then poured to 200 ml diethyl ether. The corresponding 
hydrochloride salt was recovered by filtration as a bright yellow solid. The yellow solid 
was then suspended in diethyl ether and aqueous NH4OH (2.5% v/v, 7.5 mL, ~1.2 equiv.) 
was added drop by drop under vigorous stirring until the aqueous phase was basic (pH 8-
10). The organic phase was washed with water, dried with anhydrous sodium sulfate and 
evaporated to dryness to afford the desired ethers. 
 
 Method B ( for 3b-e and 3h-l): To a solution of substituted benzyl alcohol 3 (6 
mmol) in anhydrous THF (30ml) was added sodium hydride (60% dispersion in mineral 
oil, 0.72g, 18 mmol) at 0 oC. The suspension was stirred at 0 oC for 30 minutes. Salt 2 
(1.15g, 5mmol) was added to the suspension. The mixture was stirred at r.t for 3 hours. 
Water was added to the suspension, the mixture became homogeneous. The mixture was 
extracted by ethyl acetate and washed with brine, dried over anhydrous sodium sulfate 
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and concentrated to get the crude. The crude compound was purified by flash 
chromatography (ethyl acetate: hexane 3:1). 
 
5-(((4-Fluorobenzyl)oxy)methyl)quinolin-8-ol(3a). 1H NMR (400 MHz, 
Chloroform-d) δ 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.47 (dd, J = 8.5, 1.5 Hz, 1H), 7.49 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.11 (d, J = 7.7 Hz, 
1H), 7.06 – 6.98 (m, 2H), 4.87 (s, 2H), 4.50 (s, 2H). 
 
5-(((4-Chlorobenzyl)oxy)methyl)quinolin-8-ol(3b). 1H NMR (400 MHz, 
Chloroform-d) δ 8.83 (dd, J = 4.2, 1.6 Hz, 1H), 8.51 (dd, J = 8.5, 1.6 Hz, 1H), 7.52 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.36 – 7.31 (m, 5H), 7.14 (d, J = 7.7 Hz, 
1H), 4.90 (s, 2H), 4.53 (s, 2H). 
 
5-(((4-Bromobenzyl)oxy)methyl)quinolin-8-ol(3c). 1H NMR (400 MHz, 
Chloroform-d) δ 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.47 (dd, J = 8.5, 1.6 Hz, 1H), 7.51 – 7.45 
(m, 3H), 7.41 (d, J = 7.7 Hz, 1H), 7.22 – 7.17 (m, 2H), 7.11 (d, J = 7.7 Hz, 1H), 4.87 (s, 
2H), 4.48 (s, 2H).  
 
5-(((4-(Trifluoromethyl)benzyl)oxy)methyl)quinolin-8-ol(3d). 1H NMR (400 
MHz, Chloroform-d) δ 8.75 (dd, J = 4.2, 1.6 Hz, 1H), 8.45 (dd, J = 8.5, 1.6 Hz, 1H), 7.56 
– 7.49 (m, 2H), 7.45 (dd, J = 8.5, 4.3 Hz, 1H), 7.36 (ddd, J = 7.8, 2.0, 1.2 Hz, 3H), 7.08 
(d, J = 7.7 Hz, 1H), 4.85 (s, 2H), 4.51 (s, 2H). 
 
5-(((4-Methylbenzyl)oxy)methyl)quinolin-8-ol(3e). 1H NMR (500 MHz, 
Chloroform-d) δ 8.72 (dd, J = 4.2, 1.6 Hz, 1H), 8.40 (dd, J = 8.5, 1.6 Hz, 1H), 7.40 (dd, J 
= 8.5, 4.1 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.15 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 7.8 Hz, 
2H), 7.03 (d, J = 7.7 Hz, 1H), 4.78 (s, 2H), 4.44 (s, 2H), 2.28 (s, 3H). 
 
5-(((4-Ethylbenzyl)oxy)methyl)quinolin-8-ol(3f). 1H NMR (400 MHz, 
Chloroform-d) δ 8.72 (dd, J = 4.2, 1.6 Hz, 1H), 8.41 (dd, J = 8.5, 1.5 Hz, 1H), 7.40 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.17 (d, J = 2.1 Hz, 2H), 7.11 (d, J = 8.0 Hz, 
2H), 7.03 (d, J = 7.7 Hz, 1H), 4.79 (s, 2H), 4.44 (s, 2H), 2.58 (q, J = 7.6 Hz, 2H), 1.16 (t, 
J = 7.6 Hz, 3H).  
 
5-(((4-Isopropylbenzyl)oxy)methyl)quinolin-8-ol(3g). 1H NMR (400 MHz, 
Chloroform-d) δ 8.72 (dd, J = 4.2, 1.6 Hz, 1H), 8.41 (dd, J = 8.5, 1.6 Hz, 1H), 7.40 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.18 (d, J = 4.2 Hz, 2H), 7.14 (d, J = 8.2 Hz, 
2H), 7.03 (d, J = 7.7 Hz, 1H), 4.80 (s, 2H), 4.44 (s, 2H), 2.83 (p, J = 6.9 Hz, 1H), 1.17 (d, 
J = 7.0 Hz, 6H). 
 
5-(((4-(Tert-butyl)benzyl)oxy)methyl)quinolin-8-ol(3h). 1H NMR (400 MHz, 
Chloroform-d) δ 8.67 (dd, J = 4.2, 1.6 Hz, 1H), 8.37 (dd, J = 8.5, 1.6 Hz, 1H), 7.35 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.25 (d, J = 8.5 Hz, 2H), 7.17 – 7.13 (m, 
2H), 6.98 (d, J = 7.7 Hz, 1H), 4.76 (s, 2H), 4.40 (s, 2H), 1.20 (s, 9H).  
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5-(((4-Methoxybenzyl)oxy)methyl)quinolin-8-ol(3i). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.47 (dd, J = 8.5, 1.6 Hz, 1H), 7.48 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.28 – 7.23 (m, 2H), 7.10 (d, J = 7.7 Hz, 
1H), 6.93 – 6.82 (m, 2H), 4.84 (s, 2H), 4.48 (s, 2H), 3.81 (s, 3H). 
 
5-(((4-(Benzyloxy)benzyl)oxy)methyl)quinolin-8-ol(3j). 1H NMR (500 MHz, 
Chloroform-d) δ 8.84 (d, J = 4.2 Hz, 1H), 8.51 (d, J = 8.5 Hz, 1H), 7.53 – 7.41 (m, 6H), 
7.37 (t, J = 7.3 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.16 (d, J = 7.6 Hz, 1H), 7.06 – 6.98 (m, 
2H), 5.12 (s, 2H), 4.89 (s, 2H), 4.53 (s, 2H). 
 
N-(4-(((8-Hydroxyquinolin-5-yl)methoxy)methyl)phenyl)acetamide(3k). 1H 
NMR (400 MHz, DMSO-d6) δ 9.93 (s, 1H), 9.86 (s, 1H), 8.87 (dd, J = 4.1, 1.6 Hz, 1H), 
8.47 (dd, J = 8.6, 1.6 Hz, 1H), 7.60 (dd, J = 8.6, 4.2 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.44 
(d, J = 7.8 Hz, 1H), 7.28 – 7.21 (m, 2H), 7.02 (d, J = 7.7 Hz, 1H), 4.83 (s, 2H), 4.47 (s, 
2H), 2.03 (s, 3H). 
 
5-(((3,4,5-Trimethoxybenzyl)oxy)methyl)quinolin-8-ol (3l). 1H NMR (400 
MHz, Chloroform-d) δ 8.85 (dd, J = 4.3, 1.5 Hz, 1H), 8.57 (dd, J = 8.5, 1.5 Hz, 1H), 7.53 
(dd, J = 8.5, 4.2 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 6.56 (s, 2H), 
4.92 (s, 2H), 4.50 (s, 2H), 3.86 (s, 3H), 3.84 (s, 6H) 
 
 
General Procure for the Preparation of Compounds (4a-4l) 
 
 An equimolar mixture of the substrates 3, paraformaldehyde, and the pyrrolidine 
in anhydrous ethanol (30 mL) was refluxed for 4 hours under argon. After cooling, the 
solvent was evaporated under reduced pressure. The crude compound was purified by 
flash chromatography (Dichloromethane: methanol 20: 1). 
 
5-(((4-Fluorobenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4a). 
1H NMR (400 MHz, Chloroform-d) δ 8.91 (dd, J = 4.1, 1.6 Hz, 1H), 8.40 (dd, J = 8.5, 1.7 
Hz, 1H), 7.44 (dd, J = 8.5, 4.2 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.26 (s, 1H), 7.10 – 6.97 (m, 
2H), 4.87 (s, 2H), 4.55 (s, 2H), 4.02 (s, 2H), 2.84 – 2.61 (m, 4H), 2.01 – 1.79 (m, 4H). 
HRMS (ESI): m/z calculated for C22H23FN2O2 + H
+ [M + H+]: 367.1822; Found: 
367.1828. 
 
5-(((4-Chlorobenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4b). 
1H NMR (400 MHz, Chloroform-d) δ 8.82 (dd, J = 4.1, 1.6 Hz, 1H), 8.30 (dd, J = 8.5, 1.7 
Hz, 1H), 7.34 (dd, J = 8.5, 4.1 Hz, 1H), 7.27 – 7.22 (m, 2H), 7.21 – 7.17 (m, 2H), 7.15 (s, 
1H), 4.77 (s, 2H), 4.45 (s, 2H), 3.92 (s, 2H), 2.70 – 2.56 (m, 4H), 1.88 – 1.74 (m, 4H). 
HRMS (ESI): m/z calculated for C22H23ClN2O2 + H
+ [M + H+]: 383.1526; Found: 
383.1521. 
 
5-(((4-Bromobenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4c). 
1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.2, 1.7 Hz, 1H), 8.38 (dd, J = 8.5, 1.7 
Hz, 1H), 7.49 – 7.44 (m, 2H), 7.42 (dd, J = 8.5, 4.1 Hz, 1H), 7.25 (s, 1H), 7.23 – 7.17 (m, 
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2H), 4.85 (s, 2H), 4.51 (s, 2H), 4.01 (s, 2H), 2.84 – 2.64 (m, 4H), 1.97 – 1.81 (m, 4H). 
HRMS (ESI): m/z calculated for C22H23BrN2O2 + H
+ [M + H+]: 427.1021; Found: 
427.1015.  
 
7-(Pyrrolidin-1-ylmethyl)-5-(((4-
(trifluoromethyl)benzyl)oxy)methyl)quinolin-8-ol(4d). 1H NMR (500 MHz, 
Chloroform-d) δ 8.91 (dd, J = 4.1, 1.6 Hz, 1H), 8.42 (dd, J = 8.5, 1.7 Hz, 1H), 7.61 (d, J 
= 8.0 Hz, 2H), 7.49 – 7.40 (m, 3H), 7.27 (d, J = 3.1 Hz, 1H), 4.90 (s, 2H), 4.62 (s, 2H), 
4.02 (s, 2H), 2.82 – 2.68 (m, 4H), 1.97 – 1.85 (m, 4H). HRMS (ESI): m/z calculated for 
C23H23F3N2O2 + H
+ [M + H+]: 417.1790; Found: 417.1792.  
 
5-(((4-Methylbenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4e). 
1H NMR (500 MHz, Chloroform-d) δ 8.80 (dd, J = 4.2, 1.7 Hz, 1H), 8.31 (dd, J = 8.5, 1.7 
Hz, 1H), 7.34 (dd, J = 8.5, 4.1 Hz, 1H), 7.23 (s, 1H), 7.16 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 
7.7 Hz, 2H), 4.75 (s, 2H), 4.46 (s, 2H), 3.96 (s, 2H), 2.80 – 2.65 (m, 4H), 2.28 (s, 3H), 
1.88 -1.78 (m, 4H). HRMS (ESI): m/z calculated for C23H26N2O2 + H
+ [M + H+]: 
363.2073; Found: 363.2078. 
 
5-(((4-Ethylbenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4f). 1H 
NMR (400 MHz, Chloroform-d) δ 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.30 (dd, J = 8.5, 1.7 
Hz, 1H), 7.33 (dd, J = 8.5, 4.1 Hz, 1H), 7.20 (s, 1H), 7.18 (d, J = 5.4 Hz, 2H), 7.12 (d, J = 
8.1 Hz, 2H), 4.76 (s, 2H), 4.47 (s, 2H), 3.93 (s, 2H), 2.70 – 2.62 (m, 4H), 2.58 (q, J = 7.6 
Hz, 2H), 1.88 – 1.74 m, 4H), 1.16 (t, J = 7.6 Hz, 3H). HRMS (ESI): m/z calculated for 
C24H28N2O2 + H
+ [M + H+]: 377.2229; Found: 377.2240. 
 
5-(((4-Isopropylbenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-
ol(4g). 1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.1, 1.6 Hz, 1H), 8.38 (dd, J = 
8.5, 1.6 Hz, 1H), 7.40 (dd, J = 8.5, 4.1 Hz, 1H), 7.29 (s, 1H), 7.26 – 7.20 (m, 4H), 4.85 (s, 
2H), 4.55 (s, 2H), 4.00 (s, 2H), 2.92 (p, J = 6.9 Hz, 1H), 2.78 – 2.60 (m, 4H), 1.96 – 1.80 
(m, 4H), 1.25 (d, J = 6.9 Hz, 6H). HRMS (ESI): m/z calculated for C25H30N2O2 + H
+ [M 
+ H+]: 391.2386; Found: 391.2377.  
 
5-(((4-(Tert-butyl)benzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-
ol(4h). 1H NMR (400 MHz, Chloroform-d) δ 8.81 (dd, J = 4.1, 1.6 Hz, 1H), 8.31 (dd, J = 
8.5, 1.7 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.23 – 7.19 (m, 2H), 4.78 (s, 2H), 4.47 (s, 2H), 
3.94 (s, 2H), 2.77 – 2.50 (m, 4H), 1.90 – 1.74 (m, 4H), 1.25 (s, 9H). HRMS (ESI): m/z 
calculated for C26H32N2O2 + H
+ [M + H+]: 405.2542; Found: 405.2535.  
 
5-(((4-Methoxybenzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(4i). 
1H NMR (500 MHz, Chloroform-d) δ 8.89 (dd, J = 4.1, 1.7 Hz, 1H), 8.38 (dd, J = 8.5, 1.7 
Hz, 1H), 7.41 (dd, J = 8.5, 4.1 Hz, 1H), 7.30 – 7.27 (m, 2H), 7.25 (s, 1H), 6.97 – 6.83 (m, 
2H), 4.83 (s, 2H), 4.52 (s, 2H), 4.01 (s, 2H), 3.82 (s, 3H), 2.86 – 2.62 (m, 4H), 1.96 – 
1.79 (m, 4H). HRMS (ESI): m/z calculated for C23H26N2O3 + H
+ [M + H+]: 379.2022; 
Found: 379.2025.  
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5-(((4-(Benzyloxy)benzyl)oxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-
ol(4j). 1H NMR (400 MHz, Chloroform-d) δ 8.80 (dd, J = 4.1, 1.6 Hz, 1H), 8.30 (dd, J = 
8.5, 1.7 Hz, 1H), 7.39 – 7.29 (m, 5H), 7.28 – 7.20 (m, 4H), 6.94 – 6.85 (m, 2H), 5.00 (s, 
2H), 4.75 (s, 2H), 4.44 (s, 2H), 3.97 (s, 2H), 2.80 – 2.60 (m, 4H), 1.90 – 1.76 (m, 4H). 
HRMS (ESI): m/z calculated for C29H30N2O3 + H
+ [M + H+]: 455.2335; Found: 
455.2335. 
 
N-(4-(((8-Hydroxy-7-(pyrrolidin-1-ylmethyl)quinolin-5-yl)methoxy) 
methyl)phenyl)acetamide(4k). 1H NMR (400 MHz, Chloroform-d) δ 8.81 (dd, J = 4.1, 
1.7 Hz, 1H), 8.30 (dd, J = 8.5, 1.7 Hz, 1H), 7.42 (d, J = 8.4 Hz, 2H), 7.34 (dd, J = 8.5, 4.1 
Hz, 1H), 7.25 – 7.20 (m, 2H), 7.18 (s, 1H), 4.75 (s, 2H), 4.46 (s, 2H), 3.94 (s, 2H), 2.76 – 
2.66 (m, 4H), 2.11 (s, 3H), 1.88 – 1.76 (m, 4H). HRMS (ESI): m/z calculated for 
C24H27N3O3 + H
+ [M + H+]: 406.2131; Found: 406.2136. 
 
7-(Pyrrolidin-1-ylmethyl)-5-(((3,4,5-trimethoxybenzyl)oxy)methyl)quinolin-8-
ol(4l). 1H NMR (400 MHz, Chloroform-d) δ 8.82 (dd, J = 4.1, 1.6 Hz, 1H), 8.34 (dd, J = 
8.5, 1.7 Hz, 1H), 7.34 (dd, J = 8.5, 4.1 Hz, 1H), 7.19 (s, 1H), 6.48 (s, 2H), 4.79 (s, 2H), 
4.42 (s, 2H), 3.93 (s, 2H), 3.77 (s, 3H), 3.76 (s, 6H), 2.78 – 2.48 (m, 4H), 1.89 – 1.66 (m, 
4H). HRMS (ESI): m/z calculated for C25H30N2O5 + H
+ [M + H+]: 439.2233; Found: 
439.2245. 
 
 
General Procure for the Preparation of Compounds (5a-5g) 
 
 Method A (for 5a-5d): To a solution of alcohols (6 mmol) in anhydrous 
THF(30ml) was added sodium hydride (60% dispersion in mineral oil, 0.72g, 18 mmol) 
at 0 oC. The suspension was stirred at 0 oC for 30 minutes. Salt 2 (1.15g, 5mmol) was 
added to the suspension. The mixture was stirred at r.t for 3 hours. Water was added to 
the suspension, the mixture became homogeneous. The mixture was extracted by ethyl 
acetate and washed with brine, dried over anhydrous sodium sulfate and concentrated to 
get the crude. The crude compound was purified by flash chromatography (ethyl acetate: 
hexane 3:1). 
 
 Method B (for 5e-5g): 5-chloromethyl-8-quinolinol hydrochloride 2 (1.15 g, 5 
mmol) was suspended in different alcohols (25 mmol) and the mixture was heated at 90 
°C for 2 h, during which time the solution became completely homogeneous. The 
solution was then poured to 200 ml diethyl ether. The corresponding hydrochloride salt 
was recovered by filtration as a bright yellow solid. The yellow solid was then suspended 
in diethyl ether and aqueous NH4OH (2.5% v/v, 7.5 mL, ~1.2 equiv.) was added drop by 
drop under vigorous stirring until the aqueous phase was basic (pH 8-10). The organic 
phase was washed with water, dried with anhydrous sodium sulfate and evaporated to 
dryness to afford the desired products. 
 
5-((Furan-2-ylmethoxy)methyl)quinolin-8-ol(5a). 1H NMR (400 MHz, 
Chloroform-d) δ 8.72 (dd, J = 4.3, 1.6 Hz, 1H), 8.37 (dd, J = 8.5, 1.5 Hz, 1H), 7.41 (dd, J 
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= 8.5, 4.2 Hz, 1H), 7.38 – 7.33 (m, 2H), 7.03 (d, J = 7.7 Hz, 1H), 6.32 – 6.24 (m, 2H), 
4.79 (s, 2H), 4.42 (s, 2H). 
 
5-((Thiophen-2-ylmethoxy)methyl)quinolin-8-ol(5b). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.48 (dd, J = 8.5, 1.6 Hz, 1H), 7.48 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.42 (d, J = 7.7 Hz, 1H), 7.31 (dd, J = 4.8, 1.5 Hz, 1H), 7.10 (d, J = 
7.7 Hz, 1H), 7.00 – 6.97 (m, 2H), 4.88 (s, 2H), 4.70 (s, 2H). 
 
5-((Pyridin-2-ylmethoxy)methyl)quinolin-8-ol(5c). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.58 – 8.52 (m, 2H), 7.67 (td, J = 7.7, 1.8 
Hz, 1H), 7.50 (dd, J = 8.5, 4.2 Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 7.40 (dt, J = 7.8, 1.0 Hz, 
1H), 7.21 – 7.16 (m, 1H), 7.11 (d, J = 7.7 Hz, 1H), 4.98 (s, 2H), 4.70 (s, 2H). 
 
5-((Cyclohexylmethoxy)methyl)quinolin-8-ol(5d). 1H NMR (400 MHz, 
Chloroform-d) δ 8.72 (dd, J = 4.2, 1.6 Hz, 1H), 8.43 (dd, J = 8.5, 1.6 Hz, 1H), 7.42 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.34 (d, J = 7.7 Hz, 1H), 7.02 (d, J = 7.7 Hz, 1H), 4.73 (s, 2H), 3.21 
(d, J = 6.5 Hz, 2H), 1.79 – 1.41 (m, H), 1.23 – 0.97 (m, 3H), 0.91 – 0.73 (m, 2H). 
 
5-(Ethoxymethyl)quinolin-8-ol(5e). 1H NMR (400 MHz, Chloroform-d) δ 8.73 
(dd, J = 4.2, 1.6 Hz, 1H), 8.43 (dd, J = 8.5, 1.6 Hz, 1H), 7.42 (dd, J = 8.5, 4.2 Hz, 1H), 
7.35 (d, J = 7.6 Hz, 1H), 7.03 (d, J = 7.7 Hz, 1H), 4.76 (s, 2H), 3.50 (q, J = 7.0 Hz, 2H), 
1.16 (t, J = 7.0 Hz, 3H). 
 
5-(Propoxymethyl)quinolin-8-ol(5f). 1H NMR (400 MHz, Chloroform-d) δ 8.72 
(dd, J = 4.1, 1.6 Hz, 1H), 8.44 (dd, J = 8.5, 1.6 Hz, 1H), 7.42 (dd, J = 8.6, 4.2 Hz, 1H), 
7.34 (d, J = 7.7 Hz, 1H), 7.02 (d, J = 7.7 Hz, 1H), 4.75 (s, 2H), 3.38 (t, J = 6.7 Hz, 2H), 
1.55 (dtd, J = 14.0, 7.4, 6.7 Hz, 2H), 0.83 (t, J = 7.4 Hz, 3H).  
 
5-(Butoxymethyl)quinolin-8-ol(5g). 1H NMR (400 MHz, Chloroform-d) δ 8.72 
(dd, J = 4.2, 1.6 Hz, 1H), 8.43 (dd, J = 8.5, 1.6 Hz, 1H), 7.42 (dd, J = 8.6, 4.2 Hz, 1H), 
7.34 (d, J = 7.7 Hz, 1H), 7.02 (d, J = 7.7 Hz, 1H), 4.75 (s, 2H), 3.42 (t, J = 6.6 Hz, 2H), 
1.51 (ddt, J = 8.9, 7.9, 6.4 Hz, 2H), 1.34 – 1.22 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H). 
 
 
General Procure for the Preparation of Compounds (6a-6g) 
 
 An equal molar mixture of the substrates 5, paraformaldehyde, and the pyrrolidine 
in anhydrous ethanol (30 mL) was refluxed for 4 hours under argon. After cooling, the 
solvent was evaporated under reduced pressure. The crude compound was purified by 
flash chromatography (dichloromethane: methanol 20: 1) to generate pure products. 
 
5-((Furan-2-ylmethoxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6a). 
1H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J = 4.1, 1.6 Hz, 1H), 8.33 (dd, J = 8.5, 1.6 
Hz, 1H), 7.44 (dd, J = 1.9, 0.9 Hz, 1H), 7.40 (dd, J = 8.5, 4.1 Hz, 1H), 7.25 (s, 1H), 4.83 
(s, 2H), 4.52 (s, 2H), 4.00 (s, 2H), 2.78-2.68 (m, 4H), 1.95 – 1.79 (m, 4H). HRMS (ESI): 
m/z calculated for C20H22N2O3 + H
+ [M + H+]: 339.1709; Found: 339.1711. 
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7-(Pyrrolidin-1-ylmethyl)-5-((thiophen-2-ylmethoxy)methyl)quinolin-8-
ol(6b). 1H NMR (400 MHz, Chloroform-d) δ 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 8.37 (dd, J = 
8.5, 1.7 Hz, 1H), 7.40 (dd, J = 8.5, 4.1 Hz, 1H), 7.31 (dd, J = 4.9, 1.3 Hz, 1H), 7.22 (s, 
1H), 7.04 – 6.96 (m, 2H), 4.85 (s, 2H), 4.73 (s, 2H), 3.99 (s, 2H), 2.81 – 2.56 (m, 4H), 
1.99 – 1.74 (m, 4H). HRMS (ESI): m/z calculated for C20H22N2O2S + H+ [M + H+]: 
355.1480; Found: 355.1473. 
 
5-((Pyridin-2-ylmethoxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6c). 
1H NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.2, 1.6 Hz, 1H), 8.56 (ddd, J = 4.9, 
1.8, 0.9 Hz, 1H), 8.46 (dd, J = 8.5, 1.6 Hz, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.45 – 7.39 
(m, 2H), 7.29 (s, 1H), 7.18 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 4.96 (s, 2H), 4.71 (s, 2H), 4.02 
(s, 2H), 2.82 – 2.66 (m, 4H), 1.95 – 1.84 (m, 4H). HRMS (ESI): m/z calculated for 
C21H23N3O2 + H
+ [M + H+]: 350.1869; Found: 350.1859. 
 
5-((Cyclohexylmethoxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6d). 
1H NMR (400 MHz, Chloroform-d) δ 8.80 (dd, J = 4.1, 1.7 Hz, 1H), 8.34 (dd, J = 8.5, 1.7 
Hz, 1H), 7.36 (dd, J = 8.5, 4.1 Hz, 1H), 7.24 (s, 1H), 4.71 (s, 2H), 3.98 (s, 2H), 3.24 (d, J 
= 6.5 Hz, 2H), 2.80 – 2.65 (m, 4H), 1.92 – 1.78 (m, 4H), 1.74 – 1.44 (m, 6H), 1.25 – 1.00 
(m, 3H), 0.90 – 0.70 (m, 2H). HRMS (ESI): m/z calculated for C22H30N2O2 + H+ [M + 
H+]: 355.2386; Found: 355.2385. 
 
5-(Ethoxymethyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6e). 1H NMR (400 
MHz, Chloroform-d) δ 8.90 (dd, J = 4.2, 1.6 Hz, 1H), 8.43 (dd, J = 8.5, 1.7 Hz, 1H), 7.45 
(dd, J = 8.5, 4.1 Hz, 1H), 7.29 (d, J = 1.2 Hz, 1H), 4.82 (s, 2H), 4.03 (s, 2H), 3.62 (q, J = 
7.0 Hz, 2H), 2.88 – 2.61 (m, 4H), 2.04 – 1.73 (m, 4H), 1.27 (t, J = 7.0 Hz, 3H). HRMS 
(ESI): m/z calculated for C17H22N2O2 + H
+ [M + H+]: 287.1760; Found: 287.1753. 
 
5-(Propoxymethyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6f). 1H NMR (400 
MHz, Chloroform-d) δ 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.34 (dd, J = 8.5, 1.7 Hz, 1H), 7.35 
(dd, J = 8.5, 4.1 Hz, 1H), 7.19 (s, 1H), 4.72 (s, 2H), 3.94 (s, 2H), 3.41 (t, J = 6.7 Hz, 2H), 
2.75 – 2.58 (m, 4H), 1.87 – 1.76 (m, 4H), 1.56 (dtd, J = 14.0, 7.4, 6.6 Hz, 2H), 0.85 (t, J 
= 7.4 Hz, 3H). HRMS (ESI): m/z calculated for C18H24N2O2 + H
+ [M + H+]: 315.2073; 
Found: 315.2059. 
 
5-(Butoxymethyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(6g). 1H NMR (400 
MHz, Chloroform-d) δ 8.81 (dd, J = 4.1, 1.6 Hz, 1H), 8.34 (dd, J = 8.5, 1.7 Hz, 1H), 7.35 
(dd, J = 8.5, 4.1 Hz, 1H), 7.20 (s, 1H), 4.72 (s, 2H), 3.95 (s, 2H), 3.45 (t, J = 6.6 Hz, 2H), 
2.74 – 2.58 (m, 4H), 1.90 – 1.73 (m, 4H), 1.52 (ddt, J = 8.9, 7.9, 6.4 Hz, 2H), 1.36 – 1.23 
(m, 2H), 0.82 (t, J = 7.4 Hz, 3H). HRMS (ESI): m/z calculated for C19H26N2O2 + H
+ [M 
+ H+]: 301.1916; Found: 301.1906. 
 
 
General Procure for the Preparation of Compounds (8a-8b) 
 
 To a solution of compound 7 (1 mmol) was added paraformaldehyde (1 mmol) 
and piperidine (1 mmol for 8a) or morpholine (1 mmol for 8b). The mixture was stirred 
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under reflux for 4 hours. The solvent was then evaporated to get the crude product. The 
crude product was purified by flash chromatography (dichloromethane: methanol 20: 1). 
 
5-((Benzyloxy)methyl)-7-(piperidin-1-ylmethyl)quinolin-8-ol(8a). 1H NMR 
(400 MHz, Chloroform-d) δ 8.82 (dd, J = 4.1, 1.7 Hz, 1H), 8.29 (dd, J = 8.5, 1.7 Hz, 1H), 
7.32 (dd, J = 8.5, 4.2 Hz, 1H), 7.29 – 7.20 (m, 5H), 7.09 (s, 1H), 4.76 (s, 2H), 4.49 (s, 
2H), 3.77 (s, 2H), 2.52 (s, 4H), 1.61 (p, J = 5.6 Hz, 4H), 1.44 (s, 2H). HRMS (ESI): m/z 
calculated for C22H24N2O3 + H
+ [M + H+]: 363.2073; Found: 363.2080. 
 
5-((Benzyloxy)methyl)-7-(morpholinomethyl)quinolin-8-ol(8b). 1H NMR (400 
MHz, Chloroform-d) δ 8.88 (dd, J = 4.1, 1.6 Hz, 1H), 8.40 (dd, J = 8.5, 1.6 Hz, 1H), 7.43 
(dd, J = 8.5, 4.2 Hz, 1H), 7.38 – 7.29 (m, 5H), 7.28 (s, 1H), 4.85 (s, 2H), 4.58 (s, 2H), 
3.86 (s, 2H), 3.81 – 3.75 (m, 4H), 2.70 – 2.55 (m, 4H). HRMS (ESI): m/z calculated for 
C23H26N2O2 + H
+ [M + H+]: 365.1865; Found: 365.1850. 
 
 
General Procure for the Preparation of Compounds (9a-9b) 
 
 The method to make compounds 9a-9b was the same as the way to make 
compounds 5e- 5g. 
 
5-(Phenethoxymethyl)quinolin-8-ol(9a). 1H NMR (400 MHz, Chloroform-d) δ 
8.77 (dd, J = 4.2, 1.6 Hz, 1H), 8.30 (dd, J = 8.5, 1.5 Hz, 1H), 7.40 – 7.35 (m, 2H), 7.28 – 
7.14 (m, 5H), 7.07 (d, J = 7.7 Hz, 1H), 4.82 (s, 2H), 3.72 (t, J = 7.0 Hz, 2H), 2.90 (t, J = 
7.0 Hz, 2H).  
 
5-((3-Phenylpropoxy)methyl)quinolin-8-ol(9b). 1H NMR (400 MHz, 
Chloroform-d) δ 8.80 (dd, J = 4.2, 1.6 Hz, 1H), 8.51 (dd, J = 8.5, 1.6 Hz, 1H), 7.50 (dd, J 
= 8.5, 4.2 Hz, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.25 – 7.22 (m, 2H), 7.20 – 7.14 (m, 1H), 
7.13 – 7.08 (m, 3H), 4.83 (s, 2H), 3.50 (t, J = 6.3 Hz, 2H), 2.65 (t, J = 8.6 Hz, 2H), 1.97 – 
1.86 (m, 2H).  
 
 
General Procure for the Preparation of Compounds (10a-10b) 
 
 An equimolar mixture of the substrates 9, paraformaldehyde, and the pyrrolidine 
in anhydrous ethanol (30 mL) was refluxed for 4 hours under argon. After cooling, the 
solvent was evaporated under reduced pressure. The crude product was purified by flash 
chromatography (dichloromethane: methanol 20: 1) to generate pure products. 
 
5-(Phenethoxymethyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(10a). 1H NMR 
(400 MHz, Chloroform-d) δ 8.86 (dd, J = 4.2, 1.7 Hz, 1H), 8.23 (dd, J = 8.5, 1.7 Hz, 1H), 
7.32 (dd, J = 8.5, 4.2 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.26 – 7.16 (m, 5H), 4.80 (s, 2H), 
3.98 (s, 2H), 3.74 (t, J = 7.0 Hz, 2H), 2.91 (t, J = 7.0 Hz, 2H), 2.75 – 2.65 (m, 4H), 1.95 – 
1.80 (m, 4H). HRMS (ESI): m/z calculated for C23H26N2O2 + H
+ [M + H+]: 363.2073; 
Found: 363.2060. 
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5-((3-Phenylpropoxy)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(10b). 1H 
NMR (400 MHz, Chloroform-d) δ 8.89 (dd, J = 4.1, 1.7 Hz, 1H), 8.42 (dd, J = 8.5, 1.6 
Hz, 1H), 7.43 (dd, J = 8.5, 4.1 Hz, 1H), 7.26 – 7.19 (m, 3H), 7.19 – 7.14 (m, 1H), 7.14 – 
7.10 (m, 2H), 4.80 (s, 2H), 3.99 (s, 2H), 3.53 (t, J = 6.4 Hz, 2H), 2.75 – 2.64 (m, 6H), 
1.99 – 1.83 (m, 6H). HRMS (ESI): m/z calculated for C24H28N2O2 + H+ [M + H+]: 
377.2229; Found: 377.2238. 
 
 
General Procure for the Preparation of Compounds (11a-11b) 
 
 To a solution of benzyl mercaptan (6 mmol for 12a) or N-benzymethylamine (6 
mmol for 12b) in anhydrous THF(30ml) was added sodium hydride (60% dispersion in 
mineral oil, 0.72g, 18 mmol) at 0 oC. The suspension was stirred at 0 oC for 30 minutes. 
Salt 2 (1.15g, 5mmol) was added to the suspension. The mixture was stirred at r.t for 3 
hours. Water was added to the suspension, the mixture became homogeneous. The 
mixture was extracted by ethyl acetate and washed with brine, dried over anhydrous 
sodium sulfate and concentrated to get the crude. The crude product was purified by flash 
chromatography (ethyl acetate: hexane 3:1). 
 
5-((Benzylthio)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(11a). 1H NMR 
(400 MHz, Chloroform-d) δ 8.78 (dd, J = 4.2, 1.6 Hz, 1H), 8.30 (dd, J = 8.6, 1.5 Hz, 1H), 
7.44 (dd, J = 8.5, 4.2 Hz, 1H), 7.37 – 7.26 (m, 5H), 7.06 (d, J = 7.8 Hz, 1H), 3.96 (s, 2H), 
3.65 (s, 2H). 
 
5-((Benzyl(methyl)amino)methyl)quinolin-8-ol(11b). 1H NMR (400 MHz, 
Chloroform-d) δ 8.82 (dd, J = 4.2, 1.6 Hz, 1H), 8.62 (dd, J = 8.5, 1.6 Hz, 1H), 7.47 (dd, J 
= 8.6, 4.2 Hz, 1H), 7.40 (d, J = 7.7 Hz, 1H), 7.37 – 7.32 (m, 4H), 7.32 – 7.26 (m, 1H), 
7.13 (d, J = 7.7 Hz, 1H), 3.85 (s, 2H), 3.58 (s, 2H), 2.20 (s, 3H). 
 
 
General Procure for the Preparation of Compounds (12a-12b) 
 
 To a solution of compound 11 (1 mmol) was added paraformaldehyde (1 mmol) 
and pyrrolidine( 1mmol). The mixture was stirred under reflux for 4 hours. The solvent 
was then evaporated to get the crude product. The crude product was purified by flash 
chromatography (dichloromethane: methanol 20: 1) to get a light yellow solid. 
 
5-((Benzylthio)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-ol(12a). 1H NMR 
(400 MHz, Chloroform-d) δ 8.78 (dd, J = 4.2, 1.6 Hz, 1H), 8.17 (dd, J = 8.6, 1.6 Hz, 1H), 
7.32 (dd, J = 8.6, 4.1 Hz, 1H), 7.28 – 7.15 (m, 5H), 7.14 (s, 1H), 3.97 (s, 2H), 3.89 (s, 
2H), 3.60 (s, 2H), 2.82 – 2.65 (m, 4H), 1.90– 1.80 (m, 4H). HRMS (ESI): m/z calculated 
for C22H24N2OS + H
+ [M + H+]: 365.1688; Found: 365.1689. 
 
5-((Benzyl(methyl)amino)methyl)-7-(pyrrolidin-1-ylmethyl)quinolin-8-
ol(12b). 1H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J = 4.1, 1.6 Hz, 1H), 8.57 (dd, J 
= 8.6, 1.7 Hz, 1H), 7.43 – 7.31 (m, 5H), 7.31 – 7.27 (m, 1H), 7.24 (s, 1H), 3.93 (s, 2H), 
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3.91 (s, 2H), 3.68 (s, 2H), 2.60– 2.48 (m, 4H), 2.30 (s, 3H), 1.85– 1.70 (m, 4H). HRMS 
(ESI): m/z calculated for C23H27N3O + H
+ [M + H+]: 362.2232; Found: 362.2224. 
 
 
Cell Culture and Cell Viability Assay 
 
 The anti-proliferative effect of UC-112 and its analogs were tested in human 
melanoma (A375, MDA-MB-435 and MDA-MB-435/LCC6MDR1) and human prostate 
cancer (PC-3) cell lines. All the cell lines were purchased from ATCC (American Type 
Culture Collection, Manassas, VA). The cancer cells were cultured using the 
supplemented cell culture medium as described before [246] at 37oC in a humidified 
atmosphere containing 5% CO2. 5000 cells in logarithm growing phase were seeded 
overnight into each well of a 96-well plate. Then the cells were continuously incubated 
with sequential diluted compound solution (10 nM to 100 µM, 100 µl per well) in cell 
culture medium. After 48 h treatment, the cell viability was determined in MTS assay and 
IC50 was calculated (n = 4) as described before [112, 180]. 
 
 
NCI-60 Screening 
 
 Four compounds including the parental compound UC-112 were submitted to 
National Cancer Institute for its NCI-60 cell line screening, initially tested at one 
concentration (10 µM), and subsequently selected for full five concentration testing 
following the standard protocols disclosed by NCI [247]. In brief, cells were plated into 
96 well micro-titer plates 24 h prior to the treatment of compound solution for 48 h, then 
the cell viability was read out through absorbance of sulforhodamine B (SRB) staining. 
 
 
Drug-Like Property Profiling for Compound 4g 
 
 All these experiments were performed by a contract research service company, 
Eurofins Panlabs Inc. (Study Number 100017964). Aqueous solubility (μM) was 
determined using the shake-flask method by comparing the peak area of the principal 
peak in a calibration standard (200 μM) containing organic solvent (methanol/water, 
60/40, v/v) with the peak area of the corresponding peak in a buffer sample. Metabolic 
stability study was carried out by incubating compound 4g with human liver microsomes. 
Metabolic stability which is expressed as percent of the parent compound remaining, was 
calculated by comparing the peak area of the compound at the time point relative to that 
at time-0. The half-life (T1/2) was estimated from the slope of the initial linear range of 
the logarithmic curve of compound remaining (%) vs. time. In the cytochrome P450 
inhibition study, human liver microsomes (0.1 mg/mL) were incubated with different 
substrates and compound 4g for 10 minutes. After the incubation, peak areas 
corresponding to the metabolite of each substrate were recorded. The percent of control 
activity was then calculated by comparing the peak area obtained in the presence of 
compound 4g to that obtained in the absence of compound 4g. Subsequently, the percent 
inhibition was calculated by subtracting the percent control activity from 100. 
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Caspase Functional Assay 
 
 The caspase 3/7 activity of cancer cells treated by DMSO control or compound of 
interest was analyzed using Glo Caspase-Glo 3/7 kit from Promega Corporation 
(Madison, WI) as per manufacturer’s instructions in similar protocol as described before 
[180]. The readings of relative luminescence unit were normalized by the cell viability 
read from the same well determined by compatible CytoTox-Fluor Cytotoxicity assay kit 
(Promega, WI). 
 
 
Western Blotting  
 
 Lysates of A375 cells treated by the compound solution for 24 h were used to 
determine the change of IAP protein levels through western blotting. Primary rabbit 
antibodies against survivin, XIAP, cIAP1, cIAP2, livin and GAPDH were purchased 
from Cell Signaling Technology, Inc. (Danvers, MA) and used according to manufacture 
instructions as reported previously[180]. Protein lane intensities were quantified by 
ImageJ software (US National Institutes of Health, Bethesda, MD). 
 
 
Molecular Modeling 
 
 The molecular docking studies were performed following similar procedure as 
described before [180, 248]in Schrodinger Molecular Modeling Suite 2014 (Schrodinger 
Inc., Portland, OR). All the ligands were prepared to generate various conformation 
before being docked into the SMAC AVPI binding site of a human survivin crystal 
structure (Protein Data Bank entry: 3UIH). Molecular dynamic calculation was done after 
the docking to minimize the energy of potential ligand binding poses. Results were 
visualized using the Maestro interface of the Schrodinger software. 
 
 
DARTS Assay  
 
 Drug affinity responsive target stability (DARTS) assay was performed to identify 
the protein targets of UC-112 analogs in A375 or MDA-MB-435 cell lysates following 
the protocols described in the literature [242-245]. Briefly, A375 or MDA-MB-435 
lysates were prepared in non-denaturing M-PER lysis buffer (Thermo Fisher Scientific, 
Waltham, MA) with protease and phosphatase inhibitors. Then TNC (Tris, NaCl, CaCl2) 
buffer was added into cell lysates before the total protein concentration of lysate being 
determined by BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA). The 
lysates were split into two groups: one group was added with compound of interest 
solution, the other group was added with same amount of vehicle (DMSO). The samples 
were mixed thoroughly and incubated at room temperature for 1 h. Then 10 mg/mL 
pronase stock solution was added into both compound treated or vehicle control groups to 
achieve the final dilution of 1:100, 1:300, 1:1000 and 1:3000. One aliquot of each group 
was kept as un-digested control. The proteolysis was performed at room temperature for 
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30 min before ice cold protease inhibitor stock being added into the mixture. Then SDS 
loading buffer was added into all the samples and heated to 70 ºC for 10 min. Finally, the 
results were analyzed by SDS-PAGE and immunoblotting. 
 
 
In Vivo Anti-tumor Efficacy 
 
 3 × 106 A375 cells were implanted into the left-side dorsal flank of each nude 
mouse (n = 5) to establish the human melanoma A375 tumor xenograft model as 
described previously [114, 180]. Compound 4g were first dissolved in DMSO then 
diluted by 2% methylcellulose PBS buffer. The proportion of DMSO in final solution 
was kept at lower than 5%. Mice body weight and the size of tumor were closely 
monitored during the 3 week continuous treatment (i.p. injection, one dose per day, five 
days per week). At the end point of the treatment, mice were sacrificed after anesthesia. 
A375 tumor tissues were isolated then freshly lysed on ice to check the targeted protein 
levels through Western blotting. 
 
 
TUNEL Assay 
 
 A375 tumor tissues collected from the in vivo efficacy study in the above were 
fixed in formalin phosphate buffer for one week. Then the tissues were processed to get 
paraffin embedded sections. TUNEL assay was performed using DeadEnd Fluorometric 
kit (Promega Corporation, Madison, WI) following manufacturer’s instructions. By the 
end of the experiment, VECTASHIELD Hard Set mounting medium with DAPI (Vector 
Lab, Inc., Burlingame, CA) was used to mount the tumor slides and stain the nuclei. The 
final slides were analyzed immediately under a fluorescence microscope (EVOS FL Cell 
Imaging System, Thermo Fisher Scientific Inc., NY). 
 
 
Summary 
 
 A series of novel analogs were designed and synthesized based on targeted 
structural modification of the lead compound UC-112. SAR (Figure 5-14) was 
investigated by making modifications to C ring, D ring and the linker. Several analogs 
showed excellent anti-proliferative activities and could also effectively overcome Pgp-
mediated multiple drug resistance. This scaffold as demonstrated by our most potent 
compound 4g has showed good drug-like properties which is important for further 
development. Preliminary studies of action mechanism confirmed that the new analogs 
maintain their mode of action by selectively down-regulating the level of survivin as the 
parent compound UC-112. Compound 4g effectively inhibited the growth of A375 
xenograft tumor in vivo. Further optimization of this scaffold can be performed to 
generate more potent and selective survivin inhibitors based on this unique platform. 
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Figure 5-14.. Structure activity relationships of UC-112 analogs 
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CHAPTER 6.    CONCLUSION 
 
 
 Tubulin and survivin are two important cancer drug targets for a number of 
reasons that have been reviewed in details in previous chapters. My work in the past five 
years has been focusing on the development of novel tubulin polymerization inhibitors 
and survivin inhibitors for cancer treatment. Many active compounds with potent 
antiproliferative properties have been generated. These compounds have great promise to 
be further developed as effective anticancer agents. The thoughts for the development of 
these compounds are summarized here and future directions are discussed as well. 
 
 There are many drugs targeting tubulin that have been approved for cancer 
treatment, which makes tubulin a well-validated cancer target. Among the four best 
known tubulin binding sites, no colchicine site binder has been approved for cancer 
treatment. Thus, it is highly significant to develop novel tubulin targeting agents that 
interact with the colchicine binding site. Our group has done extensive work on the 
finding of new colchicine site binders and several series of important structures have 
been produced, such as SMART and ABI series.  
 
 For the tubulin project, we tried to further optimize the previously reported ABI 
scaffold in the beginning. There are three ring systems in the general structure of ABI 
scaffold. From a classical SAR point, we tackled the optimization by making 
modifications to the three ring systems. Extensive A ring modifications on the ABI 
scaffold had been done in the previous reported papers. The previous A ring 
modifications had tried to put many commonly used substitutions to the A ring. The 
results showed both electron donating groups and electron withdrawing groups increased 
activity compared to non-substituted A ring. Different positions of substitutions had also 
been tried on the A ring of ABI structure. It was found para-positon gave optimal 
activity. So we tried the A ring modification by putting additional substitutions that had 
not been used previously to the para position of A ring. The new substitutions did not 
improve activity compared with previous most active compounds. Because the additional 
A ring modifications did not generate more potent compounds and more importantly few 
modifications had been made on the B ring in the previous work, We focused our efforts 
on the B ring modification of ABI scaffold. 
 
 Our first thought about the B ring modification was that what if we changed the 
connection positions of the three ring systems. Based on this thought, we designed a new 
template structure which reversed the position of the two major substitution groups on the 
imidazole ring of ABI structure: the benzoyl group and the aryl group. By doing so, we 
generated a series of RABI compounds.  
 
 Some of these RABI compounds showed excellent antiproliferative activities in a 
panel of cancer cell lines including multidrug resistant cells. One appreciable advantage 
of the RABI compounds is that they can circumvent the multidrug resistance that is 
associated with existing tubulin targeting agents, such as paclitaxel, or vinblastine, as 
indicated by their similar activities in sensitive cancer cells and resistant cancer cells. 
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Mechanism of actions studies showed RABI analogs maintained their ability to inhibit 
tubulin polymerization at colchicine binding site and arrest cells in G2/M phase, which 
demonstrated a similar mechanism of action as previous ABI analogs. The excellent 
activity of these compounds warranted their further development as effective anticancer 
agents. 
 
 The SAR of the new RABI template was extensively explored by introducing 
different substitutions to the three rings of this new structure. There are several 
interesting points in the SAR of RABI analogs, which provide us some insights into the 
design of tubulin polymerization inhibitors. First, the position switch of the benzoyl 
group and the phenyl group maintained the activity of most potent ABI analogs. Second, 
the 3, 4, 5-trimethoxy substituents were also required for the optimal activity in the RABI 
scaffold. These two points may suggest that the RABI analogs have similar binding mode 
as the previous ABI scaffold. Another interesting thing is that for RABI scaffold, the 
unsubstituted A ring was the best one, while in the ABI series, the substituted compounds 
showed better activity than unsubstituted A ring. This indicates that the C rings in both 
templates may bind to the same site, but the A rings of the two templates may bind to 
different areas of the pocket. The SAR of N1 position substitutions on the B ring brings 
an interesting question that what effect it will have on activity if we remove A ring. One 
possibility which comes from the modelling results is that A ring does not form any 
meaningful interaction with the binding pocket and thus removal of A ring does not affect 
activity. In this case, it is possible that removal of A ring makes the new structures better 
mimic the colchicine structure, which brings drug resistance issue that is associated with 
colchicine to the new structures. Another possibility is that A ring pushes the ring on the 
N1 position deep into the pocket for binding and thus removing A ring may decrease 
activity. Without the crystal structure of tubulin in complex with RABI compounds, it is 
hard to decide which possibility is true. The work to get the crystal structure of our RABI 
compounds bound with tubulin is currently ongoing, which will dramatically facilitate the 
design of novel tubulin polymerization inhibitors. 
 
 To further optimize the RABI scaffold, several modifications may be attempted. 
In the previous ABI analogs, the compound with 3-indole ring as A ring showed 
remarkable activity. Based on this result, different heterocyclic rings can be tried at the A 
ring position of the RABI structure, such as indole, benzofuran, and benzothiophene, 
which could form potential hydrogen bonds between the hetero atoms and surrounding 
residues. One big issue with previous ABI analogs is metabolic instability due to the 
carbonyl linker which can be easily reduced. To address this issue, the carbonyl linker 
may be incorporated into a ring system. For example we can use a pyridine ring to link B 
ring and C ring, which could still maintain the shape of the molecule but offer the 
advantage of stronger metabolic stability. For now only two rings have been tried on the 
N1 position of the imidazole ring in the RABI structure, thus different ring systems may 
be tried at that position for optimization.  
 
 The unique properties of survivin, such as the differential distribution of survivin 
in cancer cells and normal cells, the critical role of survivin in cell mitosis and survival, 
makes it a promising target for cancer treatment. Notable research work is ongoing to 
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develop selective inhibitors of this promising target. We believe that targeting survivin 
has the potential to selectively treat cancer. Our interest in survivin began with the 
identification of UC-112, which turned out to be a potent and selective survivin inhibitor. 
 
 In order to generate more potent survivin inhibitor, we performed several targeted 
modifications to the structure of UC-112. The structure of UC-112 contains four rings 
and a linker. Our modifications mainly focused on C ring, D ring and the linker. We 
utilized traditional medicinal chemistry methodologies for the structural optimization, 
which include introduction of commonly used substituents, bioisosteric replacement, and 
homologation change. By doing those modifications, a set of new analogs with good 
antiproliferative activities were generated. Several compounds in this series had IC50 
values in the nanomolar range. The success of our modifications was further supported by 
the NCI-60 cell line screening results which showed that our new compounds 
significantly improved growth inhibitory activity compared with parent compound UC-
112. The new scaffold provides a promising template for future development of effective 
survivin inhibitors, which will bring the benefit of selective cancer treatment.  
 
 Although the UC-112 analogs showed good activities, it has to be noted that most 
IC50 values are still in the micromolar range. The activity has to be further improved in 
order to be developed as effective anticancer agents. Several directions can be tried. The 
linkers between B ring and C ring in our analogs are very flexible, which could be 
unfavorable for activity considering the binding pocket of survivin is relatively small. 
Thus we can try more rigid linkers between B ring and C ring. For example, we can try 
carbonyl linker, olefin linker, and sulfonyl linker. Modelling results showed that the A 
ring of our analogs is residing in a negative site. We may try to shift the position of 
nitrogen on the A ring of UC-112 structure, which can form possible hydrogen bonds or 
ionic interactions with surrounding residues. In addition, we can try to put some amino 
acids on the D ring position of UC-112 structure, which could possibly better mimic the 
bioactive AVPI peptide. 
 
 To validate the target of these analogs, some preliminary mechanism of action 
studies were performed. The western blot results showed the new analogs selectively 
suppressed the level of survivin over other IAPs. Although this data demonstrated that 
survivin level was affected, several questions need to be answered before we can confirm 
survivin as our target. First question is that whether our compounds are inhibiting the 
upstream proteins of survivin or survivin itself. Second question is how our compounds 
downregulate survivin level, are they inhibiting the gene expression of survivin or 
promoting the degradation of survivin? Third question is that how does our compounds 
bind to survivin if they are truly targeting survivin. The X-ray crystal structure of our 
compounds bound to survivin may help answer the above questions. The work to resolve 
the crystal structure has been planned and will be performed in the near future.  
 
  
 108 
LIST OF REFERENCES 
 
 
1. Coit, D. G.; Andtbacka, R.; Anker, C. J.; Bichakjian, C. K.; Carson, W. E., 3rd; 
Daud, A.; Dilawari, R. A.; Dimaio, D.; Guild, V.; Halpern, A. C.; Hodi, F. S., Jr.; 
Kelley, M. C.; Khushalani, N. I.; Kudchadkar, R. R.; Lange, J. R.; Lind, A.; 
Martini, M. C.; Olszanski, A. J.; Pruitt, S. K.; Ross, M. I.; Swetter, S. M.; Tanabe, 
K. K.; Thompson, J. A.; Trisal, V.; Urist, M. M.; National Comprehensive 
Cancer, N. Melanoma. J Natl Compr Canc Netw, 2012, 10(3), 366-400. 
2. Leiter, U.; Garbe, C. Epidemiology of melanoma and nonmelanoma skin cancer--
the role of sunlight. Adv Exp Med Biol, 2008, 624, 89-103. 
3. Lo, J. A.; Fisher, D. E. The melanoma revolution: from UV carcinogenesis to a 
new era in therapeutics. Science, 2014, 346(6212), 945-949. 
4. Bhatia, S.; Tykodi, S. S.; Thompson, J. A. Treatment of metastatic melanoma: an 
overview. Oncology (Williston Park), 2009, 23(6), 488-496. 
5. Tsao, H.; Chin, L.; Garraway, L. A.; Fisher, D. E. Melanoma: from mutations to 
medicine. Genes Dev, 2012, 26(11), 1131-1155. 
6. Read, J.; Wadt, K. A.; Hayward, N. K. Melanoma genetics. J Med Genet, 2015. 
7. Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. Cell, 
2015, 161(7), 1681-1696. 
8. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; 
Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; 
Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. 
M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. 
J.; Flaherty, K. T.; McArthur, G. A.; Group, B.-S. Improved survival with 
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 
364(26), 2507-2516. 
9. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, 
J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; 
Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; 
Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, 
H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; 
Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; 
Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W.; Leung, S. Y.; Yuen, S. T.; 
Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. 
J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in 
human cancer. Nature, 2002, 417(6892), 949-954. 
10. Dhomen, N.; Marais, R. BRAF signaling and targeted therapies in melanoma. 
Hematol Oncol Clin North Am, 2009, 23(3), 529-545, ix. 
11. Goldinger, S. M.; Murer, C.; Stieger, P.; Dummer, R. Targeted therapy in 
melanoma - the role of BRAF, RAS and KIT mutations. EJC Suppl, 2013, 11(2), 
92-96. 
12. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors 
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 
Nature, 2010, 464(7287), 427-430. 
 109 
13. Rajalingam, K.; Schreck, R.; Rapp, U. R.; Albert, S. Ras oncogenes and their 
downstream targets. Biochimica et biophysica acta, 2007, 1773(8), 1177-1195. 
14. Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J. 
S.; Kong, X.; Koya, R. C.; Flaherty, K. T.; Chapman, P. B.; Kim, M. J.; Hayward, 
R.; Martin, M.; Yang, H.; Wang, Q.; Hilton, H.; Hang, J. S.; Noe, J.; Lambros, 
M.; Geyer, F.; Dhomen, N.; Niculescu-Duvaz, I.; Zambon, A.; Niculescu-Duvaz, 
D.; Preece, N.; Robert, L.; Otte, N. J.; Mok, S.; Kee, D.; Ma, Y.; Zhang, C.; 
Habets, G.; Burton, E. A.; Wong, B.; Nguyen, H.; Kockx, M.; Andries, L.; 
Lestini, B.; Nolop, K. B.; Lee, R. J.; Joe, A. K.; Troy, J. L.; Gonzalez, R.; Hutson, 
T. E.; Puzanov, I.; Chmielowski, B.; Springer, C. J.; McArthur, G. A.; Sosman, J. 
A.; Lo, R. S.; Ribas, A.; Marais, R. RAS mutations in cutaneous squamous-cell 
carcinomas in patients treated with BRAF inhibitors. N Engl J Med, 2012, 366(3), 
207-215. 
15. Carvajal, R. D.; Antonescu, C. R.; Wolchok, J. D.; Chapman, P. B.; Roman, R. 
A.; Teitcher, J.; Panageas, K. S.; Busam, K. J.; Chmielowski, B.; Lutzky, J.; 
Pavlick, A. C.; Fusco, A.; Cane, L.; Takebe, N.; Vemula, S.; Bouvier, N.; Bastian, 
B. C.; Schwartz, G. K. KIT as a therapeutic target in metastatic melanoma. JAMA, 
2011, 305(22), 2327-2334. 
16. Swanson, N. A.; Lee, K. K.; Gorman, A.; Lee, H. N. Biopsy techniques. 
Diagnosis of melanoma. Dermatol Clin, 2002, 20(4), 677-680. 
17. Avril, M. F.; Aamdal, S.; Grob, J. J.; Hauschild, A.; Mohr, P.; Bonerandi, J. J.; 
Weichenthal, M.; Neuber, K.; Bieber, T.; Gilde, K.; Guillem Porta, V.; Fra, J.; 
Bonneterre, J.; Saiag, P.; Kamanabrou, D.; Pehamberger, H.; Sufliarsky, J.; 
Gonzalez Larriba, J. L.; Scherrer, A.; Menu, Y. Fotemustine compared with 
dacarbazine in patients with disseminated malignant melanoma: a phase III study. 
J Clin Oncol, 2004, 22(6), 1118-1125. 
18. Bedikian, A. Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, 
U.; Pavlick, A. C.; DeConti, R.; Hersh, E. M.; Hersey, P.; Kirkwood, J. M.; 
Haluska, F. G.; Oblimersen Melanoma Study, G. Bcl-2 antisense (oblimersen 
sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen 
Melanoma Study Group. J Clin Oncol, 2006, 24(29), 4738-4745. 
19. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; 
Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, 
W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; 
Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; 
Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; 
Urba, W. J. Improved survival with ipilimumab in patients with metastatic 
melanoma. N Engl J Med, 2010, 363(8), 711-723. 
20. Topalian, S. L.; Hodi, F. S.; Brahmer, J. R.; Gettinger, S. N.; Smith, D. C.; 
McDermott, D. F.; Powderly, J. D.; Carvajal, R. D.; Sosman, J. A.; Atkins, M. B.; 
Leming, P. D.; Spigel, D. R.; Antonia, S. J.; Horn, L.; Drake, C. G.; Pardoll, D. 
M.; Chen, L.; Sharfman, W. H.; Anders, R. A.; Taube, J. M.; McMiller, T. L.; Xu, 
H.; Korman, A. J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G. D.; 
Gupta, A.; Wigginton, J. M.; Sznol, M. Safety, activity, and immune correlates of 
anti-PD-1 antibody in cancer. N Engl J Med, 2012, 366(26), 2443-2454. 
 110 
21. Ascierto, P. A.; Marincola, F. M. 2015: The Year of Anti-PD-1/PD-L1s Against 
Melanoma and Beyond. EBioMedicine, 2015, 2(2), 92-93. 
22. Ma, C.; Armstrong, A. W. Severe adverse events from the treatment of advanced 
melanoma: a systematic review of severe side effects associated with ipilimumab, 
vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog 
Treat, 2014, 25(5), 401-408. 
23. Atkins, M. B.; Lotze, M. T.; Dutcher, J. P.; Fisher, R. I.; Weiss, G.; Margolin, K.; 
Abrams, J.; Sznol, M.; Parkinson, D.; Hawkins, M.; Paradise, C.; Kunkel, L.; 
Rosenberg, S. A. High-dose recombinant interleukin 2 therapy for patients with 
metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J 
Clin Oncol, 1999, 17(7), 2105-2116. 
24. Ascierto, P. A.; Chiarion-Sileni, V.; Muggiano, A.; Mandala, M.; Pimpinelli, N.; 
Del Vecchio, M.; Rinaldi, G.; Simeone, E.; Queirolo, P. Interferon alpha for the 
adjuvant treatment of melanoma: review of international literature and practical 
recommendations from an expert panel on the use of interferon. J Chemother, 
2014, 26(4), 193-201. 
25. Daponte, A.; Signoriello, S.; Maiorino, L.; Massidda, B.; Simeone, E.; Grimaldi, 
A. M.; Caraco, C.; Palmieri, G.; Cossu, A.; Botti, G.; Petrillo, A.; Lastoria, S.; 
Cavalcanti, E.; Aprea, P.; Mozzillo, N.; Gallo, C.; Comella, G.; Ascierto, P. A.; 
Southern Italy Cooperative Oncology, G. Phase III randomized study of 
fotemustine and dacarbazine versus dacarbazine with or without interferon-alpha 
in advanced malignant melanoma. J Transl Med, 2013, 11, 38. 
26. Kidner, T. B.; Morton, D. L.; Lee, D. J.; Hoban, M.; Foshag, L. J.; Turner, R. R.; 
Faries, M. B. Combined intralesional Bacille Calmette-Guerin (BCG) and topical 
imiquimod for in-transit melanoma. J Immunother, 2012, 35(9), 716-720. 
27. Long, G. V.; Menzies, A. M.; Nagrial, A. M.; Haydu, L. E.; Hamilton, A. L.; 
Mann, G. J.; Hughes, T. M.; Thompson, J. F.; Scolyer, R. A.; Kefford, R. F. 
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic 
melanoma. J Clin Oncol, 2011, 29(10), 1239-1246. 
28. Stones, C. J.; Kim, J. E.; Joseph, W. R.; Leung, E.; Marshall, E. S.; Finlay, G. J.; 
Shelling, A. N.; Baguley, B. C. Comparison of responses of human melanoma cell 
lines to MEK and BRAF inhibitors. Front Genet, 2013, 4, 66. 
29. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. 
M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R.; Cancer 
Genome, P. Mechanism of activation of the RAF-ERK signaling pathway by 
oncogenic mutations of B-RAF. Cell, 2004, 116(6), 855-867. 
30. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. 
A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition 
of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 2010, 363(9), 
809-819. 
31. Falchook, G. S.; Long, G. V.; Kurzrock, R.; Kim, K. B.; Arkenau, T. H.; Brown, 
M. P.; Hamid, O.; Infante, J. R.; Millward, M.; Pavlick, A. C.; O'Day, S. J.; 
Blackman, S. C.; Curtis, C. M.; Lebowitz, P.; Ma, B.; Ouellet, D.; Kefford, R. F. 
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid 
tumours: a phase 1 dose-escalation trial. Lancet, 2012, 379(9829), 1893-1901. 
 111 
32. Hauschild, A.; Grob, J. J.; Demidov, L. V.; Jouary, T.; Gutzmer, R.; Millward, 
M.; Rutkowski, P.; Blank, C. U.; Miller, W. H., Jr.; Kaempgen, E.; Martin-
Algarra, S.; Karaszewska, B.; Mauch, C.; Chiarion-Sileni, V.; Martin, A. M.; 
Swann, S.; Haney, P.; Mirakhur, B.; Guckert, M. E.; Goodman, V.; Chapman, P. 
B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, 
phase 3 randomised controlled trial. Lancet, 2012, 380(9839), 358-365. 
33. Falchook, G. S.; Lewis, K. D.; Infante, J. R.; Gordon, M. S.; Vogelzang, N. J.; 
DeMarini, D. J.; Sun, P.; Moy, C.; Szabo, S. A.; Roadcap, L. T.; Peddareddigari, 
V. G.; Lebowitz, P. F.; Le, N. T.; Burris, H. A., 3rd; Messersmith, W. A.; 
O'Dwyer, P. J.; Kim, K. B.; Flaherty, K.; Bendell, J. C.; Gonzalez, R.; Kurzrock, 
R.; Fecher, L. A. Activity of the oral MEK inhibitor trametinib in patients with 
advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol, 2012, 13(8), 
782-789. 
34. Kirkwood, J. M.; Bastholt, L.; Robert, C.; Sosman, J.; Larkin, J.; Hersey, P.; 
Middleton, M.; Cantarini, M.; Zazulina, V.; Kemsley, K.; Dummer, R. Phase II, 
open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy 
versus temozolomide in patients with advanced melanoma. Clin Cancer Res, 
2012, 18(2), 555-567. 
35. Atefi, M.; von Euw, E.; Attar, N.; Ng, C.; Chu, C.; Guo, D.; Nazarian, R.; 
Chmielowski, B.; Glaspy, J. A.; Comin-Anduix, B.; Mischel, P. S.; Lo, R. S.; 
Ribas, A. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by 
co-targeting the AKT/mTOR pathway. PLoS One, 2011, 6(12), e28973. 
36. Haq, R.; Yokoyama, S.; Hawryluk, E. B.; Jonsson, G. B.; Frederick, D. T.; 
McHenry, K.; Porter, D.; Tran, T. N.; Love, K. T.; Langer, R.; Anderson, D. G.; 
Garraway, L. A.; Duncan, L. M.; Morton, D. L.; Hoon, D. S.; Wargo, J. A.; Song, 
J. S.; Fisher, D. E. BCL2A1 is a lineage-specific antiapoptotic melanoma 
oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A, 
2013, 110(11), 4321-4326. 
37. Vin, H.; Ojeda, S. S.; Ching, G.; Leung, M. L.; Chitsazzadeh, V.; Dwyer, D. W.; 
Adelmann, C. H.; Restrepo, M.; Richards, K. N.; Stewart, L. R.; Du, L.; 
Ferguson, S. B.; Chakravarti, D.; Ehrenreiter, K.; Baccarini, M.; Ruggieri, R.; 
Curry, J. L.; Kim, K. B.; Ciurea, A. M.; Duvic, M.; Prieto, V. G.; Ullrich, S. E.; 
Dalby, K. N.; Flores, E. R.; Tsai, K. Y. BRAF inhibitors suppress apoptosis 
through off-target inhibition of JNK signaling. Elife, 2013, 2, e00969. 
38. Roesch, A. Tumor heterogeneity and plasticity as elusive drivers for resistance to 
MAPK pathway inhibition in melanoma. Oncogene, 2015, 34(23), 2951-2957. 
39. Yancovitz, M.; Litterman, A.; Yoon, J.; Ng, E.; Shapiro, R. L.; Berman, R. S.; 
Pavlick, A. C.; Darvishian, F.; Christos, P.; Mazumdar, M.; Osman, I.; Polsky, D. 
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and 
metastatic melanoma. PLoS One, 2012, 7(1), e29336. 
40. Little, A. S.; Smith, P. D.; Cook, S. J. Mechanisms of acquired resistance to 
ERK1/2 pathway inhibitors. Oncogene, 2013, 32(10), 1207-1215. 
41. Johannessen, C. M.; Boehm, J. S.; Kim, S. Y.; Thomas, S. R.; Wardwell, L.; 
Johnson, L. A.; Emery, C. M.; Stransky, N.; Cogdill, A. P.; Barretina, J.; 
Caponigro, G.; Hieronymus, H.; Murray, R. R.; Salehi-Ashtiani, K.; Hill, D. E.; 
Vidal, M.; Zhao, J. J.; Yang, X.; Alkan, O.; Kim, S.; Harris, J. L.; Wilson, C. J.; 
 112 
Myer, V. E.; Finan, P. M.; Root, D. E.; Roberts, T. M.; Golub, T.; Flaherty, K. T.; 
Dummer, R.; Weber, B. L.; Sellers, W. R.; Schlegel, R.; Wargo, J. A.; Hahn, W. 
C.; Garraway, L. A. COT drives resistance to RAF inhibition through MAP 
kinase pathway reactivation. Nature, 2010, 468(7326), 968-972. 
42. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z. R.; Du, J.; 
Davis, A.; Mongare, M. M.; Gould, J.; Frederick, D. T.; Cooper, Z. A.; Chapman, 
P. B.; Solit, D. B.; Ribas, A.; Lo, R. S.; Flaherty, K. T.; Ogino, S.; Wargo, J. A.; 
Golub, T. R. Tumour micro-environment elicits innate resistance to RAF 
inhibitors through HGF secretion. Nature, 2012, 487(7408), 500-504. 
43. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R. C.; Lee, H.; Chen, Z.; Lee, 
M. K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S. F.; McArthur, G.; Sosman, 
J. A.; Ribas, A.; Lo, R. S. Melanomas acquire resistance to B-RAF(V600E) 
inhibition by RTK or N-RAS upregulation. Nature, 2010, 468(7326), 973-977. 
44. Sanchez-Laorden, B.; Viros, A.; Girotti, M. R.; Pedersen, M.; Saturno, G.; 
Zambon, A.; Niculescu-Duvaz, D.; Turajlic, S.; Hayes, A.; Gore, M.; Larkin, J.; 
Lorigan, P.; Cook, M.; Springer, C.; Marais, R. BRAF inhibitors induce 
metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating 
MEK and ERK signaling. Sci Signal, 2014, 7(318), ra30. 
45. Fedorenko, I. V.; Gibney, G. T.; Sondak, V. K.; Smalley, K. S. Beyond BRAF: 
where next for melanoma therapy? Br J Cancer, 2015, 112(2), 217-226. 
46. Marlier, J.; Cocquyt, V.; Brochez, L.; Van Belle, S.; Kruse, V. Ipilimumab, not 
just another anti-cancer therapy: hypophysitis as side effect illustrated by four 
case-reports. Endocrine, 2014, 47(3), 878-883. 
47. Torino, F.; Barnabei, A.; Paragliola, R. M.; Marchetti, P.; Salvatori, R.; Corsello, 
S. M. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary 
dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol, 
2013, 169(6), R153-164. 
48. Mita, A. C.; Mita, M. M.; Nawrocki, S. T.; Giles, F. J. Survivin: key regulator of 
mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res, 
2008, 14(16), 5000-5005. 
49. Altieri, D. C. Survivin, cancer networks and pathway-directed drug discovery. 
Nat Rev Cancer, 2008, 8(1), 61-70. 
50. Rosa, J.; Canovas, P.; Islam, A.; Altieri, D. C.; Doxsey, S. J. Survivin modulates 
microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell, 
2006, 17(3), 1483-1493. 
51. Lu, J.; Tan, M.; Huang, W. C.; Li, P.; Guo, H.; Tseng, L. M.; Su, X. H.; Yang, W. 
T.; Treekitkarnmongkol, W.; Andreeff, M.; Symmans, F.; Yu, D. Mitotic 
deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes 
to Taxol resistance. Clin Cancer Res, 2009, 15(4), 1326-1334. 
52. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat Rev 
Cancer, 2004, 4(4), 253-265. 
53. Kaur, R.; Kaur, G.; Gill, R. K.; Soni, R.; Bariwal, J. Recent developments in 
tubulin polymerization inhibitors: An overview. Eur J Med Chem, 2014, 87, 89-
124. 
54. Waterman-Storer, C. M.; Salmon, E. D. Microtubule dynamics: treadmilling 
comes around again. Curr Biol, 1997, 7(6), R369-372. 
 113 
55. Chen, W.; Zhang, D. Kinetochore fibre dynamics outside the context of the 
spindle during anaphase. Nat Cell Biol, 2004, 6(3), 227-231. 
56. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: a dynamic field of 
cancer therapeutics. Nat Rev Drug Discov, 2010, 9(10), 790-803. 
57. Noble, R. L.; Beer, C. T.; Cutts, J. H. Role of chance observations in 
chemotherapy: Vinca rosea. Ann N Y Acad Sci, 1958, 76(3), 882-894. 
58. Gigant, B.; Wang, C.; Ravelli, R. B.; Roussi, F.; Steinmetz, M. O.; Curmi, P. A.; 
Sobel, A.; Knossow, M. Structural basis for the regulation of tubulin by 
vinblastine. Nature, 2005, 435(7041), 519-522. 
59. Hu, C. B.; Chen, C. P.; Yeh, T. K.; Song, J. S.; Chang, C. Y.; Chuu, J. J.; Tung, F. 
F.; Ho, P. Y.; Chen, T. W.; Lin, C. H.; Wang, M. H.; Chang, K. Y.; Huang, C. L.; 
Lin, H. L.; Li, W. T.; Hwang, D. R.; Chern, J. H.; Hwang, L. L.; Chang, J. Y.; 
Chao, Y. S.; Chen, C. T. BPR0C261 is a novel orally active antitumor agent with 
antimitotic and anti-angiogenic activities. Cancer Sci, 2011, 102(1), 182-191. 
60. Li, W. T.; Hwang, D. R.; Chen, C. P.; Shen, C. W.; Huang, C. L.; Chen, T. W.; 
Lin, C. H.; Chang, Y. L.; Chang, Y. Y.; Lo, Y. K.; Tseng, H. Y.; Lin, C. C.; Song, 
J. S.; Chen, H. C.; Chen, S. J.; Wu, S. H.; Chen, C. T. Synthesis and biological 
evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer 
agents. J Med Chem, 2003, 46(9), 1706-1715. 
61. Arthuis, M.; Pontikis, R.; Chabot, G. G.; Quentin, L.; Scherman, D.; Florent, J. C. 
Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic 
combretastatin A4 analogues. Eur J Med Chem, 2011, 46(1), 95-100. 
62. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, 
T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative 
antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor 
cells, and lacks neurotoxicity. Cancer Res, 2001, 61(1), 392-399. 
63. El-Nakkady, S. S.; Hanna, M. M.; Roaiah, H. M.; Ghannam, I. A. Synthesis, 
molecular docking study and antitumor activity of novel 2-phenylindole 
derivatives. Eur J Med Chem, 2012, 47(1), 387-398. 
64. Bohlin, L.; Rosen, B. Podophyllotoxin derivatives: Drug discovery and 
development. Drug Discov Today, 1996, 1(8), 343-351. 
65. Wender, P. A.; Hegde, S. G.; Hubbard, R. D.; Zhang, L. Total synthesis of (-)-
laulimalide. J Am Chem Soc, 2002, 124(18), 4956-4957. 
66. Pryor, D. E.; O'Brate, A.; Bilcer, G.; Diaz, J. F.; Wang, Y.; Wang, Y.; Kabaki, 
M.; Jung, M. K.; Andreu, J. M.; Ghosh, A. K.; Giannakakou, P.; Hamel, E. The 
microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills 
cells resistant to paclitaxel and epothilones, and may not require its epoxide 
moiety for activity. Biochemistry, 2002, 41(29), 9109-9115. 
67. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, 
D. Isolation and structure of the strong cell growth and tubulin inhibitor 
combretastatin A-4. Experientia, 1989, 45(2), 209-211. 
68. Rustin, G. J.; Shreeves, G.; Nathan, P. D.; Gaya, A.; Ganesan, T. S.; Wang, D.; 
Boxall, J.; Poupard, L.; Chaplin, D. J.; Stratford, M. R.; Balkissoon, J.; Zweifel, 
M. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and 
paclitaxel in patients with advanced cancer. Br J Cancer, 2010, 102(9), 1355-
1360. 
 114 
69. Fotsis, T.; Zhang, Y.; Pepper, M. S.; Adlercreutz, H.; Montesano, R.; Nawroth, P. 
P.; Schweigerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol 
inhibits angiogenesis and suppresses tumour growth. Nature, 1994, 368(6468), 
237-239. 
70. Seegers, J. C.; Aveling, M. L.; Van Aswegen, C. H.; Cross, M.; Koch, F.; Joubert, 
W. S. The cytotoxic effects of estradiol-17 beta, catecholestradiols and 
methoxyestradiols on dividing MCF-7 and HeLa cells. J Steroid Biochem, 1989, 
32(6), 797-809. 
71. Lottering, M. L.; Haag, M.; Seegers, J. C. Effects of 17 beta-estradiol metabolites 
on cell cycle events in MCF-7 cells. Cancer Res, 1992, 52(21), 5926-5932. 
72. D'Amato, R. J.; Lin, C. M.; Flynn, E.; Folkman, J.; Hamel, E. 2-
Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin 
polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A, 
1994, 91(9), 3964-3968. 
73. Hamel, E.; Lin, C. M.; Flynn, E.; D'Amato, R. J. Interactions of 2-
methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized 
tubulin and with tubulin polymers. Biochemistry, 1996, 35(4), 1304-1310. 
74. Sweeney, C.; Liu, G.; Yiannoutsos, C.; Kolesar, J.; Horvath, D.; Staab, M. J.; 
Fife, K.; Armstrong, V.; Treston, A.; Sidor, C.; Wilding, G. A phase II 
multicenter, randomized, double-blind, safety trial assessing the 
pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol 
capsules in hormone-refractory prostate cancer. Clin Cancer Res, 2005, 11(18), 
6625-6633. 
75. James, J.; Murry, D. J.; Treston, A. M.; Storniolo, A. M.; Sledge, G. W.; Sidor, 
C.; Miller, K. D. Phase I safety, pharmacokinetic and pharmacodynamic studies 
of 2-methoxyestradiol alone or in combination with docetaxel in patients with 
locally recurrent or metastatic breast cancer. Invest New Drugs, 2007, 25(1), 41-
48. 
76. Rajkumar, S. V.; Richardson, P. G.; Lacy, M. Q.; Dispenzieri, A.; Greipp, P. R.; 
Witzig, T. E.; Schlossman, R.; Sidor, C. F.; Anderson, K. C.; Gertz, M. A. Novel 
therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase 
multiple myeloma. Clin Cancer Res, 2007, 13(20), 6162-6167. 
77. Yoshino, H.; Ueda, N.; Niijima, J.; Sugumi, H.; Kotake, Y.; Koyanagi, N.; 
Yoshimatsu, K.; Asada, M.; Watanabe, T.; Nagasu, T.; et al. Novel sulfonamides 
as potential, systemically active antitumor agents. J Med Chem, 1992, 35(13), 
2496-2497. 
78. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. 
Mechanism of action of E7010, an orally active sulfonamide antitumor agent: 
inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res, 
1997, 57(15), 3208-3213. 
79. Yamamoto, K.; Noda, K.; Yoshimura, A.; Fukuoka, M.; Furuse, K.; Niitani, H. 
Phase I study of E7010. Cancer Chemother Pharmacol, 1998, 42(2), 127-134. 
80. Michels, J.; Ellard, S. L.; Le, L.; Kollmannsberger, C.; Murray, N.; Tomlinson 
Guns, E. S.; Carr, R.; Chi, K. N. A phase IB study of ABT-751 in combination 
with docetaxel in patients with advanced castration-resistant prostate cancer. Ann 
Oncol, 2010, 21(2), 305-311. 
 115 
81. Hande, K. R.; Hagey, A.; Berlin, J.; Cai, Y.; Meek, K.; Kobayashi, H.; Lockhart, 
A. C.; Medina, D.; Sosman, J.; Gordon, G. B.; Rothenberg, M. L. The 
pharmacokinetics and safety of ABT-751, a novel, orally bioavailable 
sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res, 2006, 
12(9), 2834-2840. 
82. de Ines, C.; Leynadier, D.; Barasoain, I.; Peyrot, V.; Garcia, P.; Briand, C.; Rener, 
G. A.; Temple, C., Jr. Inhibition of microtubules and cell cycle arrest by a new 1-
deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 
613863. Cancer Res, 1994, 54(1), 75-84. 
83. Meyers, C. A.; Kudelka, A. P.; Conrad, C. A.; Gelke, C. K.; Grove, W.; Pazdur, 
R. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res, 1997, 
3(3), 419-422. 
84. Wienecke, A.; Bacher, G. Indibulin, a novel microtubule inhibitor, discriminates 
between mature neuronal and nonneuronal tubulin. Cancer Res, 2009, 69(1), 171-
177. 
85. Lu, Y.; Chen, J.; Xiao, M.; Li, W.; Miller, D. D. An overview of tubulin inhibitors 
that interact with the colchicine binding site. Pharm Res, 2012, 29(11), 2943-
2971. 
86. Romagnoli, R.; Baraldi, P. G.; Brancale, A.; Ricci, A.; Hamel, E.; Bortolozzi, R.; 
Basso, G.; Viola, G. Convergent synthesis and biological evaluation of 2-amino-
4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. J 
Med Chem, 2011, 54(14), 5144-5153. 
87. Calliste, C. A.; Le Bail, J. C.; Trouillas, P.; Pouget, C.; Habrioux, G.; Chulia, A. 
J.; Duroux, J. L. Chalcones: structural requirements for antioxidant, estrogenic 
and anti-proliferative activities. Anticancer Res, 2001, 21(6A), 3949-3956. 
88. Kumar, S. K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N. E.; Khan, S. 
R. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as 
antitumor agents. J Med Chem, 2003, 46(14), 2813-2815. 
89. Lahtchev, K. L.; Batovska, D. I.; Parushev, S. P.; Ubiyvovk, V. M.; Sibirny, A. A. 
Antifungal activity of chalcones: a mechanistic study using various yeast strains. 
Eur J Med Chem, 2008, 43(10), 2220-2228. 
90. Ducki, S. Antimitotic chalcones and related compounds as inhibitors of tubulin 
assembly. Anticancer Agents Med Chem, 2009, 9(3), 336-347. 
91. Sashidhara, K. V.; Kumar, A.; Kumar, M.; Sarkar, J.; Sinha, S. Synthesis and in 
vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer 
agents. Bioorg Med Chem Lett, 2010, 20(24), 7205-7211. 
92. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Menendez, M.; Laynez, J.; 
Andreu, J. M. Mechanism of binding of the new antimitotic drug MDL 27048 to 
the colchicine site of tubulin: equilibrium studies. Biochemistry, 1992, 31(45), 
11125-11132. 
93. Peyrot, V.; Leynadier, D.; Sarrazin, M.; Briand, C.; Rodriquez, A.; Nieto, J. M.; 
Andreu, J. M. Interaction of tubulin and cellular microtubules with the new 
antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J 
Biol Chem, 1989, 264(35), 21296-21301. 
94. Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, 
D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint, B.; Boutonnat, J. A novel 
 116 
chalcone derivative which acts as a microtubule depolymerising agent and an 
inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC 
Cancer, 2009, 9, 242. 
95. Risinger, A. L.; Westbrook, C. D.; Encinas, A.; Mulbaier, M.; Schultes, C. M.; 
Wawro, S.; Lewis, J. D.; Janssen, B.; Giles, F. J.; Mooberry, S. L. ELR510444, a 
novel microtubule disruptor with multiple mechanisms of action. J Pharmacol 
Exp Ther, 2011, 336(3), 652-660. 
96. De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; 
Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; 
Silvestri, R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. 
Structure-activity relationships and molecular modeling studies. J Med Chem, 
2006, 49(3), 947-954. 
97. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C.; 
Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R. Arylthioindoles, 
potent inhibitors of tubulin polymerization. J Med Chem, 2004, 47(25), 6120-
6123. 
98. Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, 
A.; Paper, D. H.; Burgermeister, J.; Bohmer, F. D.; Fiebig, H. H.; Burger, A. M.; 
Baasner, S.; Beckers, T. Synthetic 2-aroylindole derivatives as a new class of 
potent tubulin-inhibitory, antimitotic agents. J Med Chem, 2001, 44(26), 4535-
4553. 
99. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, 
Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. BPR0L075, a novel synthetic indole 
compound with antimitotic activity in human cancer cells, exerts effective 
antitumoral activity in vivo. Cancer Res, 2004, 64(13), 4621-4628. 
100. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-
glycoprotein: from genomics to mechanism. Oncogene, 2003, 22(47), 7468-7485. 
101. Thomas, H.; Coley, H. M. Overcoming multidrug resistance in cancer: an update 
on the clinical strategy of inhibiting p-glycoprotein. Cancer Control, 2003, 10(2), 
159-165. 
102. Geney, R.; Ungureanu l, M.; Li, D.; Ojima, I. Overcoming multidrug resistance in 
taxane chemotherapy. Clin Chem Lab Med, 2002, 40(9), 918-925. 
103. Canta, A.; Chiorazzi, A.; Cavaletti, G. Tubulin: a target for antineoplastic drugs 
into the cancer cells but also in the peripheral nervous system. Curr Med Chem, 
2009, 16(11), 1315-1324. 
104. Vats, T.; Buchanan, G.; Mehta, P.; Ragab, A.; Hvizdale, E.; Nitschke, R.; Link, 
M.; Beardsley, G. P.; Maybee, D.; Krischer, J. A study of toxicity and 
comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-
prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric 
Oncology Group study. Invest New Drugs, 1992, 10(3), 231-234. 
105. Swanton, C.; Nicke, B.; Schuett, M.; Eklund, A. C.; Ng, C.; Li, Q.; Hardcastle, T.; 
Lee, A.; Roy, R.; East, P.; Kschischo, M.; Endesfelder, D.; Wylie, P.; Kim, S. N.; 
Chen, J. G.; Howell, M.; Ried, T.; Habermann, J. K.; Auer, G.; Brenton, J. D.; 
Szallasi, Z.; Downward, J. Chromosomal instability determines taxane response. 
Proc Natl Acad Sci U S A, 2009, 106(21), 8671-8676. 
 117 
106. Bouchet, B. P.; Bertholon, J.; Falette, N.; Audoynaud, C.; Lamblot, C.; Puisieux, 
A.; Galmarini, C. M. Paclitaxel resistance in untransformed human mammary 
epithelial cells is associated with an aneuploidy-prone phenotype. Br J Cancer, 
2007, 97(9), 1218-1224. 
107. Lu, Y.; Li, C. M.; Wang, Z.; Ross, C. R., 2nd; Chen, J.; Dalton, J. T.; Li, W.; 
Miller, D. D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel 
anticancer agents: synthesis, biological evaluation, and structure-activity 
relationships. J Med Chem, 2009, 52(6), 1701-1711. 
108. Chen, J.; Wang, Z.; Li, C. M.; Lu, Y.; Vaddady, P. K.; Meibohm, B.; Dalton, J. 
T.; Miller, D. D.; Li, W. Discovery of novel 2-aryl-4-benzoyl-imidazoles 
targeting the colchicines binding site in tubulin as potential anticancer agents. J 
Med Chem, 2010, 53(20), 7414-7427. 
109. Lu, Y.; Li, C. M.; Wang, Z.; Chen, J.; Mohler, M. L.; Li, W.; Dalton, J. T.; Miller, 
D. D. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-
thiazoles analogues as potent and orally bioavailable anticancer agents. J Med 
Chem, 2011, 54(13), 4678-4693. 
110. Xu, Q.; Qi, H.; Sun, M.; Zuo, D.; Jiang, X.; Wen, Z.; Wang, Z.; Wu, Y.; Zhang, 
W. Synthesis and Biological Evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as 
Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative Activity. 
PLoS One, 2015, 10(6), e0128710. 
111. Kanthou, C.; Tozer, G. M. Microtubule depolymerizing vascular disrupting 
agents: novel therapeutic agents for oncology and other pathologies. Int J Exp 
Pathol, 2009, 90(3), 284-294. 
112. Chen, J.; Ahn, S.; Wang, J.; Lu, Y.; Dalton, J. T.; Miller, D. D.; Li, W. Discovery 
of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin 
polymerization as anti-proliferative agents. J Med Chem, 2012, 55(16), 7285-
7289. 
113. Li, C. M.; Lu, Y.; Chen, J.; Costello, T. A.; Narayanan, R.; Dalton, M. N.; 
Snyder, L. M.; Ahn, S.; Li, W.; Miller, D. D.; Dalton, J. T. Orally bioavailable 
tubulin antagonists for paclitaxel-refractory cancer. Pharm Res, 2012, 29(11), 
3053-3063. 
114. Wang, Z.; Chen, J.; Wang, J.; Ahn, S.; Li, C. M.; Lu, Y.; Loveless, V. S.; Dalton, 
J. T.; Miller, D. D.; Li, W. Novel tubulin polymerization inhibitors overcome 
multidrug resistance and reduce melanoma lung metastasis. Pharm Res, 2012, 
29(11), 3040-3052. 
115. Chen, J.; Li, C. M.; Wang, J.; Ahn, S.; Wang, Z.; Lu, Y.; Dalton, J. T.; Miller, D. 
D.; Li, W. Synthesis and anti-proliferative activity of novel 2-aryl-4-benzoyl-
imidazole derivatives targeting tubulin polymerization. Bioorganic & medicinal 
chemistry, 2011, 19(16), 4782-4795. 
116. Li, C. M.; Chen, J.; Lu, Y.; Narayanan, R.; Parke, D. N.; Li, W.; Ahn, S.; Miller, 
D. D.; Dalton, J. T. Pharmacokinetic optimization of 4-substituted 
methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral 
bioavailability. Drug metabolism and disposition: the biological fate of 
chemicals, 2011, 39(10), 1833-1839. 
 118 
117. Khalili, B.; Tondro, T.; Hashemi, M. M. Novel one-pot synthesis of (4 or 5)-aryl-
2-aryloyl-(1H)-imidazoles in water and tauto-isomerization study using NMR. 
Tetrahedron, 2009, 65(34), 6882-6887. 
118. Parkinson, E. I.; Jason Hatfield, M.; Tsurkan, L.; Hyatt, J. L.; Edwards, C. C.; 
Hicks, L. D.; Yan, B.; Potter, P. M. Requirements for mammalian 
carboxylesterase inhibition by substituted ethane-1,2-diones. Bioorganic & 
medicinal chemistry, 2011, 19(15), 4635-4643. 
119. Pelphrey, P. M.; Popov, V. M.; Joska, T. M.; Beierlein, J. M.; Bolstad, E. S.; 
Fillingham, Y. A.; Wright, D. L.; Anderson, A. C. Highly efficient ligands for 
dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii 
inspired by structural analysis. J Med Chem, 2007, 50(5), 940-950. 
120. Riley, H. A. G., A. R. General procedure for synthesis of glyoxal derivatives. 
Organic Syntheses; Wiley & Sons: New York, NY, 1943, 2, 509-510. 
121. Corelli, F.; Summa, V.; Brogi, A.; Monteagudo, E.; Botta, M. Chiral Azole 
Derivatives .2. Synthesis of Enantiomerically Pure 1-Alkylimidazoles. J Org 
Chem, 1995, 60(7), 2008-2015. 
122. Sabbah, M.; Soulere, L.; Reverchon, S.; Queneau, Y.; Doutheau, A. LuxR 
dependent quorum sensing inhibition by N,N'-disubstituted imidazolium salts. 
Bioorganic & medicinal chemistry, 2011, 19(16), 4868-4875. 
123. Xi, Z. X.; Liu, F. H.; Zhou, Y. B.; Chen, W. Z. CuI/L (L = pyridine-
functionalized 1,3-diketones) catalyzed C-N coupling reactions of aryl halides 
with NH-containing heterocycles. Tetrahedron, 2008, 64(19), 4254-4259. 
124. Leonessa, F.; Green, D.; Licht, T.; Wright, A.; Wingate-Legette, K.; Lippman, J.; 
Gottesman, M. M.; Clarke, R. MDA435/LCC6 and MDA435/LCC6MDR1: 
ascites models of human breast cancer. Br J Cancer, 1996, 73(2), 154-161. 
125. Vredenburg, M. R.; Ojima, I.; Veith, J.; Pera, P.; Kee, K.; Cabral, F.; Sharma, A.; 
Kanter, P.; Greco, W. R.; Bernacki, R. J. Effects of orally active taxanes on P-
glycoprotein modulation and colon and breast carcinoma drug resistance. Journal 
of the National Cancer Institute, 2001, 93(16), 1234-1245. 
126. Zhang, S.; Morris, M. E. Effects of the flavonoids biochanin A, morin, phloretin, 
and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther, 
2003, 304(3), 1258-1267. 
127. Dong, X.; Mattingly, C. A.; Tseng, M. T.; Cho, M. J.; Liu, Y.; Adams, V. R.; 
Mumper, R. J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles 
overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. 
Cancer Res, 2009, 69(9), 3918-3926. 
128. Barbier, P.; Dorleans, A.; Devred, F.; Sanz, L.; Allegro, D.; Alfonso, C.; 
Knossow, M.; Peyrot, V.; Andreu, J. M. Stathmin and interfacial microtubule 
inhibitors recognize a naturally curved conformation of tubulin dimers. J Biol 
Chem, 2010, 285(41), 31672-31681. 
129. Dorleans, A.; Gigant, B.; Ravelli, R. B.; Mailliet, P.; Mikol, V.; Knossow, M. 
Variations in the colchicine-binding domain provide insight into the structural 
switch of tubulin. Proc Natl Acad Sci U S A, 2009, 106(33), 13775-13779. 
130. Li, C. M.; Lu, Y.; Ahn, S.; Narayanan, R.; Miller, D. D.; Dalton, J. T. 
Competitive mass spectrometry binding assay for characterization of three 
binding sites of tubulin. J Mass Spectrom, 2010, 45(10), 1160-1166. 
 119 
131. Ambrosini, G.; Adida, C.; Altieri, D. C. A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma. Nature medicine, 1997, 3(8), 917-921. 
132. de Almagro, M. C.; Vucic, D. The inhibitor of apoptosis (IAP) proteins are 
critical regulators of signaling pathways and targets for anti-cancer therapy. 
Experimental oncology, 2012, 34(3), 200-211. 
133. Hunter, A. M.; LaCasse, E. C.; Korneluk, R. G. The inhibitors of apoptosis (IAPs) 
as cancer targets. Apoptosis : an international journal on programmed cell death, 
2007, 12(9), 1543-1568. 
134. Schimmer, A. D. Inhibitor of apoptosis proteins: translating basic knowledge into 
clinical practice. Cancer Res, 2004, 64(20), 7183-7190. 
135. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. 
Nat Rev Drug Discov, 2012, 11(2), 109-124. 
136. Ryan, B. M.; O'Donovan, N.; Duffy, M. J. Survivin: a new target for anti-cancer 
therapy. Cancer treatment reviews, 2009, 35(7), 553-562. 
137. Rauch, A.; Hennig, D.; Schafer, C.; Wirth, M.; Marx, C.; Heinzel, T.; Schneider, 
G.; Kramer, O. H. Survivin and YM155: how faithful is the liaison? Biochimica et 
biophysica acta, 2014, 1845(2), 202-220. 
138. O'Connor, D. S.; Schechner, J. S.; Adida, C.; Mesri, M.; Rothermel, A. L.; Li, F.; 
Nath, A. K.; Pober, J. S.; Altieri, D. C. Control of apoptosis during angiogenesis 
by survivin expression in endothelial cells. The American journal of pathology, 
2000, 156(2), 393-398. 
139. Waligorska-Stachura, J.; Jankowska, A.; Wasko, R.; Liebert, W.; Biczysko, M.; 
Czarnywojtek, A.; Baszko-Blaszyk, D.; Shimek, V.; Ruchala, M. Survivin--
prognostic tumor biomarker in human neoplasms--review. Ginekologia polska, 
2012, 83(7), 537-540. 
140. Kawasaki, H.; Toyoda, M.; Shinohara, H.; Okuda, J.; Watanabe, I.; Yamamoto, 
T.; Tanaka, K.; Tenjo, T.; Tanigawa, N. Expression of survivin correlates with 
apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. 
Cancer, 2001, 91(11), 2026-2032. 
141. Cheung, C. H.; Huang, C. C.; Tsai, F. Y.; Lee, J. Y.; Cheng, S. M.; Chang, Y. C.; 
Huang, Y. C.; Chen, S. H.; Chang, J. Y. Survivin - biology and potential as a 
therapeutic target in oncology. OncoTargets and therapy, 2013, 6, 1453-1462. 
142. Yang, D.; Welm, A.; Bishop, J. M. Cell division and cell survival in the absence 
of survivin. Proc Natl Acad Sci U S A, 2004, 101(42), 15100-15105. 
143. Vader, G.; Kauw, J. J.; Medema, R. H.; Lens, S. M. Survivin mediates targeting 
of the chromosomal passenger complex to the centromere and midbody. EMBO 
reports, 2006, 7(1), 85-92. 
144. Ruchaud, S.; Carmena, M.; Earnshaw, W. C. The chromosomal passenger 
complex: one for all and all for one. Cell, 2007, 131(2), 230-231. 
145. Ruchaud, S.; Carmena, M.; Earnshaw, W. C. Chromosomal passengers: 
conducting cell division. Nature reviews. Molecular cell biology, 2007, 8(10), 
798-812. 
146. Wiedemuth, R.; Klink, B.; Topfer, K.; Schrock, E.; Schackert, G.; Tatsuka, M.; 
Temme, A. Survivin safeguards chromosome numbers and protects from 
aneuploidy independently from p53. Molecular cancer, 2014, 13, 107. 
 120 
147. O'Connor, D. S.; Wall, N. R.; Porter, A. C.; Altieri, D. C. A p34(cdc2) survival 
checkpoint in cancer. Cancer cell, 2002, 2(1), 43-54. 
148. Giodini, A.; Kallio, M. J.; Wall, N. R.; Gorbsky, G. J.; Tognin, S.; Marchisio, P. 
C.; Symons, M.; Altieri, D. C. Regulation of microtubule stability and mitotic 
progression by survivin. Cancer Res, 2002, 62(9), 2462-2467. 
149. Altieri, D. C. The case for survivin as a regulator of microtubule dynamics and 
cell-death decisions. Current opinion in cell biology, 2006, 18(6), 609-615. 
150. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; 
Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis 
induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res, 1998, 
58(23), 5315-5320. 
151. Shin, S.; Sung, B. J.; Cho, Y. S.; Kim, H. J.; Ha, N. C.; Hwang, J. I.; Chung, C. 
W.; Jung, Y. K.; Oh, B. H. An anti-apoptotic protein human survivin is a direct 
inhibitor of caspase-3 and -7. Biochemistry, 2001, 40(4), 1117-1123. 
152. Grossman, D.; Kim, P. J.; Blanc-Brude, O. P.; Brash, D. E.; Tognin, S.; 
Marchisio, P. C.; Altieri, D. C. Transgenic expression of survivin in keratinocytes 
counteracts UVB-induced apoptosis and cooperates with loss of p53. The Journal 
of clinical investigation, 2001, 108(7), 991-999. 
153. Yamamoto, T.; Manome, Y.; Nakamura, M.; Tanigawa, N. Downregulation of 
survivin expression by induction of the effector cell protease receptor-1 reduces 
tumor growth potential and results in an increased sensitivity to anticancer agents 
in human colon cancer. European journal of cancer, 2002, 38(17), 2316-2324. 
154. Dohi, T.; Okada, K.; Xia, F.; Wilford, C. E.; Samuel, T.; Welsh, K.; Marusawa, 
H.; Zou, H.; Armstrong, R.; Matsuzawa, S.; Salvesen, G. S.; Reed, J. C.; Altieri, 
D. C. An IAP-IAP complex inhibits apoptosis. J Biol Chem, 2004, 279(33), 
34087-34090. 
155. Marusawa, H.; Matsuzawa, S.; Welsh, K.; Zou, H.; Armstrong, R.; Tamm, I.; 
Reed, J. C. HBXIP functions as a cofactor of survivin in apoptosis suppression. 
The EMBO journal, 2003, 22(11), 2729-2740. 
156. Duffy, M. J.; O'Donovan, N.; Brennan, D. J.; Gallagher, W. M.; Ryan, B. M. 
Survivin: a promising tumor biomarker. Cancer letters, 2007, 249(1), 49-60. 
157. Li, Y.; Ma, X.; Wu, X.; Liu, X.; Liu, L. Prognostic Significance of Survivin in 
Breast Cancer: Meta-analysis. The breast journal, 2014. 
158. Lv, S.; Dai, C.; Liu, Y.; Shi, R.; Tang, Z.; Han, M.; Bian, R.; Sun, B.; Wang, R. 
The Impact of Survivin on Prognosis and Clinicopathology of Glioma Patients: A 
Systematic Meta-Analysis. Molecular neurobiology, 2014. 
159. Monzo, M.; Rosell, R.; Felip, E.; Astudillo, J.; Sanchez, J. J.; Maestre, J.; Martin, 
C.; Font, A.; Barnadas, A.; Abad, A. A novel anti-apoptosis gene: Re-expression 
of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. 
J Clin Oncol, 1999, 17(7), 2100-2104. 
160. Tanaka, K.; Iwamoto, S.; Gon, G.; Nohara, T.; Iwamoto, M.; Tanigawa, N. 
Expression of survivin and its relationship to loss of apoptosis in breast 
carcinomas. Clin Cancer Res, 2000, 6(1), 127-134. 
161. Satoh, K.; Kaneko, K.; Hirota, M.; Masamune, A.; Satoh, A.; Shimosegawa, T. 
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor 
 121 
expression and the pathway of apoptosis in human pancreatic cancer. Pancreas, 
2001, 23(3), 251-258. 
162. Grossman, D.; McNiff, J. M.; Li, F.; Altieri, D. C. Expression and targeting of the 
apoptosis inhibitor, survivin, in human melanoma. The Journal of investigative 
dermatology, 1999, 113(6), 1076-1081. 
163. Cheung, C. H.; Sun, X.; Kanwar, J. R.; Bai, J. Z.; Cheng, L.; Krissansen, G. W. A 
cell-permeable dominant-negative survivin protein induces apoptosis and 
sensitizes prostate cancer cells to TNF-alpha therapy. Cancer cell international, 
2010, 10, 36. 
164. Ling, X.; Calinski, D.; Chanan-Khan, A. A.; Zhou, M.; Li, F. Cancer cell 
sensitivity to bortezomib is associated with survivin expression and p53 status but 
not cancer cell types. Journal of experimental & clinical cancer research : CR, 
2010, 29, 8. 
165. He, S. Q.; Rehman, H.; Gong, M. G.; Zhao, Y. Z.; Huang, Z. Y.; Li, C. H.; Zhang, 
W. G.; Chen, X. P. Inhibiting survivin expression enhances TRAIL-induced 
tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. 
Cancer biology & therapy, 2007, 6(8), 1247-1257. 
166. Moriai, R.; Tsuji, N.; Moriai, M.; Kobayashi, D.; Watanabe, N. Survivin plays as 
a resistant factor against tamoxifen-induced apoptosis in human breast cancer 
cells. Breast cancer research and treatment, 2009, 117(2), 261-271. 
167. Nomura, T.; Yamasaki, M.; Nomura, Y.; Mimata, H. Expression of the inhibitors 
of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncology reports, 
2005, 14(4), 993-997. 
168. Tirro, E.; Consoli, M. L.; Massimino, M.; Manzella, L.; Frasca, F.; Sciacca, L.; 
Vicari, L.; Stassi, G.; Messina, L.; Messina, A.; Vigneri, P. Altered expression of 
c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid 
cancer cells. Cancer Res, 2006, 66(8), 4263-4272. 
169. Adisetiyo, H.; Liang, M.; Liao, C. P.; Aycock-Williams, A.; Cohen, M. B.; Xu, 
S.; Neamati, N.; Conway, E. M.; Cheng, C. Y.; Nikitin, A. Y.; Roy-Burman, P. 
Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse 
model of prostate adenocarcinoma. PLoS One, 2013, 8(7), e69484. 
170. Mobahat, M.; Narendran, A.; Riabowol, K. Survivin as a preferential target for 
cancer therapy. International journal of molecular sciences, 2014, 15(2), 2494-
2516. 
171. Athanasoula, K.; Gogas, H.; Polonifi, K.; Vaiopoulos, A. G.; Polyzos, A.; 
Mantzourani, M. Survivin beyond physiology: orchestration of multistep 
carcinogenesis and therapeutic potentials. Cancer letters, 2014, 347(2), 175-182. 
172. Ghanbari, P.; Mohseni, M.; Tabasinezhad, M.; Yousefi, B.; Saei, A. A.; Sharifi, 
S.; Rashidi, M. R.; Samadi, N. Inhibition of Survivin Restores the Sensitivity of 
Breast Cancer Cells to Docetaxel and Vinblastine. Applied biochemistry and 
biotechnology, 2014. 
173. Wang, R.; Chen, D. Q.; Huang, J. Y.; Zhang, K.; Feng, B.; Pan, B. Z.; Chen, J.; 
De, W.; Chen, L. B. Acquisition of radioresistance in docetaxel-resistant human 
lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-
survivin/rad-51 signaling. Oncotarget, 2014. 
 122 
174. Sun, X. P.; Dong, X.; Lin, L.; Jiang, X.; Wei, Z.; Zhai, B.; Sun, B.; Zhang, Q.; 
Wang, X.; Jiang, H.; Krissansen, G. W.; Qiao, H.; Sun, X. Up-regulation of 
survivin by AKT and hypoxia-inducible factor 1alpha contributes to cisplatin 
resistance in gastric cancer. The FEBS journal, 2014, 281(1), 115-128. 
175. Buchwald, P. Small-molecule protein-protein interaction inhibitors: therapeutic 
potential in light of molecular size, chemical space, and ligand binding efficiency 
considerations. IUBMB life, 2010, 62(10), 724-731. 
176. Fuller, J. C.; Burgoyne, N. J.; Jackson, R. M. Predicting druggable binding sites at 
the protein-protein interface. Drug Discov Today, 2009, 14(3-4), 155-161. 
177. Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; 
Gautam, B.; Hassanali, M. DrugBank: a knowledgebase for drugs, drug actions 
and drug targets. Nucleic acids research, 2008, 36(Database issue), D901-906. 
178. Lagane, B.; Garcia-Perez, J.; Kellenberger, E. Modeling the allosteric modulation 
of CCR5 function by Maraviroc. Drug discovery today. Technologies, 2013, 
10(2), e297-305. 
179. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces. Journal of 
molecular biology, 1998, 280(1), 1-9. 
180. Wang, J.; Li, W. Discovery of novel second mitochondria-derived activator of 
caspase mimetics as selective inhibitor of apoptosis protein inhibitors. J 
Pharmacol Exp Ther, 2014, 349(2), 319-329. 
181. Du, J.; Kelly, A. E.; Funabiki, H.; Patel, D. J. Structural basis for recognition of 
H3T3ph and Smac/DIABLO N-terminal peptides by human Survivin. Structure, 
2012, 20(1), 185-195. 
182. Pennati, M.; Folini, M.; Zaffaroni, N. Targeting survivin in cancer therapy: 
fulfilled promises and open questions. Carcinogenesis, 2007, 28(6), 1133-1139. 
183. Coumar, M. S.; Tsai, F. Y.; Kanwar, J. R.; Sarvagalla, S.; Cheung, C. H. Treat 
cancers by targeting survivin: just a dream or future reality? Cancer treatment 
reviews, 2013, 39(7), 802-811. 
184. Nakahara, T.; Kita, A.; Yamanaka, K.; Mori, M.; Amino, N.; Takeuchi, M.; 
Tominaga, F.; Hatakeyama, S.; Kinoyama, I.; Matsuhisa, A.; Kudoh, M.; 
Sasamata, M. YM155, a novel small-molecule survivin suppressant, induces 
regression of established human hormone-refractory prostate tumor xenografts. 
Cancer Res, 2007, 67(17), 8014-8021. 
185. Wall, N. R.; O'Connor, D. S.; Plescia, J.; Pommier, Y.; Altieri, D. C. Suppression 
of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell 
apoptosis. Cancer Res, 2003, 63(1), 230-235. 
186. Meli, M.; Pennati, M.; Curto, M.; Daidone, M. G.; Plescia, J.; Toba, S.; Altieri, D. 
C.; Zaffaroni, N.; Colombo, G. Small-molecule targeting of heat shock protein 90 
chaperone function: rational identification of a new anticancer lead. J Med Chem, 
2006, 49(26), 7721-7730. 
187. Wang, H. Q.; Jin, J. J.; Wang, J. Arctigenin enhances chemosensitivity to cisplatin 
in human nonsmall lung cancer H460 cells through downregulation of survivin 
expression. Journal of biochemical and molecular toxicology, 2014, 28(1), 39-45. 
188. Huang, K.; Li, L. A.; Meng, Y. G.; You, Y. Q.; Fu, X. Y.; Song, L. Arctigenin 
Promotes Apoptosis in Ovarian Cancer Cells via the iNOS/NO/STAT3/Survivin 
Signalling. Basic & clinical pharmacology & toxicology, 2014. 
 123 
189. Hsiao, C. J.; Hsiao, G.; Chen, W. L.; Wang, S. W.; Chiang, C. P.; Liu, L. Y.; Guh, 
J. H.; Lee, T. H.; Chung, C. L. Cephalochromin induces G0/G1 cell cycle arrest 
and apoptosis in A549 human non-small-cell lung cancer cells by inflicting 
mitochondrial disruption. Journal of natural products, 2014, 77(4), 758-765. 
190. Ling, X.; Cao, S.; Cheng, Q.; Keefe, J. T.; Rustum, Y. M.; Li, F. A novel small 
molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a 
p53-independent manner, shows superior antitumor activity. PLoS One, 2012, 
7(9), e45571. 
191. Zhao, J.; Ling, X.; Cao, S.; Liu, X.; Wan, S.; Jiang, T.; Li, F. Antitumor activity 
of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly 
dependent on its primary structure and steric configuration. Molecular 
pharmaceutics, 2014, 11(2), 457-467. 
192. O'Connor, D. S.; Grossman, D.; Plescia, J.; Li, F.; Zhang, H.; Villa, A.; Tognin, 
S.; Marchisio, P. C.; Altieri, D. C. Regulation of apoptosis at cell division by 
p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A, 2000, 97(24), 
13103-13107. 
193. Lee, H. G.; Baek, J. W.; Shin, S. J.; Kwon, S. H.; Cha, S. D.; Park, W. J.; Chung, 
R.; Choi, E. S.; Lee, G. H.; Cho, C. H. Antitumor Effects of Flavopiridol on 
Human Uterine Leiomyoma In Vitro and in a Xenograft model. Reproductive 
sciences, 2014. 
194. Karp, J. E.; Garrett-Mayer, E.; Estey, E. H.; Rudek, M. A.; Smith, B. D.; Greer, J. 
M.; Drye, D. M.; Mackey, K.; Dorcy, K. S.; Gore, S. D.; Levis, M. J.; McDevitt, 
M. A.; Carraway, H. E.; Pratz, K. W.; Gladstone, D. E.; Showel, M. M.; Othus, 
M.; Doyle, L. A.; Wright, J. J.; Pagel, J. M. Randomized phase II study of two 
schedules of flavopiridol given as timed sequential therapy with cytosine 
arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute 
myelogenous leukemia. Haematologica, 2012, 97(11), 1736-1742. 
195. Bible, K. C.; Peethambaram, P. P.; Oberg, A. L.; Maples, W.; Groteluschen, D. 
L.; Boente, M.; Burton, J. K.; Gomez Dahl, L. C.; Tibodeau, J. D.; Isham, C. R.; 
Maguire, J. L.; Shridhar, V.; Kukla, A. K.; Voll, K. J.; Mauer, M. J.; Colevas, A. 
D.; Wright, J.; Doyle, L. A.; Erlichman, C.; Mayo Phase, C.; North Central 
Cancer Treatment, G. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in 
platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecologic 
oncology, 2012, 127(1), 55-62. 
196. Emami, K. H.; Nguyen, C.; Ma, H.; Kim, D. H.; Jeong, K. W.; Eguchi, M.; Moon, 
R. T.; Teo, J. L.; Kim, H. Y.; Moon, S. H.; Ha, J. R.; Kahn, M. A small molecule 
inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc 
Natl Acad Sci U S A, 2004, 101(34), 12682-12687. 
197. Azmi, A. S.; Aboukameel, A.; Bao, B.; Sarkar, F. H.; Philip, P. A.; Kauffman, 
M.; Shacham, S.; Mohammad, R. M. Selective inhibitors of nuclear export block 
pancreatic cancer cell proliferation and reduce tumor growth in mice. 
Gastroenterology, 2013, 144(2), 447-456. 
198. Etchin, J.; Sun, Q.; Kentsis, A.; Farmer, A.; Zhang, Z. C.; Sanda, T.; Mansour, M. 
R.; Barcelo, C.; McCauley, D.; Kauffman, M.; Shacham, S.; Christie, A. L.; 
Kung, A. L.; Rodig, S. J.; Chook, Y. M.; Look, A. T. Antileukemic activity of 
 124 
nuclear export inhibitors that spare normal hematopoietic cells. Leukemia, 2013, 
27(1), 66-74. 
199. Zhang, K.; Wang, M.; Tamayo, A. T.; Shacham, S.; Kauffman, M.; Lee, J.; 
Zhang, L.; Ou, Z.; Li, C.; Sun, L.; Ford, R. J.; Pham, L. V. Novel selective 
inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell 
lymphoma. Experimental hematology, 2013, 41(1), 67-78 e64. 
200. Wang, S.; Han, X.; Wang, J.; Yao, J.; Shi, Y. Antitumor effects of a novel 
chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung 
cancer cells in vitro and in mouse tumor xenografts. PLoS One, 2014, 9(3), 
e89848. 
201. Tai, Y. T.; Landesman, Y.; Acharya, C.; Calle, Y.; Zhong, M. Y.; Cea, M.; 
Tannenbaum, D.; Cagnetta, A.; Reagan, M.; Munshi, A. A.; Senapedis, W.; Saint-
Martin, J. R.; Kashyap, T.; Shacham, S.; Kauffman, M.; Gu, Y.; Wu, L.; 
Ghobrial, I.; Zhan, F.; Kung, A. L.; Schey, S. A.; Richardson, P.; Munshi, N. C.; 
Anderson, K. C. CRM1 inhibition induces tumor cell cytotoxicity and impairs 
osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic 
implications. Leukemia, 2014, 28(1), 155-165. 
202. Xia, W.; Bisi, J.; Strum, J.; Liu, L.; Carrick, K.; Graham, K. M.; Treece, A. L.; 
Hardwicke, M. A.; Dush, M.; Liao, Q.; Westlund, R. E.; Zhao, S.; Bacus, S.; 
Spector, N. L. Regulation of survivin by ErbB2 signaling: therapeutic 
implications for ErbB2-overexpressing breast cancers. Cancer Res, 2006, 66(3), 
1640-1647. 
203. Kacan, T.; Altun, A.; Altun, G. G.; Kacan, S. B.; Sarac, B.; Seker, M. M.; 
Bahceci, A.; Babacan, N. Investigation of antitumor effects of sorafenib and 
lapatinib alone and in combination on MCF-7 breast cancer cells. Asian Pacific 
journal of cancer prevention : APJCP, 2014, 15(7), 3185-3189. 
204. Robidoux, A.; Tang, G.; Rastogi, P.; Geyer, C. E., Jr.; Azar, C. A.; Atkins, J. N.; 
Fehrenbacher, L.; Bear, H. D.; Baez-Diaz, L.; Sarwar, S.; Margolese, R. G.; 
Farrar, W. B.; Brufsky, A. M.; Shibata, H. R.; Bandos, H.; Paik, S.; Costantino, J. 
P.; Swain, S. M.; Mamounas, E. P.; Wolmark, N. Lapatinib as a component of 
neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol 
B-41): an open-label, randomised phase 3 trial. Lancet Oncol, 2013, 14(12), 1183-
1192. 
205. Baselga, J.; Bradbury, I.; Eidtmann, H.; Di Cosimo, S.; de Azambuja, E.; Aura, 
C.; Gomez, H.; Dinh, P.; Fauria, K.; Van Dooren, V.; Aktan, G.; Goldhirsch, A.; 
Chang, T. W.; Horvath, Z.; Coccia-Portugal, M.; Domont, J.; Tseng, L. M.; Kunz, 
G.; Sohn, J. H.; Semiglazov, V.; Lerzo, G.; Palacova, M.; Probachai, V.; Pusztai, 
L.; Untch, M.; Gelber, R. D.; Piccart-Gebhart, M.; Neo, A. S. T. Lapatinib with 
trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, 
open-label, multicentre, phase 3 trial. Lancet, 2012, 379(9816), 633-640. 
206. Cheng, Y.; Zhang, Y.; Zhang, L.; Ren, X.; Huber-Keener, K. J.; Liu, X.; Zhou, L.; 
Liao, J.; Keihack, H.; Yan, L.; Rubin, E.; Yang, J. M. MK-2206, a novel allosteric 
inhibitor of Akt, synergizes with gefitinib against malignant glioma via 
modulating both autophagy and apoptosis. Molecular cancer therapeutics, 2012, 
11(1), 154-164. 
 125 
207. Liu, R.; Liu, D.; Xing, M. The Akt inhibitor MK2206 synergizes, but perifosine 
antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor 
AZD6244 in the inhibition of thyroid cancer cells. The Journal of clinical 
endocrinology and metabolism, 2012, 97(2), E173-182. 
208. Chowdhury, S.; Howell, G. M.; Rajput, A.; Teggart, C. A.; Brattain, L. E.; Weber, 
H. R.; Chowdhury, A.; Brattain, M. G. Identification of a novel TGFbeta/PKA 
signaling transduceome in mediating control of cell survival and metastasis in 
colon cancer. PLoS One, 2011, 6(5), e19335. 
209. Agarwal, E.; Chaudhuri, A.; Leiphrakpam, P. D.; Haferbier, K. L.; Brattain, M. 
G.; Chowdhury, S. Akt inhibitor MK-2206 promotes anti-tumor activity and cell 
death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer, 2014, 
14, 145. 
210. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; 
Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; 
Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, 
L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-
dependent kinase inhibitor. Nature structural biology, 2002, 9(10), 745-749. 
211. Pennati, M.; Campbell, A. J.; Curto, M.; Binda, M.; Cheng, Y.; Wang, L. Z.; 
Curtin, N.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Henderson, A.; 
Zaffaroni, N.; Newell, D. R. Potentiation of paclitaxel-induced apoptosis by the 
novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin 
down-regulation. Molecular cancer therapeutics, 2005, 4(9), 1328-1337. 
212. Erkel, G.; Anke, T.; Sterner, O. Inhibition of NF-kappa B activation by 
panepoxydone. Biochemical and biophysical research communications, 1996, 
226(1), 214-221. 
213. Arora, R.; Yates, C.; Gary, B. D.; McClellan, S.; Tan, M.; Xi, Y.; Reed, E.; 
Piazza, G. A.; Owen, L. B.; Dean-Colomb, W. Panepoxydone targets NF-kB and 
FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to 
mesenchymal transition in breast cancer. PLoS One, 2014, 9(6), e98370. 
214. Yaffe, P. B.; Power Coombs, M. R.; Doucette, C. D.; Walsh, M.; Hoskin, D. W. 
Piperine, an alkaloid from black pepper, inhibits growth of human colon cancer 
cells via G1 arrest and apoptosis triggered by endoplasmic reticulum stress. 
Molecular carcinogenesis, 2014. 
215. Stella, S.; Tirro, E.; Conte, E.; Stagno, F.; Di Raimondo, F.; Manzella, L.; 
Vigneri, P. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 
pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. 
Molecular cancer therapeutics, 2013, 12(6), 1085-1098. 
216. Abdelhamed, S.; Yokoyama, S.; Refaat, A.; Ogura, K.; Yagita, H.; Awale, S.; 
Saiki, I. Piperine enhances the efficacy of TRAIL-based therapy for triple-
negative breast cancer cells. Anticancer Res, 2014, 34(4), 1893-1899. 
217. Iizuka, D.; Ogura, A.; Kuwabara, M.; Inanami, O. Purvalanol A induces apoptosis 
and downregulation of antiapoptotic proteins through abrogation of 
phosphorylation of JAK2/STAT3 and RNA polymerase II. Anti-cancer drugs, 
2008, 19(6), 565-572. 
218. Zaffaroni, N.; Pennati, M.; Colella, G.; Perego, P.; Supino, R.; Gatti, L.; Pilotti, 
S.; Zunino, F.; Daidone, M. G. Expression of the anti-apoptotic gene survivin 
 126 
correlates with taxol resistance in human ovarian cancer. Cellular and molecular 
life sciences : CMLS, 2002, 59(8), 1406-1412. 
219. Cihalova, D.; Hofman, J.; Ceckova, M.; Staud, F. Purvalanol A, olomoucine II 
and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic 
effects of daunorubicin in vitro. PLoS One, 2013, 8(12), e83467. 
220. Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M. G.; Meli, 
M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D. I.; Colombo, G.; 
Altieri, D. C. Rational design of shepherdin, a novel anticancer agent. Cancer 
cell, 2005, 7(5), 457-468. 
221. Hwu, J. R.; Tseng, W. N.; Gnabre, J.; Giza, P.; Huang, R. C. Antiviral activities 
of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, 
and inhibition of tat-regulated HIV transactivation. J Med Chem, 1998, 41(16), 
2994-3000. 
222. Heller, J. D.; Kuo, J.; Wu, T. C.; Kast, W. M.; Huang, R. C. Tetra-O-methyl 
nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits 
tumoricidal activity in vivo. Cancer Res, 2001, 61(14), 5499-5504. 
223. Chang, C. C.; Heller, J. D.; Kuo, J.; Huang, R. C. Tetra-O-methyl 
nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by 
inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A, 2004, 
101(36), 13239-13244. 
224. Sun, Y.; Giacalone, N. J.; Lu, B. Terameprocol (tetra-O-methyl 
nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, 
induces radiosensitization in non-small cell lung carcinoma. Journal of thoracic 
oncology : official publication of the International Association for the Study of 
Lung Cancer, 2011, 6(1), 8-14. 
225. Khanna, N.; Dalby, R.; Tan, M.; Arnold, S.; Stern, J.; Frazer, N. Phase I/II clinical 
safety studies of terameprocol vaginal ointment. Gynecologic oncology, 2007, 
107(3), 554-562. 
226. Grossman, S. A.; Ye, X.; Peereboom, D.; Rosenfeld, M. R.; Mikkelsen, T.; 
Supko, J. G.; Desideri, S.; Adult Brain Tumor, C. Phase I study of terameprocol 
in patients with recurrent high-grade glioma. Neuro-oncology, 2012, 14(4), 511-
517. 
227. Koike, H.; Nitta, T.; Sekine, Y.; Arai, S.; Furuya, Y.; Nomura, M.; Matsui, H.; 
Shibata, Y.; Ito, K.; Oyama, T.; Suzuki, K. YM155 reverses rapamycin resistance 
in renal cancer by decreasing survivin. Journal of cancer research and clinical 
oncology, 2014. 
228. Mir, R.; Stanzani, E.; Martinez-Soler, F.; Villanueva, A.; Vidal, A.; Condom, E.; 
Ponce, J.; Gil, J.; Tortosa, A.; Gimenez-Bonafe, P. YM155 sensitizes ovarian 
cancer cells to cisplatin inducing apoptosis and tumor regression. Gynecologic 
oncology, 2014, 132(1), 211-220. 
229. Cheson, B. D.; Bartlett, N. L.; Vose, J. M.; Lopez-Hernandez, A.; Seiz, A. L.; 
Keating, A. T.; Shamsili, S.; Papadopoulos, K. P. A phase II study of the survivin 
suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. 
Cancer, 2012, 118(12), 3128-3134. 
230. Giaccone, G.; Zatloukal, P.; Roubec, J.; Floor, K.; Musil, J.; Kuta, M.; van 
Klaveren, R. J.; Chaudhary, S.; Gunther, A.; Shamsili, S. Multicenter phase II 
 127 
trial of YM155, a small-molecule suppressor of survivin, in patients with 
advanced, refractory, non-small-cell lung cancer. J Clin Oncol, 2009, 27(27), 
4481-4486. 
231. Iwai, M.; Minematsu, T.; Li, Q.; Iwatsubo, T.; Usui, T. Utility of P-glycoprotein 
and organic cation transporter 1 double-transfected LLC-PK1 cells for studying 
the interaction of YM155 monobromide, novel small-molecule survivin 
suppressant, with P-glycoprotein. Drug metabolism and disposition: the 
biological fate of chemicals, 2011, 39(12), 2314-2320. 
232. Fukuda, S.; Pelus, L. M. Survivin, a cancer target with an emerging role in normal 
adult tissues. Molecular cancer therapeutics, 2006, 5(5), 1087-1098. 
233. Satoh, K.; Kaneko, K.; Hirota, M.; Masamune, A.; Satoh, A.; Shimosegawa, T. 
Expression of survivin is correlated with cancer cell apoptosis and is involved in 
the development of human pancreatic duct cell tumors. Cancer, 2001, 92(2), 271-
278. 
234. Conway, E. M.; Zwerts, F.; Van Eygen, V.; DeVriese, A.; Nagai, N.; Luo, W.; 
Collen, D. Survivin-dependent angiogenesis in ischemic brain: molecular 
mechanisms of hypoxia-induced up-regulation. The American journal of 
pathology, 2003, 163(3), 935-946. 
235. Tu, S. P.; Jiang, X. H.; Lin, M. C.; Cui, J. T.; Yang, Y.; Lum, C. T.; Zou, B.; Zhu, 
Y. B.; Jiang, S. H.; Wong, W. M.; Chan, A. O.; Yuen, M. F.; Lam, S. K.; Kung, 
H. F.; Wong, B. C. Suppression of survivin expression inhibits in vivo 
tumorigenicity and angiogenesis in gastric cancer. Cancer Res, 2003, 63(22), 
7724-7732. 
236. Tsutsui, S.; Inoue, H.; Yasuda, K.; Suzuki, K.; Takeuchi, H.; Nishizaki, T.; 
Higashi, H.; Era, S.; Mori, M. Angiopoietin 2 expression in invasive ductal 
carcinoma of the breast: its relationship to the VEGF expression and microvessel 
density. Breast cancer research and treatment, 2006, 98(3), 261-266. 
237. Yang, Y.; Zhang, Y.; Hao, S.; Kan, Q. Periodic mesoporous organosilicas with 
bis(8-quinolinolato) dioxomolybdenum(VI) inside the channel walls. Journal of 
colloid and interface science, 2011, 362(1), 157-163. 
238. Farruggia, G.; Iotti, S.; Lombardo, M.; Marraccini, C.; Petruzziello, D.; Prodi, L.; 
Sgarzi, M.; Trombini, C.; Zaccheroni, N. Microwave assisted synthesis of a small 
library of substituted N,N'-bis((8-hydroxy-7-quinolinyl)methyl)-1,10-diaza-18-
crown-6 ethers. J Org Chem, 2010, 75(18), 6275-6278. 
239. Himmi, B.; Joly, J. P.; Hlimi, F.; Soufiaoui, M.; Kitane, S.; Bahloul, A.; Eddaif, 
A.; Sebban, A. Synthesis of novel 5,7-disubstituted 8-hydroxyquinolines. J 
Heterocyclic Chem, 2008, 45(4), 1023-1026. 
240. Uchiyama-Kokubu, N.; Watanabe, T. Establishment and characterization of 
adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with 
multidrug resistance. Anti-cancer drugs, 2001, 12(9), 769-779. 
241. Sangthong, S.; Ha, H.; Teerawattananon, T.; Ngamrojanavanich, N.; Neamati, N.; 
Muangsin, N. Overcoming doxorubicin-resistance in the NCI/ADR-RES model 
cancer cell line by novel anthracene-9,10-dione derivatives. Bioorg Med Chem 
Lett, 2013, 23(22), 6156-6160. 
242. Derry, M. M.; Somasagara, R. R.; Raina, K.; Kumar, S.; Gomez, J.; Patel, M.; 
Agarwal, R.; Agarwal, C. Target identification of grape seed extract in colorectal 
 128 
cancer using drug affinity responsive target stability (DARTS) technique: role of 
endoplasmic reticulum stress response proteins. Current cancer drug targets, 
2014, 14(4), 323-336. 
243. Lomenick, B.; Hao, R.; Jonai, N.; Chin, R. M.; Aghajan, M.; Warburton, S.; 
Wang, J.; Wu, R. P.; Gomez, F.; Loo, J. A.; Wohlschlegel, J. A.; Vondriska, T. 
M.; Pelletier, J.; Herschman, H. R.; Clardy, J.; Clarke, C. F.; Huang, J. Target 
identification using drug affinity responsive target stability (DARTS). Proc Natl 
Acad Sci U S A, 2009, 106(51), 21984-21989. 
244. Lomenick, B.; Jung, G.; Wohlschlegel, J. A.; Huang, J. Target identification using 
drug affinity responsive target stability (DARTS). Current protocols in chemical 
biology, 2011, 3(4), 163-180. 
245. Pai, M. Y.; Lomenick, B.; Hwang, H.; Schiestl, R.; McBride, W.; Loo, J. A.; 
Huang, J. Drug affinity responsive target stability (DARTS) for small-molecule 
target identification. Methods in molecular biology, 2015, 1263, 287-298. 
246. Xiao, M.; Ahn, S.; Wang, J.; Chen, J.; Miller, D. D.; Dalton, J. T.; Li, W. 
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor 
with potent anti-proliferative properties. J Med Chem, 2013, 56(8), 3318-3329. 
247. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat 
Rev Cancer, 2006, 6(10), 813-823. 
248. Lu, Y.; Chen, J.; Wang, J.; Li, C. M.; Ahn, S.; Barrett, C. M.; Dalton, J. T.; Li, 
W.; Miller, D. D. Design, synthesis, and biological evaluation of stable colchicine 
binding site tubulin inhibitors as potential anticancer agents. Journal of medicinal 
chemistry, 2014, 57(17), 7355-7366. 
 
  
 129 
VITA 
 
 
 Min Xiao was born in Anhui Province, China, in 1988. He entered East China 
University of Science and Technology in 2006 and earned a Bachelor of Science degree 
in Pharmaceutical Engineering in 2010. Then he joined Dr. Wei Li’s lab at University of 
Tennessee Health Science Center in pursuit of a Ph.D. degree in Pharmaceutical 
Sciences. 
